

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
1	Thiamine HCl, Riboflavin, Pyridoxine HCl, Niacinamide, Folic Acid, Cyanocobalamin, Calcium Pantothenate & Vitamin C Capsule	Each Hard Gelatin capsule contains:-			
		Thiamine HCl	IP	10	mg
		Riboflavin	IP	10	mg
		Pyridoxine HCl	IP	3	mg
		Niacinamide	IP	50	mg
		Folic Acid	IP	1000	mcg
		Cyanocobalamin	IP	5	mcg
		Calcium Pantothenate	IP	12.5	mg
		Vitamin C	IP	150	mg
		Approved Colour used in Capsule shell			

2	Vitamin A, Vitamin E, Vitamin C, Zinc Oxide Cupric Oxide & sodium Selenate Capsule	Each hard gelatin Capsule contains :-			
		Vitamin A ( as acetate)	IP	5000	IU
		Vitamin E ( as acetate)	IP	30	mg
		Ascorbic Acid	IP	60	mg
		Cupric Oxide			
		eq. to Copper		2	mg
		Sodium Selenate			
		eq to Selenium		40	mcg
		Zinc Oxide	IP		
		Eq. to Zinc		40	mg
Excipients		q.s			
Approved Colour used in Capsule shell					

3	Sildenafil Citrate Tablets IP	Each Filmcoated tablet contains:-			
		sildenafil Citrate	IP		
		Eq. to sildenafil		50	mg
		Excipients		q.s	
Approved colour used in Coating					

4	Betamethasone Valerate, Gentamycin Sulphate, Tolnaftate & Iodochlorohydroxyquinoline Cream	Each Gram Contains			
		Betamethasone Valerate	IP	0.61	mg
		Gentamycin Sulphate	IP		
		eq. to Gentamycin		1	mg
		Tolnaftate	IP	10	mg
		Iodochlorohydroxyquinoline	IP	10	mg
		Chlorocresol(As Preservative)	IP	1	mg
In Cream base		q.s			

5	Folic Acid Tablets IP	Each Uncoated tablet contains:-			
---	-----------------------	---------------------------------	--	--	--

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Folic Acid	IP	5	mg
		Excipients		q.s	
		Approved colour used in Tablets			
6	L-Ornithine - L-Aspartate & Pancreatin Tablets	Each Enteric coated tablet contains:-			
		L-Ornithine - L-Aspartate		150	mg
		Pancreatin	IP	100	mg
		Excipients		q.s	
		Approved colour used in Coating			
7	Doxylamine succinate, Pyridoxine HCl & Folic Acid Tablets	Each Filmcoated tablet contains:-			
		Doxylamine succinate	USP	10	mg
		Pyridoxine HCl	IP	10	mg
		Folic Acid	IP	5	mg
		Excipients		q.s	
		Approved colour used in Coating			
8	Diacerin Capsule IP	Each hard geletin capsule contains:-			
		Diacerin	IP	50	mg
		Excipients		qs	
		Approved colour used in empty capsule shell			
9	Hydroxyzine Hydrochloride Tablets IP	Each film coated tablet contains:			
		Hydroxyzine Hydrochloride	IP	25	mg
		Excipients			q.s.
		Colour: Approved colour used			
10	Cetrimide Shampoo	Cetrimide	IP	1%	w/v
	Medicated Shampoo Foam base	Medicated Shampoo Foam base		qs	
	FOR VETERINARY USE ONLY	Perfume		q.s	
11	Clobetasol Propionate, Ofloxacin, Miconazole Nitrate & Zinc Sulphate Lotion	Clobetasol Propionate	BP	0.025%	w/v
	FOR VETERINARY USE ONLY	Ofloxacin	IP	0.1%	w/v
		Miconazole Nitrate	IP	2%	w/v
		Zinc Sulphate	IP	3%	w/v
		In Lotion Base		q.s	
12	Permethrin & Coal Tar Shampoo	Permethrin		1%	w/v
		Coal Tar IP"66"	IP	0.5%	w/v

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	Medicated Shampoo Foam base FOR VETERINARY USE ONLY	Medicated Shampoo Foam base Perfume		qs q.s	
13	Ketoconazole & Chlorhexidine Gluconate Shampoo  FOR VETERINARY USE ONLY	Ketoconazole Chlorhexidine Gluconate Solution Eq. to Chlorhexidine Gluconate Medicated Shampoo Foam base Perfume Approved Colour used	IP IP	2% 4% 0.8% qs q.s	w/v w/v w/v
14	Miconazole Nitrate & Chlorhexidine Gluconate Shampoo  FOR VETERINARY USE ONLY	Miconazole Nitrate Chlorhexidine Gluconate Solution Eq. to Chlorhexidine Gluconate Medicated Shampoo Foam base Perfume Approved Colour used	IP IP	2% 2% 0.4% qs q.s	w/v w/v w/v
15	Cypermethrin Shampoo  FOR VETERINARY USE ONLY	Cypermethrin Medicated Shampoo Foam base Perfume		1% qs q.s	w/v
16	Diclofenac Gel BP	Composition Diclofenac Diethylamine eq. to Diclofenac Sodium Preservative:- Methyl Paraben Sodium Propyl Paraben Sodium In Gel base	BP IP IP	1.16% 1% 0.15% 0.1% q.s	w/w w/w
17	Aceclofenac Tablets IP	Each Filmcoated Tablets Contains:- Aceclofenac Excipients Approved Colour used in Coating	IP	100 q.s.	mg
18	Aceclofenac Sustained Release Tablets	Each Sustained Release Film coated tablet contains:- Aceclofenac Excipients Approved colour used in Tablets	IP	200 q.s	mg
19	Ginseng Powder, Vitamin A, Vitamin E , Vitamin D3, Thiamine HCl, Riboflavin, Pyridoxine HCl,	Each Hard Gelatin capsule contains:- Ginseng Powder Vitamin A( as Acetate) Vitamin E (as Acetate)	JP IP IP	200 2500 10	mg IU mg

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	Niacinamide, Folic Acid, Cyanocobalamin, Calcium Pantothenate, Vitamin C, Zinc Sulphate, Manganese Sulphate, Dibasic calcium Phosphate, Dried Ferrous Sulphate, Light magnesium Oxide & Copper sulphate Capsule	Vitamin D3	IP	200	IU
		Thiamine Mononitrate	IP	2	mg
		Riboflavin	IP	2	mg
		Pyridoxine HCl	IP	1.5	mg
		Niacinamide	IP	25	mg
		Folic Acid	IP	0.1	mg
		Cyanocobalamin	IP	1	mcg
		Calcium Pantothenate	IP	5	mg
		Vitamin C	IP	50	mg
		Zinc Sulphate	IP	1	mg
		Manganese Sulphate	BP	2	mg
		Dried Ferrous Sulphate	IP	30	mg
		Light magnesium Oxide	IP	10	mg
		Copper sulphate(anhydrous)	BP	1	mg
Dibasic calcium Phosphate	IP	25	mg		
	Approved Colour used in Capsule shell				

20	Clobetasol Propionate & Salicylic Acid Lotion	Clobetasol Propionate	IP	0.05%	w/v
		Salicylic Acid	IP	3%	w/v
		In a Lotion Base			

21	Pantoprazole Sodium & Itopride HCl Capsule	Each Hard Gelatin capsule contains:-			
		Pantoprazole Sodium	IP		
		eq. to Pantoprazole		40	mg
		(As Enteric Coated Pellets)			
		Itopride HCl		150	mg
		(As Sustained Release Pellets)			
		Excipients		qs	
	Approved Colour used in Capsule shell				

22	Paracetamol Tablets IP	Each Uncoated tablet contains:-			
		Paracetamol	IP	125	mg
		Excipients		q.s	
		Approved colour used in tablets			

23	Calamine, Diphenhydramine HCl & Camphor Lotion	Calamine	IP	8%	w/v
		Diphenhydramine HCl	IP	1%	w/v
		Camphor	BP	0.1%	w/v
		In a Lotion Base		q.s	

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
24	Ivermectin Tablets IP	Each Uncoated tablet contains:-			
		Ivermectin	IP	6	mg
		Excipients		q.s	
		Approved colour used in Tablets			

25	Ivermectin Tablets IP	Each Uncoated tablet contains:-			
		Ivermectin	IP	12	mg
		Excipients		q.s	
		Approved colour used in Tablets			

26	Cefixime Tablets IP	Each film coated tablet contains:			
		Cefixime	IP		
		Eq. to anhydrous Cefixime		200	mg
		Excipients			q.s.
		Colour: Approved colour used			

27	Cetrimide Cream IP	Cetrimide	IP	1%	w/w
		Chlorocresol(As a Preservative)	IP	0.1%	w/w
		Cream Base		q.s	

28	Cefixime Dispersible Tablets IP	Each Uncoated Dispersible tablet Contains:-			
		Cefixime	IP		
		Eq.to Anhydrous Cefixime		100	mg
		Excipients		q.s	
		Approved colour used in Tablets			

29	Thiamine HCl, Riboflavin, Pyridoxine HCl, Niacinamide, Folic Acid, Cyanocobalamin, Calcium Pantothenate, Zinc Sulphate, Manganese Sulphate & Dibasic calcium Phosphate Capsule	Each Hard Gelatin capsule contains:-			
		Thiamine HCl	IP	10	mg
		Riboflavin	IP	10	mg
		Pyridoxine HCl	IP	3	mg
		Niacinamide	IP	50	mg
		Folic Acid	IP	1000	mcg
		Cyanocobalamin	IP	5	mcg
		Calcium Pantothenate	IP	12.5	mg
		Zinc Sulphate	IP	20	mg
		Manganese Sulphate	BP	10	mg
		Dibasic calcium Phosphate	IP		
		eq. to calcium &		93.6	mg
		eq. to Phosphorus		72.8	mg
		Approved Colour used in Capsule shell			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
30	Lignocaine Gel IP	Composition			
		Lignocaine HCl	IP		
		Eq. to. Anhydrous Lignocaine Hcl		2%	w/w
		In Gel base		q.s	
31	Enrofloxacin Tablets (FOR ANIMAL USE ONLY) ( NOT FOR HUMAN USE )	Each Uncoated tablet contains:-			
		Enrofloxacin	IP	50	mg
		Excipients		q.s	
		Approved colour used in Tablets			
32	Enrofloxacin Tablets (FOR ANIMAL USE ONLY) ( NOT FOR HUMAN USE )	Each Uncoated tablet contains:-			
		Enrofloxacin	IP	150	mg
		Excipients		q.s	
		Approved colour used in Tablets			
33	Praziquantel , Pyrantel Embonate & Febantel Tablets (FOR ANIMAL USE ONLY) ( NOT FOR HUMAN USE )	Each Uncoated tablet contains:-			
		Praziquantel	IP	50	mg
		Pyrantel Embonate	IP	144	mg
		Febantel	BP	150	mg
		Excipients		q.s	
		Approved colour used in Tablets			
34	Diclofenac Diethylamine, Menthol, Linseed Oil, Methyl salicylate & Benzyl Alcohol Oil	Composition			
		Diclofenac Diethylamine	BP	1.16%	w/w
		Eq. to Diclofenac Sodium		1%	w/w
		Methyl salicylate	IP	10%	w/w
		Menthol	IP	5%	w/w
		Linseed Oil	BP	3%	w/w
		Benzyl alcohol	IP	1.0%	w/w
		(As a Preservative)			
		In Oil base		q.s	
35	Sulfaguanidine Tablets	Each Uncoated Tablet Contains:-			
		Sulfaguanidine	BP	500	mg
		Excipients		qs	
		Approved colour used in Tablets			

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT	
36	Cefixime Dispersible Tablets IP	Each Un-Coated Dispersible tablet Contains:-				
		Cefixime	IP			
		Eq.to Anhydrous Cefixime		200	mg	
		Excipients		q.s		
		Approved colour used in Tablets				

37	Methylcobalamin, Vit.B1, Vit.B6 Folic Acid, Nicotinamide, & Calcium Pantothenate, Tablets	Each Filmcoated Tablet Contains:-				
		Methylcobalamin	IP	500	mcg	
		Thiamine HCl	IP	10	mg	
		Pyridoxine HCl	IP	3	mg	
		Folic Acid	IP	1.5	mg	
		Nicotinamide	IP	45	mg	
		Calcium Pantothenate	IP	50	mg	
		Excipients			qs	
		Colour : Approved Colour Used				

38	Sildenafil Citrate Tablets IP	Each Filmcoated tablet contains:-				
		sildenafil Citrate	IP			
		Eq. to sildenafil		100	mg	
		Excipients		q.s		
		Approved colour used in Coating				

39	Lactic Acid Bacillus, Vitamin B1, Vitamin B2, Vitamin B6, Cynocobalamin, Folic Acid, Niacinamide, Calcium Pantothenate, Vitamin C & Zinc Sulphate Capsules (For Therapeutic Use)	Each hard geletin capsule contains:-				
		Lactic Acid bacillus		1000 lac	sporonges	
		Riboflavin	IP	10	mg	
		Pyridoxine Hcl	IP	3	mg	
		Thiamine Hcl	IP	10	mg	
		Cynocobalamin	IP	10	mcg	
		Folic Acid	IP	1500	mcg	
		Niacinamide	IP	75	mg	
		Calcium Pantothenate	IP	20	mg	
		Vitamin C	IP	75	mg	
		Zinc Sulphate monohydrate	IP	61.8	mg	
			qs			
		Approved colour used in empty capsule shell				

40	Indomethacin Capsules IP	Each hard geletin capsule contains:-				
		Indomethacin	IP	25	mg	
		Excipients		q.s		
		Approved colour used in empty capsule shell				

41	Ferrous Fumarate, Folic Acid,	Each hard geletin capsule contains:-				
----	-------------------------------	--------------------------------------	--	--	--	--

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	Vitamin B12,Zinc,Copper & Manganese Capsules	Ferrous Fumarate	IP	125	mg
		Folic Acid	IP	1	mg
		Vitamin B12	IP	5	mcg
		Zinc Sulphate monohydrate	IP	2.5	mg
		Copper Suphate	IP	2.5	mg
		Manganese Sulphate	IP	2.5	mg
		Excipients		qs	
		Approved colour used in empty capsule shell			

42	Ferrous Sulphate & Foilc acid Capsules	Each hard geletin sustained releasencapsule contains:-			
		Dried Ferrous Sulphate	IP	150	mg
		(In Time Release Form)			
		Folic Acid	IP	500	mcg
		Excipients		qs	
		Approved colour used in empty capsule shell			

43	Ferrous Fumarate,Folic Acid, Vitamin B12,Zinc,Copper& Manganese Capsules	Each hard geletin capsule contains:-			
		Ferrous Fumarate	IP	304	mg
		Eq. to Elemental Iron		100	mg
		Folic Acid	IP	1.5	mg
		Vitamin B12	IP	10	mcg
		Zinc Sulphate monohydrate	IP		
		Eq. to elemental zinc		15	mg
		Copper Suphate	IP	2.5	mg
		Manganese Sulphate	IP	2.5	mg
		Excipients		qs	
		Approved colour used in empty capsule shell			

44	Diphenhydramine HCl Capsules	Each hard geletin capsule contains:-			
		Diphenhydramine HCl	IP	25	mg
		Excipients		q.s	
				Approved colour used in empty capsule shell	

45	Gentamycin cream IP	Gentamycin sulphate	IP		
		eq. to Gentamycin		0.10%	w/w
		Gentamycin Base (1000 units per gm)			
		Water Miscible Base		q.s	

46	Ciprofloxacin Hcl, Fluocinolone, Clotrimazole Cream	Ciprofloxacin Hcl	IP		
		eq to Ciprofloxacin		0.50%	w/w
		Fluocinolone Acetonide	IP	0.025%	w/w
		Clotrimazole	IP	1.00%	w/w
		Preservative:			
		Sodium Methyl Paraben	IP	0.20%	w/w

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Sodium Propyl Paraben	IP	0.10%	w/w
		Cream Base		q.s	

47	Neomycin Sulphate Cream IP	Neomycin Sulphate	IP	0.50%	w/w
		(3500 Units Per Gm)			
		Suitable Cream Base		q.s	

48	Vitamin B1,Vitamin B2, Vitamin B6,Nicotinamide, Folic Acid, Calcium pantothenate, Cynocobalamin&L-lysine monohydrochloride Capsules	Each hard geletin capsule contains:-			
		Thiamine Hcl	IP	10	mg
		Riboflavin	IP	10	mg
		Pyridoxine Hcl	IP	3	mg
		Nicotinamide	IP	50	mg
		Folic Acid	IP	1000	mcg
		Calcium Pantothenate	IP	20	mg
		L-lysine Monohydrochloride	USP	150	mg
		Cynocobalamin	IP	5	mcg
		Excipients		qs	
		Approved colour used in empty capsule shell			

49	Nitrofurazone cream USP	Nitrofurazone	USP	0.20%	w/w
		Cream base		q.s	

50	Salicylic Acid Corn Caps	Each Corn Cap is Filled With Ointment			
		Salicylic Acid	IP	45.00%	w/w
		Ointment Base	qs		

51	Salicylic Acid Corn Caps	Each Corn Cap is Filled With Ointment			
		Salicylic Acid	IP	50.00%	w/w
		Ointment Base	qs		

52	Lycopene , Vitamin A, Vitamin C, Zinc Sulphate & Selenium Capsule	Each Hard Gelatin capsule contains:-			
		Lycopene 10%	USP	2	mg
		Vitamin A( as Acetate) powder form	IP	2500	IU
		Vitamin C	IP	50	mg
		Zinc Sulphate	IP	27.45	mg
		Sodium Selenate			
		Eq. to Selenium		70	mcg
		Excipients		qs	
		Approved Colour used in Capsule shell			

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
--------	--------------------------------------	-------------	---------------	----------	------

53	Lactobacillus Sporogenes, Fungal Diastase, Papain, simethicone, Vitamin B1, Vitamin B2, Vitamin B6 Niacinamide, Folic Acid, D-panthenol Capsules	Each hard geletin capsule contains:-			
		Lactobacillus Sporogenes		40x10 <sup>6</sup>	
		Fungal Diastase(1:800)	IP	25	mg
		Papain	IP	20	mg
		Simethicone	IP	40	mg
		Vitamin B1	IP	1	mg
		Vitamin B2	IP	2.5	mg
		Vitamin B6	IP	0.5	mg
		Niacinamide	IP	15	mg
		Folic Acid	IP	75	mcg
		D-panthenol	IP	1	mg
		Excipients		qs	
Approved colour used in empty capsule shell					

54	Artesunate Tablets	Each Uncoated tablet Contains:-			
		Artesunate	IP	50	mg
		Excipients		q.s	
		Approved colour used in Tablets			

55	Piracetam Tablets	Each Film coated Tablet Contains:-			
		Piracetam	IP	1200	mg
		Excipients		q.s	
		Approved colour used in Coating			

56	Mirtazapine Tablets IP	Each un coated Tablet Contains:-			
		Mirtazapine	IP	7.5	mg
		Excipients		q.s	
		Approved colour used in Tablet			

57	Mirtazapine Tablets IP	Each un coated Tablet Contains:-			
		Mirtazapine	IP	15	mg
		Excipients		q.s	
		Approved colour used in Tablet			

58	Dothiepin Hcl Tablets IP	Each Film coated Tablet Contains:-			
		Dothiepin Hcl	IP	25	mg
		Excipients		q.s	

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Approved colour used in Coating			

59	Dothiepin Hcl Tablets IP	Each Film coated Tablet Contains:-			
		Dothiepin Hcl	IP	75	mg
		Excipients		q.s	
		Approved colour used in Coating			

60	Haloperidol Tablets IP	Each un coated Tablet Contains:-			
		Haloperidol	IP	10	mg
		Excipients		q.s	
		Approved colour used in Tablet			

61	Paroxetine sustained Release Tablets IP	Each Enteric coated Sustained Release Tablet Contains:-			
		Paroxetine Hcl	IP		
		Eq. to Paroxetine		25	mg
		Excipients		q.s	
		Approved colour used in Coating			

62	Escitalopram Oxalate Tablets IP	Each Film coated Tablet Contains:-			
		Escitalopram Oxalate	IP		
		Eq. to Escitalopram		10	mg
		Excipients		q.s	
		Approved colour used in Coating			

63	Escitalopram Oxalate Tablets IP	Each Film coated Tablet Contains:-			
		Escitalopram Oxalate	IP		
		Eq. to Escitalopram		20	mg
		Excipients		q.s	
		Approved colour used in Coating			

64	Clobetasol Propionate, Gentamycin, miconazole Nitrate Cream	Clobetasol Propionate	IP	0.05%	w/w
		Gentamycin Sulphate	IP		
		eq. to Gentamycin		0.10%	w/w
		miconazole Nitrate	IP	2.00%	w/w
		Cream Base		q.s	

65	Vitamin B1, Vitamin B2, Vitamin B6, Niacinamide & Di-Calcium Phosphate capsules (for prophylactic use)	Each hard geletin capsule contains:-			
		Vitamin B1	IP	1	mg
		Vitamin B2	IP	1	mg
		Vitamin B6	IP	0.65	mg

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT,HIMACHAL PRADESH  
List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Niacinamide	IP	15	mg
		Di-calcium Phosphate	IP	50	mg
		Excipients		q.s	
		Approved colour used in empty capsule shell			

66	Nimesulide Tablets (in Betacyclodextrine)Tablets	Each un coated Tablet Contains:-			
		Nimesulide	BP	200	mg
		(in Betacyclodextrine)			
		Excipients		q.s	
		Approved colour used in Tablet			

67	Paroxetine sustained Release Tablets IP	Each Enteric coated Sustained Release Tablet Contains:-			
		Paroxetine Hcl	IP		
		Eq. to Paroxetine		12.5	mg
		Excipients		q.s	
		Approved colour used in Coating			

68	Flupentixol & Melitracen Tablets	Each Film coated Tablet Contains:-			
		Flupentixol Dihydrochloride	BP		
		Eq.to Flupentixol		0.5	mg
		Melitracen Hcl			
		Eq. to Melitracen		10	mg
		Excipients		q.s	
		Approved colour used in Coating			

69	Vitamin A,Vitamin B1, Vitamin B2,Vitamin B6, Vitamin B12,Vitamin C, Vitamin E,Vitamin D3, Niacinamide,folic acid, Calcium D-Pantothenate, Biotin,Manganese,Copper, Magnesium,Iodine,Selenium, Chromium,Molybdenum Capsules	Each hard geletin capsule contains:-			
		Vitamin A(as Acetate)	IP	5000	IU
		Thiamine Hcl	IP	10	mg
		Riboflavin	IP	10	mg
		Pyridoxine Hcl	IP	2	mg
		Cynocobalamin	IP	7.5	mcg
		Ascorbic Acid(coated)	IP	50	mg
		Vitamin D3	IP	400	IU
		Vitamin E(as Acetate)	IP	25	IU
		Niacinamide	IP	50	mg

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	(For Therapeutic Use)	Folic Acid	IP	1	mg
		Calcium D-pantothenate	IP	10	mg
		Biotin	BP	150	mcg
		Zinc(as Zinc Sulphate Monohydrate)	IP	63	mg
		Magnesium(as Magnesium Hydroxide)	IP	30	mg
		Manganese(as Manganese Sulphate)	USP	2.8	mg
		Copper(as Copper Sulphate)	IP	2	mg
		Potassium Iodide	IP		
		Eq to Iodine		150	mcg
		Selenium(as Sodium Selenate)		60	mcg
		Chromium(as Chromium Picolinate)	USP	65	mcg
		Sodium Molybdate Dihydrate	BP		
		Eq to Molybdenum		25	mcg
		Excipients		qs	
Approved colour used in empty capsule shell					

70	Salicylic Acid Corn caps	Salicylic Acid	IP	40.00%	w/w
		Excipients	qs		

71	Levofloxacin & Ornidazole Tablets	Each Film Coated Tablet Contains:-			
		Levofloxacin Hemihydrate			
		Eq.to Levofloxacin	IP	250	mg
		Ornidazole	IP	500	mg
		Excipients		q.s	
Approved colour used in Coating					

72	Ofloxacin & Tinidazole Tablets	Each Film Coated Tablet Contains:-			
		Ofloxacin	IP	200	mg
		Tinidazole	IP	600	mg
		Excipients		q.s	
Approved colour used in Coating					

73	Thiamine mononitrate, Riboflavin, Nicotinic Acid, Pyridoxine Hcl, Cyanocobalamin, Niacinamide, Calcium Pantothenate, Biotin, Folic Acid & Vitamin C Tablets	Each Film coated Tablet Contains:-			
		Thiamine mononitrate	IP	10	mg
		Riboflavin	IP	10	mg
		Nicotinic Acid	IP	25	mg
		Pyridoxine Hcl	IP	3	mg
		Cyanocobalamin	IP	15	mcg
		Niacinamide	IP	75	mg
		Calcium Pantothenate	IP	50	mg
		Biotin	BP	260	mcg
		Folic acid	IP	1.5	mg

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		vitamin C	IP	150	mg
		Excipients		q.s	
		Approved colour used in Coating			

74	Amoxicillin & Potassium Clavulanate Dispersible Tablets	Each Uncoated dispersible Tablet Contains:-			
		Amoxicillin Tryhydrate	IP		
		Eq. to Amoxicillin		200	mg
		Potassium Clavulanate Diluted	IP		
		Eq to Clavulanic acid		28.5	mg
		Excipients		q.s	

75	Amoxicillin & Potassium Clavulanate Tablets IP	Each Film coated Tablet Contains:-			
		Amoxicillin Tryhydrate	IP		
		Eq. to Amoxicillin		500	mg
		Potassium Clavulanate Diluted	IP		
		Eq to Clavulanic acid		125	mg
		Excipients		q.s	
		Approved colour used in Coating			

76	Amoxicillin & Potassium Clavulanate Tablets IP	Each Film coated Tablet Contains:-			
		Amoxicillin Tryhydrate	IP		
		Eq. to Amoxicillin		250	mg
		Potassium Clavulanate Diluted	IP		
		Eq to Clavulanic acid		125	mg
		Excipients		q.s	
		Approved colour used in Coating			

77	Fluocinolone Acetonide, Neomycin Sulphate & Clotrimazole Cream	Fluocinolone Acetonide	IP	0.01%	w/w
		Neomycin Sulphate	IP		
		eq. to Neomycin		0.35%	w/w
		Clotrimazole	IP	1.00%	w/w
		Chlorocresol(as Preservative)	IP	0.10%	w/w
		Cream Base		q.s	

78	Thiamine mononitrate, Riboflavin, Pyridoxine Hcl, Cyanocobalamin, Niacinamide, Calcium Pantothenate, Biotin, Folic Acid & Vitamin C,	Each hard geletin capsule contains:-			
		Thiamine mononitrate	IP	10	mg
		Riboflavin	IP	10	mg
		Pyridoxine Hcl	IP	3	mg
		Cyanocobalamin	IP	15	mcg

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	Zinc Sulphate Capsules (For Therapeutic Use)	Niacinamide	IP	100	mg
		Calcium Pantothenate	IP	50	mg
		Biotin	BP	100	mcg
		Folic acid	IP	1.5	mg
		vitamin C	IP	150	mg
		Zinc Sulphate Monohydrate	IP	41.4	mg
		Excipients		q.s	
		Approved colour used in empty capsule shell			

79	Amoxicillin Trihydrate, Cloxacillin Sodium & Lactic Acid bacillus Capsules	Each hard geletin capsule contains:-			
		Amoxicillin Tryhydrate	IP		
		Eq.to Amoxicillin		250	mg
		Cloxacillin Sodium	IP		
		Eq.to Cloxacillin		250	mg
		Lactic Acid Bacillus		60	million spores
		Excipients		qs	
		Approved colour used in empty capsule shell			

80	Ampicillin Trihydrate, Cloxacillin Sodium & Lactic Acid bacillus Capsules	Each hard geletin capsule contains:-			
		Ampicillin Trihydrate	IP		
		Eq.to Ampicillin		250	mg
		Cloxacillin Sodium	IP		
		Eq.to Cloxacillin		250	mg
		Lactic Acid Bacillus		60	million spores
		Excipients		qs	
		Approved colour used in empty capsule shell			

81	Roxithromycin & Ambroxol HCl Tablets	Each Film coated Tablet Contains:-			
		Roxithromycin	IP	150	mg
		Ambroxol Hcl	IP	60	mg
		Excipients		q.s	
				Approved colour used in Coating	

82	Diclofenac Potassium Tablets	Each Film Coated Tablet Contains:-			
		Diclofenac Potassium	BP	50	mg
		Excipients		q.s	
				Approved colour used in Coating	

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
83	Gamma Benzene Hexachloride Lotion USP	Gamma Benzene Hexachloride	USP	1.00%	w/v
		Emulsion Base		q.s	
84	Salicylic Acid,&Lanoline Corn Caps	Each Corn Cap is Filled With Ointment			
		Salicylic Acid	IP	50.00%	w/w
		Lanoline		10.00%	w/w
		Paraffin Base	qs		
85	Doxylamine Succinate, Pyridoxine HCl & Folic Acid Tablets	Each Enteric Coated Tablet Contains:-			
		Doxylamine Succinate	USP	20	mg
		Pyridoxine HCl	IP	20	mg
		Folic Acid	IP	5	mg
		Excipients		q.s	
86	Paracetamol Cetirizine HCl & Phenylephrine HCl Tablets	Each Uncoated tablet contains:			
		Paracetamol	IP	500	mg
		Cetirizine HCl	IP	5	mg
		Phenylephrine HCl	IP	5	mg
		Excipients		q.s.	
		Colour:Approved colour used			
87	Trimethoprim & Sulphamethoxazole Bolus (For animal use only) (Not for human use)	Each Uncoated Bolus contains:-			
		Trimethoprim	IP	200	mg
		Sulphamethoxazole	IP	1	gm
		Excipients		q.s	
88	Trimethoprim & Sulphamethoxazole Bolus (For animal use only) (Not for human use)	Each Uncoated Bolus contains:-			
		Trimethoprim	IP	400	mg
		Sulphamethoxazole	IP	2	gm
		Excipients		q.s	
89	Salicylic Acid,Lactic acid & Triclosan Cream	Salicylic Acid	IP	1.50%	w/w
		Lactic acid	IP	8.00%	w/w
		Triclosan	BP	0.10%	w/w
		In Cream Base		q.s	

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
90	Isoxsuprine HCl (SR)Tablets	Each Sustained Released Tablet Contains:-			
		Isoxsuprine HCl	IP	40	mg
		Excipients		q.s	
		Approved colour used in Coating			
91	Clotrimazole Lotion USP	Clotrimazole	IP	1%	w/v
		Chlorocresol(As Preservative)	IP	0.1%	w/v
		Lotion Base		q.s	
92	Nimesulide Tablets (in Betacyclodextrine) Tablets	Each un coated Dispersible Tablet Contains:-			
		Nimesulide (in Betacyclodextrine)	BP	100	mg
		Excipients		q.s	
		Approved colour used in Tablet			
93	Rosiglitazone Tablets	Each Film Coated Tablet Contains:-			
		Rosiglitazone maleate			
		Eq. to Rosiglitazone		2	mg
		Excipients		q.s	
Approved colour used in Coating					
94	Ofloxacin Tablets IP	Each Film Coated Tablet Contains:-			
		Ofloxacin	IP	300	mg
		Excipients		q.s	
		Approved colour used in Coating			
95	Vitamin A,Vitamin E Vitamin C,Vitamin B1, Vitamin B2,Vitamin B6, Nicotinamide, Folic Acid,Vitamin D3 Calcium Pantothenate,Zinc, Selenium,Chromium,Copper, Manganese,Phosphorous, Iodine& Potassium Capsules (For Therapeutic Use)	Each hard geletin capsule contains:-			
		Vitamin A(as Acetate)	IP	2500	IU
		Vitamin E	IP	10	mg
		Vitamin C	IP	50	mg
		Vitamin B1	IP	2	mg
		Vitamin B2	IP	3	mg
		Vitamin B6	IP	1	mg
		Vitamin D3	IP	200	IU
		Nicotinamide	IP	20	mg
		Folic Acid	IP	0.3	mg
		Copper(as Copper Sulphate)	IP	0.5	mg
		Manganese(as manganese sulphate)	USP	0.5	mg
Zinc(as Zinc Sulphate)	IP	10	mg		
Di-Basic calcium Phosphate	IP	75	mg		

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Eq.to Calcium Phosphorus		58	mg
		Potassium Iodate	IP		
		Eq.to iodine		0.1	mg
		Calcium D-Pantothenate	IP	5	mg
		Potassium Sulphate	IP		
		Eq.to Potassium		2	mg
		Excipients		qs	
		Approved colour used in empty capsule shell			

96	Ciprofloxacin Cream	Ciprofloxacin Hcl	IP		
		eq.to Ciprofloxacin		0.50%	w/w
		In Cream Base		q.s	

97	Gentamicin cream IP	Gentamicin sulphate	IP		
		eq. to Gentamycin		0.30%	w/w
		In Cream Base		q.s	

98	Vitamin A,Vitamin E Vitamin C,Vitamin B1, Vitamin B2,Vitamin B6 Vitamin B12,Nicotinamide Folic Acid, Calcium Pantothenate,Zinc, Selenium, Chromium Capsules (For Therapeutic Use)	Each hard geletin capsule contains:-			
		Vitamin A(as Acetate)	IP	5000	IU
		Vitamin E(Tocopheryl Acetate)	IP	25	IU
		Vitamin C(Coated)	IP	50	mg
		Vitamin B1	IP	10	mg
		Vitamin B2	IP	10	mg
		Vitamin B6	IP	3	mg
		Vitamin B12	IP	5	mcg
		Nicotinamide	IP	50	mg
		Folic Acid	IP	1	mg
		Calcium D-Pantothenate	IP	12.5	mg
		Zinc(as Zinc Sulphate Monohydrate)	IP	2.5	mg
		Selenium(as Sodium Selenate)		60	mcg
		Chromium(as Chromium Picolinate)		65	mcg
Excipients		qs			
	Approved colour used in empty capsule shell				

99	Carbonyl Iron, Cyanocobalamin, Foile acid,Zinc Sulphate & Ascorbic Acid Capsules	Each hard geletin capsule contains:-			
		Carbonyl Iron		100	mg
		Cynocobalamin	IP	15	mcg
		Zinc Sulphate Monohydrate	IP	61.8	mg
		Folic Acid	IP	500	mcg
		Ascorbic Acid(Coated)	IP	50	mg
	Excipients		qs		

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Approved colour used in empty capsule shell			

100	Betacarotine, Vitamin A, Vitamin E, Vitamin C, Copper, Manganese, Zinc & Selenium Capsules (For Therapeutic Use)	Each hard gelatin capsule contains:-			
		Betacarotine 20% Dispersion	BP	10	mg
		Vitamin A	IP	5000	IU
		Vitamin E (Tocopheryl Acetate)	IP	10	IU
		Vitamin C	IP	25	mg
		Copper (as Cupric Oxide)	BP	500	mcg
		Manganese (as Manganese Sulphate)	IP	500	mcg
		Zinc (as Zinc Sulphate Monohydrate)	IP	5	mg
		Selenium (as Sodium Selenate)		50	mcg
		Excipients		qs	
		Approved colour used in empty capsule shell			

101	Diclofenac Sodium Tablets IP (Not for Veterinary Use)	Each Filmcoated Tablet contains:-			
		Diclofenac Sodium	IP	50	mg
		Excipients		q.s	
		Approved colour used in Coating			

102	Diclofenac Sodium & Paracetamol Tablets IP (Not for Veterinary Use)	Each Uncoated Tablet Contains:-			
		Diclofenac Sodium	IP	50	mg
		Paracetamol	IP	325	mg
		Excipients		q.s	
		Approved colour used in Tablets			

103	Cetirizine Hydrochloride Tablets IP	Each Uncoated Tablet Contains:-			
		Cetirizine Hydrochloride	IP	10	mg
		Excipients		q.s	
		Approved colour used in Tablets			

104	Cefixime Tablets IP	Each Uncoated tablet Contains:-			
		Cefixime	IP		
		Eq. to Anhydrous Cefixime		200	mg
		Excipients		q.s	
		Approved colour used in Tablets			

105	Mometasone Furoate Cream IP	Mometasone Furoate	IP	0.1%	w/w
		Cream base		q.s	

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
106	Aceclofenac Paracetamol Tablets	Each Filmcoated tablet contains:-			
		Aceclofenac	IP	100	mg
		Paracetamol	IP	325	mg
		Excipients		q.s	
		Approved colour used in Tablets			
107	Clindamycin Phosphate Gel USP	Clindamycin Phosphate	IP		
		Eq. to Clindamycin		1%	w/w
		Gel base		q.s	
108	Amoxicillin Trihydrate Dispersible Tablets IP	Each Un- coated Dispersible tablet Contain:-			
		Amoxicillin Trihydrate	IP		
		eq. to Amoxicillin		250	mg
		Approved Colour used in tablets			
109	Ketoconazole & Prepared Coal tar Solution	Ketoconazole	IP	2%	w/v
		Prepared coal Tar	IP(1966)	2%	w/v
		Sampoo Base		q.s	
		Approved Colour(s) Only may be used			
110	Clotrimazole Cream IP	Clotrimazole	IP	1%	w/w
		Chlorocresol(As a Preservative)	IP	0.1%	w/w
		Cream Base		q.s	
111	Clobetasol Propionate, Miconazole Nitrate, Neomycin Sulphate, Zinc Sulphate Cream	Clobetasol Propionate	USP	0.05%	w/w
		Miconazole Nitrate	IP	2%	w/w
		Neomycin Sulphate	IP		
		eq. to Neomycin		0.5%	w/w
		Zinc Sulphate	IP	2%	w/w
		Chlorocresol	IP	0.1%	w/w
		(As Preservative)			
		In cream Base		q.s	
112	Hydroquinone Cream USP	Hydroquinone	USP	4%	w/w
		In cream Base		q.s	
113	Hydroquinone, Tretinoin & Mometasone Furoate Cream	Hydroquinone	USP	2%	w/w
		Tretinoin	IP	0.025%	w/w
		Mometasone Furoate	IP	0.1%	w/w
		In cream Base		q.s	

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
114	Xylometazoline HCl., Nasal Solution USP.	Xylometazoline HCl.	IP	0.1%	w/v
		Benzalkonium Chloride	IP	0.01%	w/v
		In Solution base		q.s	
115	Lornoxicam & Paracetamol Tablets	Each Film Coated Tablet Contains:-			
		Lornoxicam		8	mg
		Paracetamol	IP	325	mg
		Excipients		q.s	
		Approved colour used in Coating			
116	Beclomethasone Dipropionate, Clotrimazole & Neomycin Sulphate Cream	Beclomethasone Dipropionate	IP	0.025%	w/w
		Neomycin Sulphate	IP		
		eq.to Neomycin		0.5%	w/w
		Clotrimazole	IP	1%	w/w
		Chlorocresol(As Preservative)	IP	0.1%	w/w
		In cream Base		q.s	
117	Clobetasol Propionate, Neomycin Sulphate & Miconazole Nitrate Cream	Clobetasol Propionate	USP	0.05%	w/w
		Neomycin Sulphate	IP	0.5%	w/w
		Miconazole Nitrate	IP	2%	w/w
		In a Cream Base			
118	Diclofenac Diethylamine, Oleum Lini, Methylsalicylate, & Menthol Gel	Diclofenac Diethylamine	BP	1.16%	w/w
		eq. to Diclofenac Sodium		1%	w/w
		Oleum Lini	BP	3%	w/w
		Menthol	IP	5%	w/w
		Methyl salicylate	IP	10%	w/w
		Benzyl Alcohol(As Preservative)	IP	0.1%	w/w
		In Gel Base		q.s	
119	Povidone Iodine Ointment USP	Povidone Iodine	IP	5%	w/w
		eq. to Available Iodine (0.5% w/w)			
		Water Soluble Ointment Base		q.s.	
120	Povidone Iodine, Metronidazole & Aloe Vera Ointment	Povidone Iodine	IP	5%	w/w
		eq. to Available Iodine (0.5% w/w)			
		Metronidazole Benzoate	IP		
		eq. to Metronidazole		1%	w/w
		Aloe Vera	IP	1.5%	w/w
Water Soluble Ointment Base					
121	Silver Sulfadiazine & Chlorhexidine Gluconate Cream	Silver Sulfadiazine	USP	1%	w/w
		Chlorhexidine Gluconate Solution	IP		

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		eq. to Chlorhexidine Gluconate		0.2%	w/w
		In cream Base		q.s	

122	Clotrimazole & Beclomethasone Dipropionate Lotion	Clotrimazole	IP	1%	w/w
		Beclomethasone Dipropionate	IP	0.025%	w/w
		Lotion Base		q.s	

123	Pantoprazole & Domperidone Capsule IP	Each hard geletin capsule contains:-			
		Pantoprazole Sodium	IP		
		eq.to Pantoprazole		40	mg
		(As enteric coated Pellets)			
		Domperidone	IP	30	mg
		(Sustained release Pellets)			
		Excipients		qs	
		Approved colour used in empty capsule shell			

124	Diclofenac Diethylamine, Oleum Lini, Methylsalicylate, & Menthol Gel (NOT FOR VETERINARY USE)	Diclofenac Diethylamine	BP	1.16%	w/w
		eq. to Diclofenac Sodium		1%	w/w
		Oleum Lini	BP	3%	w/w
		Menthol	IP	0.5%	w/w
		Methyl salicylate	IP	10%	w/w
		Benzyl Alcohol(As Preservative)	IP	0.1%	w/w
		In Gel Base		q.s	

125	Beclomethasone Dipropionate, Neomycin Sulphate Cream	Beclomethasone Dipropionate	IP	0.025%	w/w
		Neomycin Sulphate	IP		
		eq.to Neomycin		0.5%	w/w
		Chlorocresol(As Preservative)	IP	0.1%	w/w
		In cream Base		q.s	

126	Miconazole Nitrate, Fluocinolone Acetonide & Neomycin Cream	Miconazole Nitrate	IP	2%	w/w
		Fluocinolone Acetonide	IP	0.01%	w/w
		Neomycin Sulphate	IP		
		eq. to Neomycin		0.5%	w/w
		Chlorocresol(As Preservative)	IP	0.1%	w/w
		In Cream base		q.s	

127	Levocetirizine Tablets IP	Each Film Coated Tablet Contains:-			
		Levocetirizine Hydrochloride	IP	5	mg
		Excipients		q.s	
		Approved colour used in Coating			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
128	Levocetirizine & Montelukast Tablets IP	Each Film Coated Tablet Contains:-			
		Levocetirizine HCl.	IP	5	mg
		Montelukast Sodium	IP		
		Eq. to Montelukast		10	mg
		Excipients		q.s	
		Approved colour used in Coating			
129	Diclofenac Potassium, Paracetamol & Chlorzoxazone Tablets (Not for Veterinary Use)	Each Uncoated Tablet contains:-			
		Diclofenac Potassium	BP	50	mg
		paracetamol	IP	325	mg
		Chlorzoxazone	USP	250	mg
		Excipients		q.s	
		Approved colour used in Tablets.			
130	Deflazacort Tablets	Each Uncoated tablet contains:-			
		Deflazacort		6	mg
		Excipients		q.s	
		Approved colour used in Tablets			
131	Calcium Citrate, Magnesium Hydroxide, Zinc Sulphate & Vitamin D3 Tablets	Each Film Coated Tablet Contains:-			
		Calcium citrate	USP	1000	mg
		Magnesium Hydroxide	IP		
		eq. to Magnesium		100	mg
		Zinc Sulphate Monohydrate	IP		
		eq. to Zinc		4	mg
		Vitamin D3	IP	200	IU
		Excipients		q.s	
		Approved colour used in Coating			
132	Telmisartan & Hydrochlorothiazide Tablets IP	Each Uncoated Tablet contains:-			
		Telmisartan	IP	40	mg
		Hydrochlorothiazide	IP	12.5	mg
		Excipients		q.s	
		Approved colour used in Tablets.			
133	Calcium with & Vitamin D3 Tablets IP	Each Film Coated Tablet Contains:-			
		Calcium Carbonate		1.25	gm
		From an organic Source (Oyster Shell)			
		eq. to Elemental Calcium		500	mg
		Vitamin D3	IP	250	IU
		Excipients		q.s	
		Approved colour used in Coating			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
134	Amlodipine & Atenolol Tablets IP	Each Uncoated Tablet Contains:-			
		Amlodipine Besilate	IP		
		eq. to Amlodipine		5	mg
		Atenolol	IP	50	mg
		Excipients		q.s	
		Approved colour used in Tablets			
135	Pantoprazole Tablets IP	Each Enteric Coated Tablet contains:-			
		Pantoprazole Sodium	IP		
		eq. to pantoprazole		40	mg
		Excipients		q.s	
		Approved colour used in Coating			
136	Paracetamol, Pheylephrine HCl., Chlorpheniramine, Meleate & Caffeine anhydrous Tablets.	Each Uncoated Tablet Contains:-			
		Paracetamol	IP	325	mg
		Phenylephrine Hydrochloride	IP	5	mg
		Chlorpheniramine Meleate	Ip	4	mg
		Caffeine Anhydrous	IP	25	mg
		Excipients		q.s	
		Approved colour used in Tablets			
137	Aceclofenac & Paracetamol Tablets	Each Uncoated Tablet Contains:-			
		Aceclofenac	IP	100	mg
		Paracetamol	IP	325	mg
		Excipients		q.s	
		Approved colour used in Tablets			
138	Paracetamol Tablets IP	Each Uncoated tablet contains:-			
		Paracetamol	IP	650	mg
		Excipients		q.s	
		Approved colour used in tablets			
139	Paracetamol Tablets IP	Each Uncoated tablet contains:-			
		Paracetamol	IP	500	mg
		Excipients		q.s	
		Approved colour used in tablets			
140	Erythromycin stearate & Bromhexine HCl Tablets	Each Film Coated Tablet Contains:-			
		Erythromycin stearate	IP		
		eq to Erythromycin		250	mg
		Bromhexine HCl	IP	8	mg

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Excipients		q.s	
		Approved colour used in Coating			
141	Erythromycin stearate & Bromhexine HCl Tablets	Each Film Coated Tablet Contains:-			
		Erythromycin stearate	IP		
		eq to Erythromycin		500	mg
		Bromhexine HCl	IP	8	mg
		Excipients		q.s	
		Approved colour used in Coating			
142	Diethyl Carbamazine Citrate & Levocetirizine HCl tablets	Each Film Coated Tablet Contains:-			
		Diethyl Carbamazine Citrate	IP	100	mg
		Levocetirizine HCl	IP	2.5	mg
		Excipients		q.s	
		Approved colour used in Coating			
143	Azithromycin Tablets IP	Each Film Coated Tablet Contains:-			
		Azithromycin	IP		
		eq. to anhydrous Azithromycin		250	mg
		Excipients		q.s	
		Approved colour used in Coating			
144	Azithromycin Tablets IP	Each Film Coated Tablet Contains:-			
		Azithromycin	IP		
		eq. to anhydrous Azithromycin		500	mg
		Excipients		q.s	
		Approved colour used in Coating			
145	Rabeprazole Sodium & Domperidone Capsule	Each hard geletin capsule contains:-			
		Rabeprazole Sodium (As enteric coated pellets)	IP	20	mg
		Domperidone (As Sustained release pellets)	IP	30	mg
		Excipients		qs	
		Approved colour used in empty capsule shell			
146	Omeprazole Capsule IP	Each hard geletin capsule contains:-			
		Omeprazole	IP	20	mg
		As enteric coated pellets			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH  
List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Excipients		qs	
		Approved colour used in empty capsule shell			

147	Omeprazole & Domperidone Capsule IP	Each hard geletin capsule contains:-			
		Omeprazole	IP	20	mg
		(As enteric coated pellets)			
		Domperidone	IP	10	mg
		(As pellets)			
		Excipients		qs	
		Approved colour used in empty capsule shell			

148	Carbonyl Iron, Zinc Sulphate & Folic Acid Capsules	Each hard gelatin capsule Contains:-			
		Carbonyl Iron			
		Eq. to Elemental Iron		100	mg
		Zinc Sulphate Monohydrate	IP	61.8	mg
		Eq. to Elemental Zinc 22.5mg)			
		Folic Acid	IP	0.5	mg
		Excipients		q.s	
		Approved colour used in Capsule shell			

149	Amoxicillin Tablets BP vet  (For animal use only) (Not for human use)	Each Uncoated tablet contains:-			
		Amoxicillin Trihydrate	IP		
		eq. to Amoxicillin		1500	mg
		Excipients		q.s	
		Approved colour used in Tablets			

150	Albendazole Bolus  (For animal use only) (Not for human use)	Each Uncoated Bolus contains:-			
		Albendazole	IP	3	gm
		Excipients		q.s	
		Approved colour used in Bolus			

151	Albendazole & Ivermectin Bolus  (For animal use only) (Not for human use)	Each Uncoated Bolus contains:-			
		Albendazole	IP	3	gm
		Ivermectin	IP	100	mg
		Excipients		q.s	
		Approved colour used in Bolus			

152	Ciprofloxacin & Tinidazole Bolus	Each Uncoated Bolus contains:-			
		Ciprofloxacin HCl	IP		
		eq. to Ciprofloxacin		1500	mg
		Tinidazole Bolus	IP	1800	mg

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	(For animal use only) (Not for human use)	Excipients Approved colour used in Bolus		q.s	
153	Enrofloxacin Bolus  (For animal use only) (Not for human use)	Each Uncoated Bolus contains:- Enrofloxacin Excipients Approved colour used in Bolus	IP(Vet.)	1500 q.s	mg
154	Fenbendazole Bolus  (For animal use only) (Not for human use)	Each Uncoated Bolus contains:- Fenbendazole Excipients Approved colour used in Bolus	IPvet	3 q.s	gm
155	Fenbendazole & Ivermectin Bolus  (For animal use only) (Not for human use)	Each Uncoated Bolus contains:- Fenbendazole Ivermactin Excipients Approved colour used in Bolus	IPvet IP	3 100 q.s	gm mg
156	Levamisole HCl & Oxyclozanide Bolus  (For animal use only) (Not for human use)	Each Uncoated Bolus contains:- Levamisole HCl & Oxyclozanide Bolus Excipients Approved colour used in Bolus	IP IP vet	2 4 q.s	gm gm
157	Meloxicam & Paracetamol Bolus  (For animal use only) (Not for human use)	Each Uncoated Bolus contains:- Meloxicam Paracetamol Excipients Approved colour used in Bolus	BP IP	100 1500 q.s	mg mg
158	Nimesulide & Paracetamol Bolus  (For animal use only) (Not for human use)	Each Uncoated Bolus contains:- Nimesulide Paracetamol Excipients Approved colour used in Bolus	BP IP	400 1500 q.s	mg mg
159	Norfloxacin & Tinidazole Bolus  (For animal use only) (Not for human use)	Each Uncoated Bolus contains:- Norfloxacin Tinidazole Excipients Approved colour used in Bolus	IP IP	1200 1800 q.s	mg mg
160	Sulphadimidine	Each Uncoated tablet contains:-			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	Tablets BP vet (For animal use only) (Not for human use)	Sulphadimidine	BP	0.5	gm
		Excipients		q.s	
		Approved colour used in Tablets			

161	Sulphadimidine Tablets BP vet (For animal use only) (Not for human use)	Each Uncoated tablet contains:-			
		Sulphadimidine	BP	5	gm
		Excipients		q.s	
		Approved colour used in Tablets			

162	Rabeprazole Sodium Tablets IP	Each Enteric Coated tablet Contains:-			
		Rabeprazole Sodium	IP	20	mg
		Excipients		q.s	
		Approved colour used in Coating			

163	Rabeprazole Sodium & Domperidone Tablets	Each Enteric Coated tablet Contains:-			
		Rabeprazole Sodium	IP	20	mg
		Domperidone	IP	10	mg
		Excipients		q.s	
		Approved colour used in Coating			

164	Pantoprazole & Domperidone Tablets	Each Enteric Coated tablet Contains:-			
		Pantoprazole Sodium	IP		
		eq. to Pantoprazole		40	mg
		Domperidone	IP	10	mg
		Excipients		q.s	
		Approved colour used in Coating			

165	Ofloxacin & Ornidazole Tablets IP	Each Film Coated tablet Contains:-			
		Ofloxacin	IP	200	mg
		Ornidazole	IP	500	mg
		Excipients		q.s	
		Approved colour used in Coating			

166	Ofloxacin Tablets IP	Each Film Coated tablet Contains:-			
		Ofloxacin	IP	400	mg
		Excipients		q.s	
		Approved colour used in Coating			

167	Ofloxacin Tablets IP	Each Film Coated tablet Contains:-			
		Ofloxacin	IP	200	mg
		Excipients		q.s	

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Approved colour used in Coating			

168	Levofloxacin Tablets IP	Each Film Coated tablet Contains:-			
		Levofloxacin Hemihydrate	IP		
		eq. to Levofloxacin		250	mg
		Excipients		q.s	
		Approved colour used in Coating			

169	Levofloxacin Tablets IP	Each Film Coated tablet Contains:-			
		Levofloxacin Hemihydrate	IP		
		eq. to Levofloxacin		500	mg
		Excipients		q.s	
		Approved colour used in Coating			

170	Glimepiride & Metformin HCl. Pioglitazone Tablets Note:- Package insert as per notification of Ministry of Health & Family Welfare No.GSR520(E)	Each Uncoated tablet Contains:-			
		Glimepiride	IP	2	mg
		Metformin Hcl.	IP	500	mg
		Pioglitazone HCl.	IP		
		eq. of Pioglitazone		15	mg
		Excipients		q.s	
Approved colour used in Tablets					

171	Glimepiride & Metformin HCl. Pioglitazone Tablets Note:- Package insert as per notification of Ministry of Health & Family Welfare No.GSR520(E)	Each Uncoated tablet Contains:-			
		Glimepiride	IP	1	mg
		Metformin Hcl.	IP	500	mg
		Pioglitazone HCl.	IP		
		eq. of Pioglitazone		15	mg
		Excipients		q.s	
Approved colour used in Tablets					

172	Glimepiride & Metformin HCl. Tablets	Each Uncoated tablet Contains:-			
		Glimepiride	IP	1	mg
		Metformin Hcl.	IP	500	mg
		Excipients		q.s	
		Approved colour used in Tablets			

173	Glimepiride & Metformin HCl. Tablets	Each Uncoated tablet Contains:-			
		Glimepiride	IP	2	mg
		Metformin Hcl.	IP	500	mg
		Excipients		q.s	
		Approved colour used in Tablets			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
174	Clobetasol Propionate Cream IP	Clobetasol Propionate	IP	0.05%	w/w
		Preservatives:-			
		Methyl Paraben	IP	0.08%	w/w
		Propyl Paraben	IP	0.04%	w/w
		In Cream base		q.s	
175	Cinnarizine Tablets IP	Each Filmcoated tablet Contains:-			
		Cinnarizine	IP	25	mg
		Excipients		q.s	
		Approved colour used in Tablets			
176	Ciprofloxacin Tablets IP	Each Film Coated tablet Contains:-			
		Ciprofloxacin HCl.	IP		
		eq. to Ciprofloxacin		250	mg
		Excipients		q.s	
		Approved colour used in Coating			
177	Ciprofloxacin Tablets IP	Each Film Coated tablet Contains:-			
		Ciprofloxacin HCl.	IP		
		eq. to Ciprofloxacin		500	mg
		Excipients		q.s	
		Approved colour used in Coating			
178	Aceclofenac, Paracetamol & Chlorzoxazone Tablets	Each Uncoated tablet Contains:-			
		Aceclofenac	IP	100	mg
		Paracetamol	IP	325	mg
		Chlorzoxazone	USP	250	mg
		Excipients		q.s	
		Approved colour used in Tablets			
179	Aciclovir Tablets IP	Each Uncoated tablet Contains:-			
		Aciclovir	IP	200	mg
		Excipients		q.s	
		Approved colour used in Tablets			
180	Aciclovir Tablets IP	Each Uncoated tablet Contains:-			
		Aciclovir	IP	400	mg
		Excipients		q.s	
		Approved colour used in Tablets			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
181	Atenolol Tablets IP	Each Uncoated tablet Contains:-			
		Atenolol	IP	50	mg
		Excipients		q.s	
		Approved colour used in Tablets			
182	Aciclovir Tablets IP	Each Uncoated tablet Contains:-			
		Aciclovir	IP	800	mg
		Excipients		q.s	
		Approved colour used in Tablets			
183	Amlodipine Tablets IP	Each Uncoated tablet Contains:-			
		Amlodipine Besilate	IP		
		eq. to Amlodipine		5	mg
		Excipients		q.s	
184	Mupirocin Ointment IP	Mupirocin	IP	2%	w/w
		Ointment Base		q.s	
185	Ofloxacin & Cefixime Tablets	Each Filmcoated tablet Contains:-			
		Ofloxacin	IP	200	mg
		Cefixime	IP		
		eq. to anhydrous Cefixime		200	mg
		Excipients		q.s	
186	Gliclazide(MR) & Metformin HCl.(ER) Tablets	Each Uncoated tablet Contains:-			
		Gliclazide(MR)	IP	80	mg
		Metformin HCl.(ER)	IP	500	mg
		Excipients		q.s	
187	Levocetirizine Tablets IP	Each Uncoated tablet Contains:-			
		Levocetirizine HCl.	IP	5	mg
		Excipients		q.s	
		Approved colour used in Tablets			
188	Glibenclamide & Metformin HCl. Tablets	Each Uncoated tablet Contains:-			
		Glibenclamide	IP	5	mg
		Metformin HCl.	IP	500	mg
		Excipients		q.s	
189	Diltiazem Tablets IP	Each Uncoated tablet Contains:-			
		Diltiazem HCl.	IP	30	mg

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Excipients		q.s	
		Approved colour used in Tablets			
190	Diltiazem Tablets IP	Each Uncoated tablet Contains:-			
		Diltiazem HCl.	IP	60	mg
		Excipients		q.s	
		Approved colour used in Tablets			
191	Cinnarizine Tablets IP	Each Uncoated tablet Contains:-			
		Cinnarizine	IP	25	mg
		Excipients		q.s	
		Approved colour used in Coating			
192	Atenolol Tablets IP	Each Uncoated tablet Contains:-			
		Atenolol	IP	25	mg
		Excipients		q.s	
		Approved colour used in Tablets			
193	Amitriptyline Tablets IP	Each Filmcoated tablet Contains:-			
		Amitriptyline HCl.	IP	10	mg
		Excipients		q.s	
		Approved colour used in Coating			
194	Amitriptyline Tablets IP	Each Filmcoated tablet Contains:-			
		Amitriptyline HCl.	IP	25	mg
		Excipients		q.s	
		Approved colour used in Coating			
195	Amlodipine Tablets IP	Each Uncoated tablet Contains:-			
		Amlodipine Besilate	IP		
		eq. to Amlodipine		2.5	mg
		Excipients		q.s	
		Approved colour used in Tablets			
196	Simvastatin Tablet BP	Each Uncoated tablet contains:-			
		Simvastatin	BP	10	mg
		Excipients		qs	
		Approved colour used in Tablet			
197	Metformin Hydrochloride Tablets IP	Each Uncoated Tablets Contains:-			
		Metformin Hydrochloride	IP	500	mg
		Excipients		qs	
		Approved colour used in Tablets			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
198	Losartan Potassium Tablets IP	Each Film coated Tablets Contains:-			
		Losartan Potassium	IP	25	mg
		Excipients		q.s	
		Approved colour used in Coating			

199	Losartan Potassium Tablets IP	Each Film coated Tablets Contains:-			
		Losartan Potassium	IP	50	mg
		Excipients		q.s	
		Approved colour used in Coating			

200	Losartan Potassium & Hydrochlorothiazide Tablets IP.	Each Filmcoated Tablets Contains:-			
		Losartan Potassium	IP	50	mg
		Hydrochlorothiazide	IP	12.5	mg
		Excipients		q.s	
		Approved colour used in Coating			

201	Glimepiride Tablet IP	Each Uncoated Tablets Contains:-			
		Glimepiride	IP	1	mg
		Excipients		q.s	
		Approved colour used in Tablet			

202	Glimepiride Tablet IP	Each Uncoated Tablets Contains:-			
		Glimepiride	IP	2	mg
		Excipients		q.s	
		Approved colour used in Tablet			

203	Atorvastatin Calcium Tablets IP	Each Uncoated tablet contains:-			
		Atorvastatin Calcium	IP		
		eq. to Atorvastatin		20	mg
		Excipients		q.s	
		Approved colour used in tablets			

204	Atorvastatin Calcium Tablets IP	Each Uncoated tablet contains:-			
		Atorvastatin Calcium	IP		
		eq. to Atorvastatin		5	mg
		Excipients		q.s	
		Approved colour used in tablets			

205	Atorvastatin Calcium Tablets IP	Each Uncoated tablet contains:-			
		Atorvastatin Calcium	IP		
		eq. to Atorvastatin		10	mg
		Excipients		q.s	

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Approved colour used in tablets			

206	Rabeprazole Sodium(EC) & Itopride Hydrochloride(SR) Capsules	Each hard gelatin capsule contains:			
		Rabeprazole Sodium (As Enteric coated Pellets)	IP	20	mg
		Itopride Hydrochloride (As Sustained release pellets)		150	mg
		Excipients		q.s	
		Approved colour used in Empty cap. Shells			

207	Voglibose Tablets IP	Each Uncoated tablet contains:-			
		Voglibose	IP	0.2	mg
		Excipients		q.s	
		Approved colour used in tablets			

208	Voglibose Tablets IP	Each Uncoated tablet contains:-			
		Voglibose	IP	0.3	mg
		Excipients		q.s	
		Approved colour used in tablets			

209	Voglibose & Metformin Tablets	Each Uncoated tablet contains:-			
		Voglibose	IP	0.2	mg
		Metformin	IP	500	mg
		Excipients		q.s	
		Approved colour used in tablets			

210	Methylcobalamin, Vit.A, Vit.D3, Vit.E, Vit.B1, Riboflavin, B6., Niacinamide, Calcium Pantothenate, Vit.C, Folic Acid, Biotin,	Each Filmcoated Tablet Contains:-			
		Methylcobalamin	IP	500	mcg
		Vit.A (Acetate)	IP	5000	IU
		Vit.D3	IP	400	IU
		Vit.E (50%)	IP	25	IU
		Vit.B1	IP	10	mg

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	L-Glutamic Acid, DI-Methionine, Magnesium Oxide manganese, Copper, Zinc, Chromium, Selenium Tablets	Riboflavin	IP	10	mg
		Vit.B6	IP	3	mg
		Niacinamide	IP	50	mg
		Calcium Pantothenate	IP	12.5	mg
		Vit. C (Coated)	IP	100	mg
		Folic Acid	IP	1500	mcg
		Biotin	BP	60	mcg
		L-Glutamic Acid	IP	100	mg
		DI-Methionine	IP	25	mg
		Magnesium Oxide	IP	30	mg
		Manganese Sulphate	IP		
		eq. to Manganese		2.5	mg
		Copper Sulphate Anhydrous	BP	2.5	mg
		Zinc Sulphate Monohydrate	IP		
		eq.to Zinc		22.5	mg
		Chromium Picolenate	BP		
		eq. to Chromium		100	mcg
		Sodium Selenite	IP		
		eq. to Selenium		60	mcg
		Excipient	IP	q.s	
		Approved colour used in Coating.			

211	Metformin(SR) & Voglibose Tablets	Each Uncoated tablet contains:-			
		Voglibose	IP	0.3	mg
		Metformin (SR)	IP	500	mg
		Excipients		q.s	
		Approved colour used in Tablet			

212	Clopidogrel Bisulphate Tablets IP	Each Filmcoated Tablet Contains:-			
		Clopidogrel Bisulphate	IP		
		Eq. to Clopidogrel		75	mg
		Excipients		q.s	
		Approved colour used in Coating			

213	Betahistine Hydrochloride Tablets IP	Each Uncoated Tablets Contains:-			
		Betahistine Hydrochloride	IP	8	mg
		Excipients		qs	
		Approved colour used in Tablets			

214	Betahistine Hydrochloride Tablets IP	Each Uncoated Tablets Contains:-			
		Betahistine Hydrochloride	IP	16	mg

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH  
List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Excipients		qs	
		Approved colour used in Tablets			
215	Methylcobalamin, Alpha Lipoic Acid, Benfotiamine, Vit.B6, Biotin & Folic Acid Capsules	Each Hard Gelatin Cap. Shell Contains:-			
		Methylcobalamin	IP	1500	mcg
		Alpha Lipoic Acid	USP	200	mg
		Benfotiamine		50	mg
		Vit B6	IP	3	mg
		Biotin	BP	5	mg
		Foile Acid	IP	1.5	mg
		Approved colour used in Cap. Shell.			
216	Ramipril Tablets IP	Each Uncoated tablet contains:-			
		Ramipril	IP	2.5	mg
		Excipients		q.s	
		Approved colour used in Tablet			
217	Ramipril Tablets IP	Each Uncoated tablet contains:-			
		Ramipril	IP	5	mg
		Excipients		q.s	
		Approved colour used in Tablet			
218	Paracetamol, Diclofenac Potassium & Serratiopeptidase Tablets (Not for Veterinary Use)	Each Filmcoated tablet contains:-			
		Paracetamol	IP	325	mg
		Diclofenac Potassium	BP	50	mg
		Serratiopeptidase	IP	10	mg
		(Eq. to 20000 units of Enzymatic activity)			
		Excipients		q.s	
		Approved colour used in Coating			
219	Metoprolol Tablets IP	Each Uncoated tablet contains:-			
		Metoprolol Tartrate	IP	25	mg
		Excipients		q.s	
		Approved colour used in Tablet			
220	Metoprolol Tablets IP	Each Uncoated tablet contains:-			
		Metoprolol Tartrate	IP	50	mg
		Excipients		q.s	
		Approved colour used in Tablet			
221	Diclofenac Sodium Tablets IP (Not for Veterinary Use)	Each Entericcoated tablet contains:-			
		Diclofenac Sodium	IP	50	mg
		Excipients		q.s	

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Approved colour used in Coating			
222	Ondansetron Tablets IP	Each un-coated Tablets Contains:-			
		Ondansetron	IP	4	mg
		Excipients		q.s	
		Approved colour used in Coating			
223	Methylcobalamin Tablets	Each Filmcoated Tablets Contains:-			
		Methylcobalamin	IP	1500	mcg
		Excipients		q.s	
		Approved colour used in Coating			
224	Methylprednisolone Tablets IP	Each Uncoated Tablets Contains:-			
		Methylprednisolone	IP	4	mg
		Excipients		q.s	
		Approved colour used in Tablet			
225	Methylprednisolone Tablets IP	Each Uncoated Tablets Contains:-			
		Methylprednisolone	IP	16	mg
		Excipients		q.s	
		Approved colour used in Tablet			
226	Enalapril Maleate Tablets IP	Each Uncoated tablet contains:-			
		Enalapril Maleate	IP	5	mg
		Excipients		q.s	
		Approved colour used in tablets			
227	Cefpodoxime Proxetil Tablets IP	Each Uncoated Tablets Contains:-			
		Cefpodoxime Proxetil	IP		
		Eq. to Cefpodoxime		50	mg
		Excipients		q.s	
		Approved colour used in Tablets			
228	Cefpodoxime Proxetil Tablets IP	Each Uncoated Tablets Contains:-			
		Cefpodoxime Proxetil	IP		
		Eq. to Cefpodoxime		100	mg
		Excipients		q.s	
		Approved colour used in Tablets			
229	Cefpodoxime Proxetil Tablets IP	Each Uncoated Tablets Contains:-			
		Cefpodoxime Proxetil	IP		
		Eq. to Cefpodoxime		200	mg

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Excipients		q.s	
		Approved colour used in Tablets			
230	Cefixime Tablets IP	Each Uncoated Tablets Contains:-			
		Cefixime	IP		
		Eq. to Anhydrous Cefixime		50	mg
		Excipients		q.s	
		Approved colour used in Tablets			
231	Cefixime Tablets IP	Each Uncoated Tablets Contains:-			
		Cefixime	IP		
		Eq. to Anhydrous Cefixime		100	mg
		Excipients		q.s	
		Approved colour used in Tablets			
232	Telmisartan Tablets IP	Each Uncoated Tablets Contains:-			
		Telmisartan	IP	40	mg
		Excipients		qs	
		Approved colour used in Tablets			
233	Pioglitazone Tablets IP Note:- Package insert as per notification of Ministry of Health & Family Welfare No.GSR520(E)	Each Uncoated tablet contains:-			
		Pioglitazone HCl	IP		
		eq. to Pioglitazone		15	mg
		Excipients		q.s	
		Approved colour used in tablets			
234	Pioglitazone Tablets IP Note:- Package insert as per notification of Ministry of Health & Family Welfare No.GSR520(E)	Each Uncoated tablet contains:-			
		Pioglitazone HCl	IP		
		eq. to Pioglitazone		30	mg
		Excipients		q.s	
		Approved colour used in tablets			
235	Rosuvastatin Tablets IP	Each Uncoated Tablets Contains:-			
		Rosuvastatin Calcium	IP		
		eq. to Rosuvastatin		10	mg
		Excipients		q.s	
		Approved colour used in Tablets			
236	Rosuvastatin Tablets IP	Each Uncoated Tablets Contains:-			
		Rosuvastatin Calcium	IP		
		eq. to Rosuvastatin		20	mg
		Excipients		q.s	

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH  
List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Approved colour used in Tablets			
237	Serratiopeptidase Tablets IP	Each Enteric coated tablets Contains:-			
		Serratiopeptidase (20,000 Enzymatic Units)	IP	10	mg
		Excipients		q.s..	
		Approved Colour used in Coating			
238	Serratiopeptidase Tablets IP	Each Enteric coated tablets Contains:-			
		Serratiopeptidase (40,000 Enzymatic Units)	IP	20	mg
		Excipients		q.s..	
		Approved Colour used in Coating			
239	Telmisartan & Amlodipine Besilate Tablets	Each Uncoated Tablet contains:-			
		Telmisartan	IP	40	mg
		Amlodipine Besilate eq. to Amlodipine	IP	5	mg
		Excipients		q.s	
		Approved colour used in Tablets.			
240	Nimesulide Tablets Not for Children below 12years of age	Each Uncoated Tablets Contains:-			
		Nimesulide	BP	100	mg
		Excipients		q.s..	
		Approved Colour used in tablets			
241	Metformin Tablets IP 500mg (SR)	Each Uncoated Sustained Release Tablets Contains:-			
		Metformin HCl	IP	500	mg
		Excipients		q.s	
		Approved colour used in Tablets			
242	Metformin Tablets IP 1000mg (SR)	Each Uncoated Sustained Release Tablets Contains:-			
		Metformin HCl	IP	1000	mg
		Excipients		q.s	
		Approved colour used in Tablets			
243	Mefenamic Acid & Dicyclomine HCl. Tablets IP	Each Uncoated Tablets Contains:-			
		Mefenamic Acid	IP	250	mg
		Dicyclomine HCl.	IP	10	mg
		Excipients		q.s..	
		Approved Colour used in Tablets			
244	Gliclazide Tablets IP	Each Uncoated Tablets Contains:-			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Gliclazide	IP	80	mg
		Excipients		qs	
		Approved colour used in Tablets			
245	Dicyclomine HCl & Paracetamol Tablets	Each Uncoated Tablet contains:-			
		Dicyclomine HCl	IP	20	mg
		paracetamol	IP	325	mg
		Excipients		q.s	
		Approved colour used in Tablets.			
246	Dexamethasone Tablets IP	Each Uncoated Tablet contains:-			
		Dexamethasone	IP	0.5	mg
		Excipients		q.s	
		Approved colour used in Tablets.			
247	Clopidogrel Bisulphate & Asprin Tablets	Each Filmcoated Tablets Contains:-			
		Clopidogrel Bisulphate	IP		
		Eq. to Clopidogrel		75	mg
		Asprin	IP	150	mg
		Excipients		q.s..	
		Approved Colour used in Coating			
248	Betamethasone Tablets IP	Each Uncoated Tablets Contains:-			
		Betamethasone	IP	0.5	mg
		Excipients		q.s	
		Approved colour used in Tablets			
249	Aceclofenac & Thiocolchicoside Tablets	Each Filmcoated Tablets Contains:-			
		Aceclofenac	IP	100	mg
		Thiocolchicoside		4	mg
		Excipients		q.s	
		Approved colour used in Coating			
250	Aceclofenac & Thiocolchicoside Tablets	Each Filmcoated Tablets Contains:-			
		Aceclofenac	IP	100	mg
		Thiocolchicoside	IP	8	mg
		Excipients		q.s	
		Approved colour used in Coating			
251	Calamine, Zinc Oxide, Bentonite, Glycerin & Sodium Citrate Lotion	Calamine	IP	15%	w/v
		Zinc Oxide	IP	5%	w/v
		Bentonite	IP	3%	w/v
		Glycerin	IP	5%	w/v
		Sodium Citrate	IP	0.05%	w/v
		Lotion Base		q.s	

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH  
List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
252	Ursodeoxycholic Acid Tablets IP	Each Uncoated tablet contains:-			
		Ursodeoxycholic Acid	IP	150	mg
		Excipients		q.s	
		Approved colour used in tablets			
253	Ursodeoxycholic Acid Tablets IP	Each Uncoated tablet contains:-			
		Ursodeoxycholic Acid	IP	300	mg
		Excipients		q.s	
		Approved colour used in tablets			
254	Linezolid Tablets IP	Each Uncoated Tablets Contains:-			
		Linezolid	IP	600	mg
		Excipients		q.s	
		Approved colour used in Tablets			
255	Carvedilol Tablets IP	Each Uncoated Tablets Contains:-			
		Carvedilol	IP	3.125	mg
		Excipients		q.s	
		Approved colour used in Tablets			
256	Calcium with & Vitamin D3 Tablets IP	Each Uncoated Tablet Contains:-			
		Calcium Carbonate		1.25	gm
		From an organic Source (Oyster Shell)			
		eq. to Elemental Calcium		500	mg
		Vitamin D3	IP	250	IU
		Excipients		q.s	
257	Acarbose Tablets IP	Each Uncoated Tablets Contains:-			
		Acarbose	IP	25	mg
		Excipients		qs	
		Approved colour used in Tablets			
258	Acarbose Tablets IP	Each Uncoated Tablets Contains:-			
		Acarbose	IP	50	mg
		Excipients		qs	
		Approved colour used in Tablets			
259	Paracetamol &	Each Uncoated Tablets Contains:-			

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	Caffeine Tablets IP	Paracetamol	IP	325	mg
		Caffeine (Anhydrous )	IP	25	mg
		Excipients		q.s	
		Approved colour used in Tablets			

260	Paracetamol Cetirizine HCl & Phenylephrine HCl Tablets	Each Uncoated tablet contains:			
		Paracetamol	IP	325	mg
		Cetirizine HCl	IP	5	mg
		Phenylephrine HCl	IP	5	mg
		Excipients		q.s.	
		Colour:Approved colour used			

261	Tizanidine HCl & Nimesulide Tablets <b>Not for children below 12 years of age.</b>	Each Uncoated Tablets Contains:-			
		Tizanidine HCl	IP		
		Eq. to Tizanidine		2	mg
		Nimesulide	BP	100	mg
		Excipients		q.s	
		Approved colour used in Tablets			

262	Nimesulide Paracetamol & Chlorzoxazone Tablets <b>Not for children below 12 years of age.</b>	Each Uncoated Tablet contains:-			
		Nimesulide	BP	100	mg
		paracetamol	IP	325	mg
		Chlorzoxazone	USP	250	mg
		Excipients		q.s	
		Approved colour used in Tablets.			

263	Lactic acid Bacillus Tablets	Each Uncoated Tablets Contains:-			
		Lactic acid Bacillus		100	Millin
		Excipients		q.s	Spores
		Approved colour used in Tablets			

264	Iron(III) Hydroxide polymaltose Complex & Folic Acid Tablets	Each Uncoated Chewable Tablets contains:-			
		Iron(III) Hydroxide polymaltose Complex			
		Eq. To Elemental Iron		100	mg
		Folic Acid	IP	350	mcg
		Excipients		q.s	
		Approved colour used in Tablets			

265	Dextromethorphan HBr, CPM & Phenylephrine HCl Tablets	Each Uncoated Tablets Contains:-			
		Dextromethorphan HBr,	IP	10	mg
		Phenylephrine HCl	IP	5	mg
		Chlorpheniramine Maleate	IP	2	mg
		Excipients		q.s	

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Approved colour used in Tablets			

266	Ciprofloxacin HCl & Tinidazole Tablets	Each Film coated tablet contains:-			
		Ciprofloxacin HCl	IP		
		eq. to Ciprofloxacin		500	mg
		Tinidazole	IP	600	mg
		Excipients		q.s	
		Approved colour used in Coating			

267	Carbonyl Iron, Zinc Sulphate & Folic Acid Capsules	Each hard gelatin capsule Contains:-			
		Carbonyl Iron			
		Eq. to Elemental Iron		50	mg
		Zinc Sulphate Monohydrate	IP	61.8	mg
		Eq. to Elemental Zinc 22.5mg)			
		Folic Acid	IP	0.5	mg
		Excipients		q.s	
		Approved colour used in Capsule shell			

268	Aceclofenac and Serratiopeptidase Tablets	Each Film Coated Tablet Contains:-			
		Aceclofenac	IP	100	mg
		Serratiopeptidase(As enteric coated granules)	IP	15	mg
		(30000 enzymatic units of serratiopeptidase)			
		Excipients		q.s	
		Approved colour used in Coating			

269	Beclomethasone Dipropionate & Clotrimazole Cream	Beclomethasone Dipropionate	IP	0.025%	w/w
		Clotrimazole	IP	1%	w/w
		Chlorocresol(As Preservative)	IP	0.1%	w/w
		In cream Base		q.s	

270	Clindamycin Phosphate & Nicotinamide Gel	Clindamycin Phosphate	BP		
		Eq. to Clindamycin		1%	w/w
		Nicotinamide	IP	4%	w/w
		Gel base		q.s	

271	Urea, Lactic Acid , Propylene Glycol & Liquid Paraffin Cream	Urea	IP	10%	w/w
		Lactic Acid	IP	10%	w/w
		Propylene Glycol	IP	10%	w/w
		Liquid Paraffin	IP	10%	w/w
		Cream Base		qs	

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
272	Diclofenac Diethylamine, Oleum Lini, Methylsalicylate, Menthol & Capsaicin Gel.	Diclofenac Diethylamine	BP	1.16%	w/w
		eq. to Diclofenac Sodium		1%	w/w
		Oleum Lini	BP	3%	w/w
		Menthol	IP	5%	w/w
		Methyl salicylate	IP	10%	w/w
		Capsaicin	USP	0.025%	w/w
		Benzyl Alcohol(As Preservative)	IP	1%	w/w
		In Gel Base		q.s	
273	Ketoconazole Shampoo	Ketoconazole	IP	2%	w/w
		Shampoo Base		qs	
		Apprved Colour used			
274	Permethrin Lotion	Permethrin		5%	w/v
		Formaldehyde Solution (as Preservative)	BP	0.1%	w/v
		Lotion Base		q.s	
275	Permethrin Cream	Permethrin		5%	w/v
		Formaldehyde Solution (as Preservative)	BP	0.1%	w/v
		Cream Base		q.s	
276	Loperamide Tablets IP	Each Uncoated Tablets Contains:-			
		Loperamide HCl.	IP	2	mg
		Excipients		qs	
		Approved colour used in Tablets			
277	Levocetirizine HCl.& Montelukast Sodium Dispersible Tablet	Each Dispersible tablet contains:-			
		Levocetirizine HCL.	IP	2.5	mg
		Montelukast Sodium	IP		
		eq. to montelukast		4	mg
		Excipients		q.s	
		Approved Colour used in Tablets			
278	Fexofenadine HCl.Tablets IP	Each Filmcoated tablet contains:-			
		Fexofenadine HCl.	IP	180	mg
		Excipients		q.s	
		Approved Colour used in Coating			
279	Fluconazole Tablet IP	Each Uncoated tablet contains:-			
		Fluconazole	IP	150	mg
		Excipients		q.s	

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Approved Colour used in Tablet			
280	Doxycycline Hyclate Tablets USP	Each FilmCoated tablet contains:-			
		Doxycycline Hyclate	IP		
		eq. to Doxycycline		100	mg
		Excipients		q.s	
		Approved Colour used in Coating			
281	Bisacodyl Tablets IP	Each Enteric Coated tablet contains:-			
		Bisacodyl	IP	5	mg
		Excipients		q.s	
		Approved Colour used in Coating			
282	Cefuroxime Axetil Tablets IP	Each Filmcoated tablet contains:-			
		Cefuroxime Axetil	IP		
		eq.to Cefuroxime		250	mg
		Excipients		q.s	
		Approved colour used in Coating			
283	Cefuroxime Axetil Tablets IP	Each Filmcoated tablet contains:-			
		Cefuroxime Axetil	IP		
		eq.to Cefuroxime		500	mg
		Excipients		q.s	
		Approved colour used in Coating			
284	Loperamide Capsules	Each Hard Gelatin Capsules Contains:-			
		Loperamide HCl.	IP	2	mg
		Excipients		qs	
		Approved colour used in Capsule shell			
285	Methylcobalamin, Alpha Lipoic Acid, Biotin, Pyridoxine & Folic Acid Capsules	Each hard gelatin Capsule contains:-			
		Methylcobalamin	IP	1500	mcg
		Alpha Lipoic Acid	USP	200	mcg
		Biotin	BP	30	mcg
		Pyridoxine	IP	3	mg
		Foile Acid	IP	1500	mcg
		Excipients		q.s	
		Approved colour used in Capsule shell.			
286	Benzoyl Peroxide Cream IP	Composition:-			
		Benzoyl Peroxide	IP	2.5%	w/w
		Cream Base		q.s	

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
287	Clindamycin Phosphate & Adapalene Gel	Composition			
		Clindamycin Phosphate	IP		
		eq.to Clindamycin		1%	w/w
		Adapalene		0.1%	w/w
		In Gel base		q.s	

288	Fusidic Acid Cream IP	Composition:-			
		Fusidic Acid	IP	2%	w/w
		Potassium Sorbate (As a Preservative)	BP	0.275%	w/w
		Cream Base		q.s	

289	Tacrolimus Cream	Composition:-			
		Tacrolimus	USP	0.03%	w/w
		Chlorocresol (As preservative)	IP	0.1%	w/w
		Cream Base		q.s	

290	Itraconazole Capsules BP	Each Hard gelatin Capsule Contains:-			
		Itraconazole (In the form of Pellets)	BP	100	mg
		Excipients		q.s	
		Approved colour used in Capsule Shell			

291	Telmisartan Tablets IP	Each Uncoated Tablets Contains:-			
		Telmisartan	IP	20	mg
		Excipients		qs	
		Approved colour used in Tablets			

292	Etoricoxib Tablets IP	Each Uncoated tablet contains:-			
		Etoricoxib	IP	60	mg
		Excipients		q.s	
		Approved colour used in Tablets			

293	Etoricoxib Tablets IP	Each Uncoated tablet contains:-			
		Etoricoxib	IP	90	mg
		Excipients		q.s	
		Approved colour used in Tablets			

294	Etoricoxib Tablets IP	Each Uncoated tablet contains:-			
		Etoricoxib	IP	120	mg
		Excipients		q.s	

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Approved colour used in Tablets			

295	Atorvastatin Calcium Tablets IP	Each Uncoated Tablets Contains:-			
		Atorvastatin Calcium	IP		
		eq. to Atorvastatin		40	mg
		Excipients		qs	
		Approved colour used in Tablets			

296	Telmisartan & Amlodipine Besilate Tablets IP	Each Uncoated Tablet Contains:-			
		Telmisartan	IP	80	mg
		Amlodipine Besilate	IP		
		eq. to Amlodipine		5	mg
		Excipients		qs	
Approved colour used in Tablets					

297	Diclofenac sodium & Serratiopeptidase Tablets (Not for Veterinary Use)	Each Enteric coated tablet contains:-			
		Diclofenac sodium	IP	50	mg
		Serratiopeptidase (eq. to 20,000 Enzymatic units)	IP	10	mg
		Excipients		q.s	
		Approved colour used in Coating			

298	Aceclofenac, Methyl salicylate, Menthol, Linseed Oil & Capsaicin Gel	Composition			
		Aceclofeanc	IP	1.5%	w/w
		Methyl salicylate	IP	10%	w/w
		Menthol	IP	5%	w/w
		Linseed Oil	BP	3%	w/w
		capsaicin	USP	0.025%	w/w
		Benzyl alcohol (As a Preservative)	IP	1%	w/w
		In Gel base		q.s	

299	Aceclofenac(SR) & Rabeprazole sodium(EC) Capsules	Each Hard Gelatin capsule contains:-			
		Aceclofenac (As Sustained Release Pellets)	IP	200	mg
		Rabeprazole sodium (As Enteric coated pellets)	IP	20	mg
		Excipients		q.s	
		Approved Colour used in Capsule shell			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
300	Rosuvastatin Tablets IP	Each Uncoated tablet contains:-			
		Rosuvastatin Calcium	IP		
		Rosuvastatin		5	mg
		Excipients		q.s	
		Approved colour used in Tablets			
301	Cefixime & Ofloxacin Tablets	Each Uncoated tablet contains:-			
		Cefixime	IP		
		eq. to Anhydrous Cefixime		100	mg
		Ofloxacin	IP	100	mg
		Excipients		q.s	
Approved colour used in Tablets					
302	Ibuprofen Gel IP	Ibuprofen	IP	15%	w/w
		Preservative :-			
		Propyl Paraben Sodium	IP	0.1%	
		Methyl Paraben Sodium	IP	0.15%	
		Gel Base		qs	
303	Miconazole Nitrate Cream IP	Miconazole Nitrate	IP	2%	w/w
		Chlorocresol (As Preservative)	IP	0.1%	w/w
		Cream Base		q.s.	
304	Tamsulosin (MR) & Dutasteride Tablets	Each Uncoated Tablet contains:-			
		Tamsulosin (MR)	IP	0.4	mg
		Dutasteride	IP	0.5	mg
		Excipients		q.s	
		Approved colour used in Tablets.			
305	Telmisartan Tablets IP	Each Uncoated Tablets Contains:-			
		Telmisartan	IP	80	mg
		Excipients		qs	
		Approved colour used in Tablets			
306	Telmisartan & Metoprolol succinate(ER) Tablets	Each Uncoated Tablet contains:-			
		Telmisartan	IP	40	mg
		Metoprolol succinate (ER)	IP	50	mg
		Excipients		q.s	

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Approved colour used in Tablets.			

307	Telmisartan & Hydrochlorothiazide Tablets IP	Each Uncoated Tablet contains:-			
		Telmisartan	IP	80	mg
		Hydrochlorothiazide	IP	12.5	mg
		Excipients		q.s	
		Approved colour used in Tablets.			

308	Terbinafine Tablets IP	Each Uncoated tablet Contains:-			
		Terbinafine HCl	IP		
		Eq. to Terbinafine		250	mg
		Excipients		q.s	
		Approved colour used in Tablets			

309	Nimesulide & Paracetamol Tablets (Not for Below 12years age of Children)	Each Uncoated Tablet Contains:-			
		Nimesulide	BP	100	mg
		Paracetamol	IP	325	mg
		Excipients		q.s	
		Approved colour used in Tablets			

310	Metformin HCl & Voglibose Tablets	Each Uncoated tablet contains:-			
		Voglibose	IP	0.3	mg
		Metformin HCl	IP	500	mg
		Excipients		q.s	
		Approved colour used in Tablet			

311	Metoprolol succinate Extended Release Tablets IP	Each Uncoated Extended Release Tablets contains			
		Metoprolol succinate	IP	25	mg
		Excipients		q.s	
		Approved Colour used in Tablets			

312	Metoprolol succinate Extended Release Tablets IP	Each Uncoated Extended Release Tablets contains			
		Metoprolol succinate	IP	50	mg
		Excipients		q.s	
		Approved Colour used in Tablets			

313	Metoprolol succinate Extended Release Tablets IP	Each Uncoated Extended Release Tablets contains			
		Metoprolol succinate	IP	100	mg
		Excipients		q.s	
		Approved Colour used in Tablets			

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
--------	--------------------------------------	-------------	---------------	----------	------

314	Gliclazide & Metformin HCl. Tablets	Each Uncoated tablet Contains:-			
		Gliclazide	IP	80	mg
		Metformin HCl.	IP	500	mg
		Excipients		q.s	
		Approved colour used in Tablets			

315	Febuxostat Tablets	Each Filmcoated Tablets contains			
		Febuxostat		40	mg
		Excipients		q.s	
		Approved Colour used in Coating			

316	Febuxostat Tablets	Each Filmcoated Tablets contains			
		Febuxostat		80	mg
		Excipients		q.s	
		Approved Colour used in Coating			

317	Cilnidipine Tablets IP	Each Filmcoated Tablets Contains:-			
		Cilnidipine	IP	5	mg
		Excipients		qs	
		Approved colour used in Coating			

318	Cilnidipine Tablets IP	Each Filmcoated Tablets Contains:-			
		Cilnidipine	IP	10	mg
		Excipients		qs	
		Approved colour used in Coating			

319	Doxofylline(SR) & Montelukast Sodium Tablets	Each Uncoated Tablet Contains:-			
		Doxofylline (SR)	IP	400	mg
		Montelukast Sodium	IP		
		eq. to montelukast		10	mg
		Excipients		q.s	
Approved colour used in Tablets					

320	S-Amlodipine Besilate & Atenolol Tablets	Each Uncoated Tablet Contains:-			
		S-Amlodipine Besilate	IP		
		eq. to Amlodipine		5	mg
		Atenolol	IP	50	mg
		Excipients		q.s	
Approved colour used in Tablets					

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
321	Levosulpiride (SR) & Rabeprazole sodium(EC) Capsules	Each Hard Gelatin capsule contains:-			
		Levosulpiride		75	mg
		(As Sustained Release Pellets)			
		Rabeprazole sodium	IP	20	mg
		(As Enteric coated pellets)			
		Excipients		q.s	
		Approved Colour used in Capsule shell			
322	Albendazole Tablets IP	Each Uncoated Tablets contains			
		Albendazole	IP	400	mg
		Excipients		qs	
		Approved colour used in Tablets			
323	Terbinafine Cream IP	Composition:-			
		Terbinafine Hydrochloride	IP	1%	w/w
		Preservative:-			
		Benzyl Alcohol	IP	1%	w/w
		In Cream base		q.s	
324	Rosuvastatin & Fenofibrate Tablets IP	Each Film coated tablet contains:-			
		Rosuvastatin Calcium	IP		
		Eq. to Rosuvastatin		10	mg
		Fenofibrate	IP	145	mg
		Excipients		q.s	
		Approved colour used in Coating			
325	Rosuvastatin Tablets IP	Each Film coated tablet contains:-			
		Rosuvastatin Calcium	IP		
		Eq. to Rosuvastatin		10	mg
		Excipients		q.s	
		Approved colour used in Coating			
326	Rosuvastatin Tablets IP	Each Film coated tablet contains:-			
		Rosuvastatin Calcium	IP		
		eq. to Rosuvastatin		5	mg
		Excipients		q.s	
		Approved colour used in Coating			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
327	Telmisartan & Hydrochlorothiazide Tablets IP	Each Film coated Tablet contains:-			
		Telmisartan	IP	40	mg
		Hydrochlorothiazide	IP	12.5	mg
		Excipients		q.s	
		Approved colour used in Coating			
328	Fexofenadine HCl. Tablets IP	Each Filmcoated tablet contains:-			
		Fexofenadine HCl.	IP	120	mg
		Excipients		q.s	
		Approved Colour used in Coating			
329	Esomeprazole Gastro Resistant Tablets IP	Each enteric coated tablets contains:-			
		Esomeprazole Magnesium Trihydrate	IP		
		Eq. to Esomeprazole		40	mg
		Excipients		q.s.	
		Approved colour used in Coating			
330	Thiocolchicoside and Etoricoxib Tablets	Each film coated tablet contains-			
		Thiocolchicoside	IP	4	mg
		Etoricoxib	IP	60	mg
		Excipients		q.s.	
		Colour: Approved colour used			
331	Thiocolchicoside and Ketoprofen Tablets	Each film coated tablet contains-			
		Thiocolchicoside	IP	4	mg
		Ketoprofen	IP	50	mg
		Excipients		q.s.	
		Colour: Approved colour used			
332	Thiocolchicoside and Ketoprofen Tablets	Each film coated tablet contains-			
		Thiocolchicoside	IP	8	mg
		Ketoprofen	IP	100	mg
		Excipients		q.s.	
		Colour: Approved colour used			
333	Serratiopeptidase Tablets IP	Each enteric coated tablet contains:-			
		Serratiopeptidase	IP	5	mg

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		(as 10,000 enzymatic units of serratiopeptidase)			
334	Piroxicam Tablets	Each uncoated tablet contains:-			
		Piroxicam	IP	20	mg
		Excipients		q.s.	
		Colour: Approved colour used			
335	Pregabalin(SR) and Methylcobalamin Tablets	Each film coated tablet contains:-			
		Pregabalin ( SR )	IP	75	mg
		Methylcobalamin	IP	1500	mcg
		Excipients		q.s.	
Colour: Approved colour used					
336	Fluconazole Tablets IP	Each uncoated tablet contains:-			
		Fluconazole	IP	200	mg
		Excipients		q.s.	
		Approved Colour used in Tablet			
337	Nitazoxanide and Ofloxacin Tablets	Each film coated tablet contains:-			
		Nitazoxanide		500	mg
		Ofloxacin	IP	200	mg
		Excipients		q.s.	
Colour: Approved colour used					
338	Montelukast and Fexofenadine Hydrochloride Tablets	Each film coated tablet contains:-			
		Montelukast Sodium	IP		
		Eq. to Montelukast		10	mg
		Fexofenadine Hydrochloride	IP	120	mg
Excipients		q.s.			
Colour: Approved colour used					
339	Fluconazole Tablets IP	Each uncoated tablet contains:-			
		Fluconazole	IP	400	mg
		Excipients		q.s.	
		Colour: Approved colour used			
340	Etoricoxib and Paracetamol Tablets	Each uncoated tablet contains:-			
		Etoricoxib	IP	60	mg
		Paracetamol	IP	325	mg
		Excipients		q.s.	

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Colour: Approved colour used			
341	Etodolac and Paracetamol Tablets	Each film coated tablet contains:			
		Etodolac	IP	400	mg
		Paracetamol	IP	325	mg
		Excipients		q.s.	
		Colour: Approved colour used			
342	Etodolac and Thiocolchicoside Tablets	Each film coated tablet contains:			
		Etodolac	IP	400	mg
		Thiocolchicoside	IP	4	mg
		Excipients		q.s.	
		Colour: Approved colour used			
343	Compound Sodium Bicarbonate Tablets IP	Each uncoated tablet contains:-			
		Sodium bicarbonate	IP	300	mg
		Pippermint Oil		q.s	
		Excipients		q.s..	
344	Lycopene, Vitamin A Vitamin C, Vitamin E, Zinc Sulphate and Selenium Capsules	Each hard gelatin capsule contains:-			
		Lycopene 10%	USP	2	mg
		Vitamin A	IP	2500	IU
		(as acetate)			
		Vitamin C	IP	50	mg
		Vitamin E	IP	10	IU
		(as Tocopheryl acetate)			
		Zinc Sulphate	IP	27.5	mg
		Selenium		70	mcg
		(as sodium selenate)			
		Excipients		q.s.	
Approved colour used in empty capsule					
345	Acebrophylline Capsules	Each hard gelatin capsule contains:-			
		Acebrophylline		100	mg
		Excipients		q.s.	
		Approved colour used in empty capsule shells			

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
346	Methylcobalamin, Pregabalin, Vitamin B6, Folic Acid and Benfotiamine Capsules	Each hard gelatin capsule contains:-			
		Methylcobalamin	IP	750	mcg
		Pregabalin	IP	75	mg
		Vitamin B6	IP	1.5	mg
		Folic Acid	IP	750	mcg
		Benfotiamine		7.5	mg
		Excipients		q.s.	
		Approved colour used in empty capsule shells			
347	Omeprazole Gastro - resistant capsules IP	Each hard gelatin capsule contains:-			
		Omeprazole	IP	40	mg
		(as Gastro-resistant pellets)			
		Excipients		q.s.	
		Approved colour used in empty capsule			
348	Esomeprazole and Domperidone DSR Capsules	Each hard gelatin capsule contains:-			
		Esomeprazole Magnesium Trihydrate	IP		
		Eq. to Esomeprazole		20	mg
		(as enteric coated pellets)			
		Domperidone maleate	IP		
		Eq. to Domperidone		30	mg
		(as sustained release pellets)			
		Excipients		q.s.	
		Approved colour used in empty capsule shells			
349	Trioxsalen Tablets USP	Each uncoated tablet contains:			
		Trioxsalen	USP	5	mg
		Excipients			q.s.
		Approved Colour used in Tablets			
350	Trioxsalen Tablets USP	Each uncoated tablet contains:			
		Trioxsalen	USP	25	mg
		Excipients			q.s.
351	Metaxalone and Diclofenac Potassium Tablets (Not for Veterinary Use)	Each uncoated tablet contains:			
		Metaxalone		400	mg
		Diclofenac Potassium	IP	50	mg

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH  
List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Excipients			q.s.
352	Levetiracetam Tablets USP	Each uncoated tablet contains:			
		Levetiracetam	USP	500	mg
		Excipients			q.s.
353	Citicoline Tablets IP	Each uncoated tablet contains:			
		Citicoline Sodium	IP		
		Eq. to Citicoline		500	mg
		Excipients			q.s.
		Colour: Approved colour used			
354	Citicoline and Piracetam Tablets	Each uncoated tablet contains:			
		Citicoline Sodium	IP		
		Eq. to Citicoline		500	mg
		Piracetam	IP	400	mg
		Excipients			
355	Ketoconazole Cream	Composition			
		Ketoconazole	IP	2%	w/w
		In a cream base			q.s.
356	Esomeprazole and Domperidone DSR Capsules	Each hard gelatin capsule contains:			
		Esomeprazole Magnesium Trihydrate	IP		
		Eq. to Esomeprazole (as enteric coated pellets)		40	mg
		Domperidone Maleate	IP		
		Eq. to Domperidone (as sustained release pellets)		30	mg
		Excipients			q.s.
357	Mometasone Furoate Topical Solution USP	Composition:			
		Mometasone Furoate	USP	0.1%	w/v
		Lotion base			q.s.
358	Sertaconazole and Zinc Pyrithione Shampoo	Composition			
		Sertaconazole	BP	2%	w/v
		Zinc Pyrithione		1%	w/v
		Shampoo base			q.s.
359	Sucralfate, Metronidazole and Povidone Iodine Ointment	Composition			
		Each gram contains:			
		Sucralfate	USP	70	mg
		Metronidazole	IP	10	mg
		Povidone Iodine	IP	50	mg

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Cream base			q.s.
360	Ramipril and Hydrochlorothiazide Tablets	Each uncoated tablet contains:			
		Ramipril	IP	2.5	mg
		Hydrochlorothiazide	IP	12.5	mg
		Excipients			q.s.
361	Ramipril and Hydrochlorothiazide Tablets	Each uncoated tablet contains:			
		Ramipril	IP	5	mg
		Hydrochlorothiazide	IP	25	mg
		Excipients			q.s.
362	Methylprednisolone Tablets IP	Each uncoated tablet contains:			
		Methylprednisolone	IP	8	mg
		Excipients			q.s.
363	Methylcobalamin Tablets	Each film coated tablet contains:			
		Methylcobalamin	IP	500	mcg
		Excipients			q.s.
		Colour: Approved colour used			
364	Glimepiride and Metformin Hydrochloride (SR) Tablets	Each uncoated tablet contains:			
		Glimepiride	IP	2	mg
		Metformin Hydrochloride (As Sustained Release)	IP	500	mg
		Excipients			q.s.
365	Diclofenac Potassium and Paracetamol Tablets (Not for Veterinary Use)	Each un coated tablet contains:			
		Diclofenac Potassium	BP	50	mg
		Paracetamol	IP	325	mg
		Excipients			q.s.
366	Bisoprolol Fumarate Tablets USP	Each film coated tablet contains:			
		Bisoprolol Fumarate	USP	2.5	mg
		Excipients			q.s.
		Colour: Approved colour used			
367	Bisoprolol Fumarate Tablets USP	Each film coated tablet contains:			
		Bisoprolol Fumarate	USP	5	mg
		Excipients			q.s.
		Colour: Approved colour used			
368	Methylcobalamin and Pregabalin Capsules IP	Each hard gelatin capsule contains:			
		Methylcobalamin	IP	750	mcg

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Pregabalin	IP	75	mg
		Excipients			q.s.
		Colour: Approved colour used			

369	Lignocaine Hydrochloride Gel IP	Composition:			
		Lignocaine Hydrochloride	IP		
		Eq. to Anhydrous Lignocaine Hydrochloride		2%	w/w
		Methyl Paraben	IP	0.061%	w/w
		Propyl Paraben	IP	0.027%	w/w
		Water soluble Gel Base in Purified Water	IP		q.s.

370	Roxithromycin Tablets IP	Each uncoated tablet contains:			
		Roxithromycin	IP	150	mg
		Excipients			q.s.

371	Ondansetron Mouth Dissolving Tablets IP	Each un coated mouth dissolving tablet contains:			
		Ondansetron Hydrochloride	IP		
		Eq. to Ondansetron		4	mg.
		Excipients			q.s.
		Colour: Approved colour used			

372	Glipizide and Metformin Hydrochloride Tablets	Each un coated tablet contains:			
		Glipizide	IP	5	mg
		Metformin Hydrochloride	IP	500	mg
		Excipients			q.s.

373	Diclofenac Potassium and Serratiopeptidase Tablets (Not for Veterinary Use)	Each enteric coated tablet contains:			
		Diclofenac Potassium	IP	50	
		Serratiopeptidase ( eq. to 20,000 enzymatic units	IP	10	mg
		Excipients			q.s.
		Colour: Approved colour used			

374	Betamethasone Tablets IP	Each un coated tablet contains:			
		Betamethasone	IP	1	mg
		Excipients			q.s.
Approved colour used in Tablets					

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
375	Pantoprazole (as enteric coated pellets) and Domperidone (as sustained release pellets) Capsules IP	Each hard gelatin capsule contains:			
		Pantoprazole Sodium	IP		
		Eq. to Pantoprazole (as enteric coated pellets)		40	mg.
		Domperidone	IP	10	mg
		(as sustained release pellets)			
		Excipients			q.s.
		Colour: Approved colour used			
376	Methylcobalamin, Calcium, Calcitriol, Folic Acid, Pyridoxine Hydrochloride and Zinc Capsule	Each hard gelatin capsule contains:			
		Methylcobalamin	IP	500	mcg
		Calcium Carbonate	IP		
		Eq. to elemental Calcium		250	mg
		Calcitriol	IP	0.25	mcg
		Folic Acid	IP	1.5	mg
		Pyridoxine Hydrochloride	IP	3	mg
		Zinc (as Zinc Sulphate)	IP	7.5	mg
		Excipients			q.s.
Approved colour used in empty capsule shells					
377	Fluconazole Tablets IP	Each un coated tablet contains:			
		Fluconazole	IP	50	mg
		Excipients			q.s.
378	Calcitriol , Calcium and Zinc Capsules	Each hard gelatin capsule contains:			
		Calcitriol	IP	0.25	mcg
		Calcium Carbonate	IP		
		Eq. to elemental Calcium		200	mg
		Zinc(as Zinc Sulphate)	IP	7.5	mg
		Excipients			q.s.
379	Tacrolimus Ointment 0.1%w/w (NFI)	Composition			
		Tacrolimus	USP	0.1%	w/w
		Ointment base			q.s.

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH  
List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
380	Olmesartan Medoxomil Tablets IP	Each film coated tablet contains:			
		Olmesartan Medoxomil	IP	40	mg
		Excipients			q.s.
		Colour: Approved colour used			
381	Isosorbide Mononitrate Tablets IP	Each un coated tablet contains:			
		Diluted Isosorbide Mononitrate	IP		.
		Eq. to Isosorbide Mononitrate		20	mg
		Excipients			q.s.
382	Domperidone Tablets IP	Each un coated tablet contains:			
		Domperidone	IP	10	mg.
		Excipients			q.s.
383	Itraconazole Capsule BP	Each hard gelatin capsule contains:			
		Itraconazole Pellets	BP		
		Eq. to itraconazole		200	mg.
		Excipients			q.s.
384	Tranexamic Acid and Mefenamic Acid Tablets	Each film coated tablet contains:			
		Tranexamic Acid	IP	500	mg
		Mefenamic Acid	IP	250	
		Excipients			q.s.
		Colour: Approved colour used			
385	Mefenamic acid and Dicyclomine Hydrochloride Tablets IP	Each uncoated tablet contains:			
		Mefenamic acid	IP	250	mg
		Dicyclomine Hydrochloride	IP	20	mg
		Excipients			q.s.
		Approved Colour used in Tablets			
386	Mefenamic Acid and Drotaverine Hydrochloride Tablets	Each film coated tablet contains:			
		Drotaverine Hydrochloride	IP	80	mg.
		Mefenamic Acid	IP	250	mg
		Excipients			q.s.
		Colour: Approved colour used			
387	Glimepiride and Metformin Hydrochloride (SR) Tablets	Each uncoated tablet contains:			
		Glimepiride	IP	1	mg
		Metformin Hydrochloride	IP		mg

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH  
List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		(As Sustained Release)		500	
		Excipients			q.s.

388	Finasteride Tablets IP	Each un coated tablet contains:			
		Finasteride	IP	5	mg
		Excipients			q.s.

389	Diclofenac Potassium Paracetamol and Serratiopeptidase Tablets (NOT FOR VETERINARY USE)	Each film coated tablet contains:			
		Diclofenac Potassium	BP	50	mg
		Paracetamol	IP	325	mg
		Serratiopeptidase (As enteric coated granules 30,000 units of enzymatic activity of	IP	15	mg
		Excipients			q.s.
		Colour: Approved colour used			

390	Amoxicillin Dispersible Tablets IP	Each uncoated dispersible tablet contains:			
		Amoxycillin Trihydrate	IP		
		Eq. to Amoxycillin		125	mg
		Excipients			q.s.

391	Aceclofenac, Paracetamol and Serratiopeptidase Tablets	Each film coated tablet contains:			
		Aceclofenac	IP	100	mg
		Paracetamol	IP	325	mg
		Serratiopeptidase (As enteric coated granules 20,000 units of enzymatic activity of Serratiopeptidase)	IP	10	mg
		Excipients			q.s.
		Colour: Approved colour used			

392	Aceclofenac, Paracetamol and Serratiopeptidase Tablets	Each film coated tablet contains:			
		Aceclofenac	IP	100	mg
		Paracetamol	IP	325	mg
		Serratiopeptidase (As enteric coated granules 30,000 units of enzymatic activity of Serratiopeptidase)	IP	15	mg
		Excipients			q.s.

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Colour: Approved colour used			

393	Pantoprazole Sodium Tablets IP	Each enteric coated tablet contains:			
		Pantoprazole Sodium	IP		
		Eq. to Pantoprazole		20	mg
		Excipients		qs	
		Colour: Approved colour used			

394	Levocarnitine Tablets USP	Each film coated tablet contains:			
		Levocarnitine	USP	200	mg
		Excipients		qs	
		Colour: Approved colour used			

395	Diclofenac Sodium and Serratiopeptidase Tablets (Not for Veterinary Use)	Each film coated tablet contains:			
		Diclofenac Sodium	IP	50	mg
		Serratiopeptidase	IP	10	mg
		as enteric coated granules)			
		(20,000 enzymatic units of Serratiopeptidase)			
		Excipients		qs	
Colour: Approved colour used					

396	Calcium Pantothenate Tablets IP	Each film coated tablet contains:			
		Calcium Pantothenate	IP	100	mg
		Excipients		qs	
Colour: Approved colour used					

397	Pantoprazole and Levosulpiride Capsules	Each hard gelatin capsule contains:			
		Pantoprazole Sodium	IP		
		Eq. to Pantoprazole		40	mg
		Levosulpiride		75	mg
		Excipients		qs	
Colour: Approved colour used					

398	Rifaximin Tablets	Each film coated tablet contains:			
		Rifaximin	BP	400	mg
		Excipients		qs	

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Colour: Approved colour used			
399	Paracetamol, Phenylephrine Hydrochloride, Caffeine and Diphenhydramine Hydrochloride Tablets	Each un coated tablet contains:			
		Paracetamol	IP	325	mg
		Phenylephrine Hydrochloride	IP	5	mg
		Caffeine (anhydrous)	IP	30	mg
		Diphenhydramine Hydrochloride	IP	25	mg
		Excipients:		qs	
		Approved colour used in Tablet			
400	Olmesartan Medoxomil Tablets 20mg	Each film coated tablet contains:			
		Olmesartan Medoxomil	IP	20	mg
		Excipients		qs	
		Colour: Approved colour used			
401	Labetalol Hydrochloride Tablets IP	Each film coated tablet contains:			
		Labetalol Hydrochloride	IP	100	mg
		Excipients		qs	
		Colour: Approved colour used			
402	Finasteride Tablets IP	Each film coated tablet contains			
		Finasteride	IP	5	mg
		Excipients		qs	
		Colour: Approved colour used			
403	Diclofenac Potassium and Paracetamol Tablets (NOT FOR VETERINARY USE)	Each film coated tablet contains:			
		Diclofenac Potassium	BP	50	mg
		Paracetamol	IP	325	mg
		Excipients		qs	
		Colour: Approved colour used			
404	Orlistat Capsule USP	Each hard gelatin capsule contains:			
		Orlistat	USP	100	mg
		Excipients		qs	
		Approved colour used in empty capsule shells			
405	Simvastatin Tablets IP 5mg	Each film coated tablet contains:			
		Simvastatin	IP	5	mg
		Excipients		qs	
		Colour: Approved colour used			

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
406	Montelukast Tablets IP	Each film coated tablet contains:			
		Montelukast Sodium	IP		
		Eq. to Montelukast		10	mg
		Excipients		qs	
		Colour: Approved colour used			
407	Levetiracetam Tablets USP	Each un coated tablet contains:			
		Levetiracetam	USP	250	mg
		Excipients		qs	
408	Etodolac Tablets IP	Each film coated tablet contains:			
		Etodolac	IP	400	mg
		Excipients		qs	
		Colour: Approved colour used			
409	Duloxetine Tablets	Each film coated contains:			
		Duloxetine Hydrochloride	IP		
		Eq. to Duloxetine		10	mg
		Excipients		qs	
		Colour : Approved colour used			
410	Cyanocobalamin, Chromium Picolinate, Folic Acid, Nicotinamide, Pyridoxine Hydrochloride, Selenius Acid and Zinc Sulphate Monohydrate Tablets	Each film coated tablet contains:			
		Cyanocobalamin	IP	15	mcg
		Chromium Picolinate	USP	250	mcg
		Folic Acid	IP	1500	mcg
		Nicotinamide	IP	100	mg
		Pyridoxine Hydrochloride	IP	3	mg
		Selenius Acid	USP	100	mcg
		Zinc Sulphate Monohydrate	IP	61.8	mg
		Eq. to elemental Zinc		22.5	mg
		Excipients		qs	
		Colour: Approved colour used			
411	Cefixime and Lactic acid bacillus Tablets	Each film coated tablet contains:			
		Cefixime	IP		
		Eq. to Anhydrous Cefixime		200	mg
		Lactic acid bacillus		60	Million spores
Colour: Approved colour used					
412	Fenbendazole Tablets	Each uncoated tablet contains:			
		Fenbendazole	IP(vet.)	150	mg
		Excipients		qs	

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
--------	--------------------------------------	-------------	---------------	----------	------

413	Mometasone Furoate and Terbinafine Cream	Composition:			
		Mometasone Furoate	IP	0.1%	w/w
		Terbinafine Hydrochloride	IP	1%	w/w
		Water soluble base		qs	

414	Sildenafil Tablets IP 25mg	Each film coated tablet contains:			
		Sildenafil Citrate	IP		
		Eq. to Sildenafil		25	mg
		Excipients			qs
		Colour: Approved colour used			

415	Olmesartan Medoxomil and Hydrochlorothiazide Tablets IP	Each film coated tablet contains:			
		Olmesartan Medoxomil	IP	40	mg
		Hydrochlorothiazide	IP	12.5	mg
		Excipients			qs
		Colour: Approved colour used			

416	Methylcobalamin and Gabapentin Tablets	Each film coated tablet contains:			
		Methylcobalamin	IP	500	mcg
		Gabapentin	IP	300	mg
		Excipients			qs
		Colour: Approved colour used			

417	Drotaverine Hydrochloride Tablets IP 80mg	Each film coated tablet contains:			
		Drotaverine Hydrochloride	IP	80	mg
		Excipients			qs
		Colour: Approved colour used			

418	Tolperisone Hydrochloride and Paracetamol Tablets	Each uncoated tablet contains:			
		Tolperisone Hydrochloride		150	mg
		Paracetamol	IP	325	mg
		Excipients		qs	

419	Telmisartan Tablets IP 40mg	Each film coated tablet contains:			
		Telmisartan	IP	40	mg
		Excipients		qs	
		Colour: Approved colour used			

420	Nortriptyline Hydrochloride	Each film coated tablet contains:			
-----	-----------------------------	-----------------------------------	--	--	--

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH  
List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	Tablets IP 10mg	Nortriptyline Hydrochloride Eq.	IP	10	mg
		to Nortriptyline			
		Excipients			qs
		Colour: Approved colour used			

421	Moxifloxacin Tablets 400mg	Each film coated tablet contains:			
		Moxifloxacin Hydrochloride Eq. to Moxifloxacin	IP	400	mg
		Excipients			qs
		Colour: Approved colour used			

422	Levocetirizine Hydrochloride Tablets IP 10mg	Each film coated tablet contains:			
		Levocetirizine Hydrochloride	IP	10	mg
		Excipients			qs
		Colour: Approved colour used			

423	Ketoconazole Tablets IP 200mg	Each un coated tablet contains:			
		Ketoconazole	IP	200	mg
		Excipients			qs
		Colour: Approved colour used			

424	Amlodipine Tablets IP 10mg	Each uncoated tablet contains:			
		Amlodipine Besilate	IP		
		Eq. to Amlodipine		10	mg
		Excipients		qs	

425	Tamsulosin Hydrochloride Tablets 0.4mg (Modified release)	Each film coated tablet contains:			
		Tamsulosin Hydrochloride (as modified release)	IP	0.4	mg
		Excipients		qs	
		Colour: Approved colour used			

426	Levocetirizine Hydrochloride and Ambroxol Hydrochloride Tablets	Each film coated tablet contains:			
		Levocetirizine Hydrochloride	IP	5	mg
		Ambroxol Hydrochloride	IP	30	mg
		Excipients		qs	
		Colour: Approved colour used			

427	Clobetasol Propionate, Gentamycin, Tolnaftate,	Composition:			
		Clobetasol Propionate	IP	0.05%	w/w

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	Iodochlorhydroxyquinolin and Clotrimazole Cream	Gentamycin Sulphate	IP		
		Eq. to Gentamycin		0.1%	w/w
		Tolnaftate	IP	1%	w/w
		Iodochlorhydroxyquinoline	IP	1%	w/w
		Clotrimazole	IP	1%	w/w
		In a cream base			qs

428	Stanozolol Tablets USP	Each uncoated tablet contains:			
		Stanozolol	USP	2	mg
		Excipients		qs	
		Colour: Approved colour used			

429	Levocetirizine Hydrochloride and Ambroxol Hydrochloride Tablets	Each film coated tablet contains:			
		Levocetirizine Hydrochloride	IP	5	mg
		Ambroxol Hydrochloride	IP	60	mg
		Excipients		qs	
Colour: Approved colour used					

430	Cefixime dispersible Tablets IP	Each uncoated dispersible tablet contains:			
		Cefixime	IP		
		Eq. to Anhydrous Cefixime		50	mg
		Excipients		q.s	
Colour: Approved colour used					

431	Clobetasol Propionate, Gentamycin Tolnaftate, Iodochlorhydroxyquinoline and Ketoconazole Cream	Composition:-Each gram contains:-			
		Clobetasol Propionate	IP	0.5	mg
		Gentamycin Sulphate	IP		
		Eq. to Gentamycin		1	mg
		Tolnaftate	IP	10	mg
		Iodochlorhydroxyquinoline	IP	10	mg
		Ketoconazole	IP	20	mg
In a cream base					

432	Acetaminophen Tablets	Each uncoated tablet contains:			
		Acetaminophen	IP	500	mg
		Excipients		qs	
		Colour: Approved colour used			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
--------	--------------------------------------	-------------	---------------	----------	------

433	Potassium Nitrate, Sodium monofluorophosphate  and Triclosan Paste	Composition:-Each gram contains:-			
		Potassium Nitrate	BP	5%	w/w
		Sodium Monofluorophosphate	USP	0.7%	w/w
		Triclosan	USP	0.3%	w/w
		Presently Flavoured Paste Base		qs	

434	Amoxicillin Capsules IP	Each hard gelatin capsule contains:			
		Amoxicillin Trihydrate	IP		
		Eq. to Amoxicillin		250	mg
		Excipients		q.s	
Approved colour used					

435	Amoxicillin Capsules IP	Each hard gelatin capsule contains:			
		Amoxicillin Trihydrate	IP		
		Eq. to Amoxicillin		500	mg
		Excipients		q.s	
Approved colour used					

436	Cephalexin Capsules IP	Each hard gelatin capsule contains:			
		Cephalexin	IP		
		Eq. to Anhydrous Cephalexin		250	mg
		Excipients		q.s	
Approved colour used					

437	Cephalexin Capsules IP	Each hard gelatin capsule contains:			
		Cephalexin	IP		
		Eq. to Anhydrous Cephalexin		500	mg
		Excipients		q.s	
Approved colour used					

438	Ampicillin Capsules IP	Each hard gelatin capsule contains:			
		Ampicillin Trihydrate	IP		
		Eq. to Ampicillin		500	mg
		Excipients		q.s	
Approved colour used					

439	Ampicillin Capsules IP	Each hard gelatin capsule contains:			
-----	------------------------	-------------------------------------	--	--	--

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Ampicillin Trihydrate	IP		
		Eq. to Ampicillin		250	mg
		Excipients		q.s	
		Approved colour used			

440	Amoxicillin Oral Suspension IP	Each 5ml of reconstituted suspension contains:			
		Amoxicillin Trihydrate	IP		
		Eq. to Amoxicillin		125	mg
		In a flavoured suspension base		q.s	
		Approved colour used			

441	Amoxicillin Oral Suspension IP	Each 5ml of reconstituted suspension contains:			
		Amoxicillin Trihydrate	IP		
		Eq. to Amoxicillin		250	mg
		In a flavoured suspension base		q.s	
		Approved colour used			

442	Ampicillin Oral Suspension IP	Each 5ml of reconstituted suspension contains:			
		Ampicillin Trihydrate	IP		
		Eq. to Ampicillin		125	mg
		In a flavoured suspension base		q.s	
		Approved colour used			

443	Cefixime Oral Suspension IP	Each 5ml of reconstituted suspension contains:			
		Cefixime Trihydrate	IP		
		Eq. to Anhydrous Cefixime		100	mg
		In a flavoured suspension base		q.s	
		Approved colour used			

444	Cefpodoxime Oral Suspension IP	Each 5ml of reconstituted suspension contains:			
		Cefpodoxime proxetil	IP		
		Eq. to Cefpodoxime		50	mg
		In a flavoured suspension base		q.s	
		Approved colour used			

445	Cefpodoxime Oral Suspension IP	Each 5ml of reconstituted suspension contains:			
		Cefpodoxime proxetil	IP		
		Eq. to Cefpodoxime		100	mg
		In a flavoured suspension base		q.s	
		Approved colour used			

446	Paracetamol Paediatric Oral Suspension IP	Each 5ml contains:			
		Paracetamol	IP	125	mg

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH  
List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Excipients		q.s	
		Approved colour used			

447	Paracetamol Paediatric Oral Suspension IP	Each 5ml contains:			
		Paracetamol	IP	250	mg
		Excipients		q.s	
		Approved colour used			

448	Levocetirizine Hydrochloride Syrup IP	Each 5ml contains:			
		Levocetirizine Hydrochloride	IP	2.5	mg
		Excipients		q.s	
		Approved colour used			

449	Levocetirizine Hydrochloride and Montelukast Suspension	Each 5ml contains:			
		Levocetirizine Hydrochloride	IP	2.5	mg
		Montelukast Sodium	IP		
		Eq. to Montelukast		4	mg
		Excipients		q.s	
Approved colour used					

450	Cetirizine Hydrochloride Syrup IP	Each 5ml contains:			
		Cetirizine Hydrochloride	IP	5	mg
		Excipients		q.s	
Approved colour used					

451	Cefixime Oral Suspension IP	Each 5ml of reconstituted suspension contains:			
		Cefixime Trihydrate	IP		
		Eq. to Anhydrous Cefixime		50	mg
		In a flavoured suspension base		q.s	

452	Azithromycin oral Suspension IP (For Paediatric use)	Composition: Each 5ml contains:			
		Azithromycin dihydrate	IP		
		Eq. to Anhydrous Azithromycin		100	mg
Colour: Approved Colour Used					

453	Azithromycin oral Suspension IP (For Paediatric use)	Composition: Each 5ml contains:			
		Azithromycin dihydrate	IP		
		Eq. to Anhydrous Azithromycin		200	mg
Colour: Approved Colour Used					

454	Piracetam Tablets	Each uncoated Tablet contains :-			
-----	-------------------	----------------------------------	--	--	--

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Piracetam	IP	800	mg
		Excipients		qs	
		Colour:- Approved colour used			

455	Pantoprazole Sodium (EC) & Levosulpiride (SR) Capsule	Each hard gelatin Capsule contains :			
		Pantoprazole Sodium	IP		
		Eq. to Pantoprazole (Enteric Coated Pellets)		40	mg
		Levosulpiride (Sustained Release Pellets)		75	mg
		Excipients		qs	
		Approved Colour Used in Empty Capsule Shell			

456	Phenylephrine HCl, Paracetamol, Chlorpheniramine Maleate, Sodium Citrate & Menthol Syrup	Each 5ml contains:			
		Phenylephrine HCl	IP	5	mg
		Paracetamol	IP	125	mg
		Chlorpheniramine Maleate	IP	0.5	mg
		Sodium Citrate	IP	60	mg
		Menthol	IP	1	mg
Colour: Approved Colour Used					

457	Ambroxol Hydrochloride, Salbutamol Sulphate, Guaiphenesin and Menthol Syrup	Each 5ml contains:			
		Ambroxol Hydrochloride	IP	15	mg
		Guaiphenesin	IP	50	mg
		Salbutamol Sulphate	IP	1	mg
		Menthol	IP	1	mg
Colour: Approved Colour Used					

458	Ambroxol Hydrochloride, Terbutaline Sulphate, Guaiphenesin and Menthol Syrup	Each 5ml contains:			
		Ambroxol hydrochloride	IP	15	mg
		Terbutaline Sulphate	IP	1.25	mg
		Guaiphenesin	IP	50	mg
		Menthol	IP	2.5	mg
Colour: Approved Colour Used					

459	Benzoic acid & salicylic acid Ointment IP	COMPOSITION			
		Benzoic acid	IP	6%	w/w
		salicylic acid	IP	3%	w/w
		Ointment base		qs	

460	Luliconazole Cream.	Composition:-			
-----	---------------------	---------------	--	--	--

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Luliconazole		1%	w/w
		Preservative:-			
		Benzyl Alcohol	IP	1%	w/w
		Cream Base		q. s.	

461	White Petroleum Jelly IP	COMPOSITION			
		White Petroleum Jelly	IP	100%	w/w

462	Norfloxacin Tablets IP	Each film coated tablet contains :-			
		Norfloxacin	IP	400	mg
		Excipients		qs	
		Approved colour used in coating			

463	Norfloxacin & Tinidazole Tablets	Each film coated tablet contains :-			
		Norfloxacin	IP	400	mg
		Tinidazole	IP	600	mg
		Excipients		q.s	
Approved colour used in coating					

464	Hydroxychloroquine Tablets IP	Each film coated tablet contains :-			
		Hydroxychloroquine Sulphate	IP	200	mg
		Excipients		qs	
		Approved colour used in coating			

465	Hydroxychloroquine Tablets IP	Each film coated tablet contains :-			
		Hydroxychloroquine Sulphate	IP	300	mg
		Excipients		qs	
		Approved colour used in coating			

466	Hydroxychloroquine Tablets IP	Each film coated tablet contains :-			
		Hydroxychloroquine Sulphate	IP	400	mg
		Excipients		qs	
		Approved colour used in coating			

467	Atorvastatin & Fenofibrate Tablets IP	Each film coated tablet contains :-			
		Atorvastatin Calcium	IP		
		Eq. to Atorvastatin		10	mg
		Fenofibrate	IP	145	mg
		Excipients		qs	
Approved colour used in coating					

468	Fluoxetine Hydrochloride	Each hard gelatin capsule shell contains :-			
-----	--------------------------	---	--	--	--

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH  
List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	Capsules IP	Fluoxetine Hydrochloride eq. to Fluoxetine	IP	20	mg
Approved colour used in Capsule shell.					

469	Albendazole Oral Suspension IP (Vet.) VETERINARY USE NOT FOR HUMAN USE	Each 5ml Contains:			
		Albendazole	IP	125	mg
		In a syrupy Base		q.s.	
		Colour: Approved colour used			

470	Lactulose Solution USP	Each 15ml contains:			
		Lactulose Concentrate	USP		
		Eq. to Lactulose		10	gm
		Colour: Approved colour used			

471	Cyproheptadine Hydrochloride Syrup IP	Each 5ml contains:			
		Cyproheptadine Hydrochloride	IP	2	mg
		Colour: Approved colour used			

472	Aluminium Hydroxide, Magnesium Hydroxide and Simethicone Suspension. IP	Each 5ml. contains:			
		Aluminium Hydroxide	IP	250	mg
		Magnesium Hydroxide	IP	250	mg
		Simethicone	IP	50	mg
Colour: Approved colour used					

473	Albendazole Oral Suspension IP	Each 5ml contains:			
		Albendazole	IP	200	mg
		Colour: Approved colour used			

474	Mefenamic Acid & Paracetamol Tablet	Each Uncoated Tablet Contains			
		Mefenamic Acid	IP	250	mg
		Paracetamol	IP	325	Mg
		Excipients		q.s.	
Colour: Approved Colour used					

475	Albendazole & Ivermectin Tablet	Each Uncoated Chewable Tablet Contains			
		Albendazole	IP	400	mg
		Ivermectin	IP	6	Mg
		Excipients		q.s.	
Colour: Approved Colour used					

476	Albendazole & Ivermectin Tablet	Each Uncoated Chewable Tablet Contains			
		Albendazole	IP	400	mg
		Ivermectin	IP	12	Mg
		Excipients		q.s.	

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Colour: Approved Colour used			

477	Sucralfate Oral Suspension	Each 10ml contains:			
		Sucralfate	IP	1000	mg
		In a flavoured syrup base		q.s.	
		Colour: Sunset Yellow Supra			

478	Sucralfate & Oxetacaine Oral suspension	Each 10ml Contains:			
		Sucralfate	IP	1000	mg
		Oxetacaine	BP	20	mg
		In a flavoured syrup base			q.s.
		Colour: Approved Colour			

479	Phenylephrine & Chlorpheniramine Maleate Oral Drops	Each ml contains:			
		Phenylephrine Hydrochloride	IP	2.5	mg
		Chlorpheniramine Maleate	IP	1	mg
		In a Flavoured Syrup Base		q.s.	
		Colour: Approved colour used			

480	Phenylephrine & Chlorpheniramine Maleate Syrup IP	Each 5ml contains:			
		Phenylephrine Hydrochloride	IP	5	mg
		Chlorpheniramine Maleate	IP	2	mg
		In a Flavoured Syrup Base		q.s.	
		Colour: Approved colour used			

481	Mefenamic Acid & Paracetamol Suspension	Each 5ml contains			
		Mefenamic Acid	IP	50	mg
		Paracetamol	IP	125	Mg
		In a flavoured syrup base		q.s.	
		Colour: Approved Colour Used			

482	Ibuprofen & Paracetamol Suspension	Each 5ml contains			
		Ibuprofen	IP	100	mg
		Paracetamol	IP	162.5	mg
		In a flavoured syrupy base		q.s.	
		Colour: Approved Colour Used			

483	Ferric Ammonium Citrate, Folic Acid & Cyanocobalamin Syrup	Each 10 ml contains:			
		Ferric Ammonium Citrate	IP	160	mg
		Folic Acid	IP	1	mg
		Cyanocobalamin	IP	7.5	mcg
		In a Flavoured Syrup Base		q.s.	
		Colour: Approved colour used			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		For Therapeutic use			

484	Dried Aluminium Hydroxide Gel, Magnesium Hydroxide & Oxetacaine Suspension	Each 5ml contains:			
		Dried Aluminium Hydroxide Gel	IP	291	mg
		Magnesium Hydroxide	IP	98	mg
		Oxetacaine	BP	10	mg
		In a flavoured syrup base		q.s.	
		Colour: approved colour added			

485	Diphenhydramine HCL , Ammonium Chloride, Sodium Citrate & Menthol Syrup	Each 5 ml contains			
		Diphenhydramine Hydrochloride	IP	14.08	mg
		Ammonium Chloride	IP	138	mg
		Sodium Citrate	IP	57.03	mg
		Menthol	IP	1.14	mg
		In a Flavoured Syrup Base		q.s.	
Colour:Approved colour used					

486	Albendazole & Ivermectin Suspension	Each 5ml Contains			
		Albendazole	IP	200	mg
		Ivermectin	IP	3	mg
		In a flavoured Suspension Base		q.s.	
Colour: Approved Colour used					

487	Albendazole & Ivermectin Suspension	Each 5ml Contains			
		Albendazole	IP	200	mg
		Ivermectin	IP	1.5	mg
		In a flavoured Suspension Base		q.s.	
Colour: Approved Colour used					

488	CyproheptadineHCl & Tricholine Citrate Syrup	Each 5ml contains:			
		Cyproheptadine HCL	IP	2	mg
		TricholineCitrate(65%)	IP	275	mg
		In a Flavoured Sorbitol Base		q.s.	
Colour:Approved colour used					

489	Cetirizine Hydrochloride, Phenylephrine Hydrochloride &Paracetamol Suspension	Each 5 ml contains:			
		Cetirizine Hydrochloride	IP	2	mg
		Phenylephrine Hydrochloride	IP	5	mg
		Paracetamol	IP	125	mg
		In a Flavoured Syrup Base		q.s.	
Colour: Approved Colour					

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH  
List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
490	Choline Salicylate, Lignocaine Hydrochloride and Benzalkonium Chloride Solution Gel	Composition:			
		Choline Salicylate Solution	BP		
		Eq. to Choline Salicylate		8.70%	w/w
		Lignocaine Hydrochloride	IP	2%	w/w
		Benzalkonium Chloride Solution	IP	0.01%	w/w
		In a pleasant flavoured Gel base		q.s.	
491	Ciprofloxacin, Metronidazole, Terbinafine Hydrochloride & Clobetasol Propionate Cream	Composition:			
		Ciprofloxacin Hydrochloride	IP		
		Eq. to Ciprofloxacin		1.00%	w/w
		Metronidazole Benzoate	IP		
		Eq. to Metronidazole		1.00%	w/w
		Terbinafine Hydrochloride	IP	1.00%	w/w
		Clobetasol Propionate	IP	0.05%	w/w
		Methyl Paraben	IP	0.16%	w/w
Propyl Paraben	IP	0.033%	w/w		
		In a cream base		q.s.	
492	Clobetasol Propionate & Salicylic Acid Cream	Composition:			
		Clobetasol Propionate	IP	0.05%	w/w
		Salicylic acid	IP	3%	w/w
		Ointment Base		q.s.	
493	Clobetasol Propionate, Gentamicin, Miconazole Nitrate & Zinc oxide Cream	Composition:			
		Clobetasol Propionate	IP	0.05%	w/w
		Gentamicin Sulphate	IP		
		Eq. to Gentamicin		0.20%	w/w
		Miconazole Nitrate	IP	2%	w/w
		Zinc Oxide	IP	0.10%	w/w
		Chlorocresol (as preservative)	IP	0.10%	w/w
		Cream Base		q.s.	
494	Fusidic Acid & Clobetasol Propionate Cream	Composition:			
		Fusidic Acid	IP	2%	w/w
		Clobetasole Propionate	IP	0.05%	w/w
		Cream Base		q.s.	
495	Fusidic Acid, Clobetasol Propionate & Clotrimazole Cream	Composition:			
		Fusidic Acid	IP	2%	w/w
		Clobetasole Propionate	IP	0.05%	w/w

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH  
List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Clotrimazole	IP	1%	w/w
		Cream Base		q.s.	
496	Fusidic Acid , Beclomethasone Dipropionate & Chlorocresol Cream	Composition: Fusidic Acid	IP	2%	w/w
		BeclomethasoneDipropionate	IP	0.025%	w/w
		Chlorocresol	IP	0.10%	w/w
		Cream Base		q.s.	
497	Gamma Benzene Hexachloride & Cetrimide Lotion	Composition: Gamma BenzeneHexachloride	IP	1%	w/w
		Cetrimide	IP	0.10%	w/w
		In a Lotion Base		q.s.	
498	Ketoconazole & Zinc Pyrithione Anti Dandruff Topical Lotion Shampoo	Composition: Ketoconazole	IP	2%	w/w
		Zinc Pyrithione		1%	w/w
		Anti Dandruff Topical Lotion Shampoo Base		q.s.	
499	Ketoconazole, Neomycin, Tolnaftate, Iodochlorhydroxyquinoline, & Clobetasol Propionate Cream.	Composition: Ketoconazole	IP	2.00%	w/w
		Neomycin Sulphate Eq. to Neomycin	IP	0.10%	w/w
		Tolnaftate	IP	1.00%	w/w
		Iodochlorhydroxyquinoline	IP	1.00%	w/w
		Clobetasol Propionate	IP	0.05%	w/w
		In a cream base		q.s.	
500	Mupirocin & Fluticasone Propionate Ointment	Composition: Mupirocin	IP	2%	w/w
		Fluticasone Propionate	IP	0.005%	w/w
		In a Ointment Base		q.s.	
501	Mupirocin & Beclomethasone Dipropionate Ointment	Composition: Mupirocin	IP	2%	w/w
		BeclomethasoneDipropionate	IP	0.025%	w/w
		In a Ointment Base		q.s.	
502	Mupirocin & Sucralfate Ointment	Composition: Mupirocin	IP	2%	w/w
		Sucralfate	IP	7%	w/w
		In a Ointment Base		q.s.	

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
503	Ofloxacin, Ornidazole, Itraconazole & Clobetasol Propionate Cream	Composition:			
		Ofloxacin	IP	0.75%	w/w
		Ornidazole	IP	2.00%	w/w
		Itraconazole	BP	1.00%	w/w
		Clobetasol Propionate	IP	0.05%	w/w
		Methyl Paraben	IP	0.20%	w/w
		Propyl Paraben	IP	0.02%	w/w
	In a cream base			q.s.	
504	Ampicillin Trihydrate & Dicloxacillin Sodium Capsules	Each Hard Gelatin Capsules contains			
		Ampicillin Trihydrate	IP	250	mg
		Eq. to Ampicillin			
		Dicloxacillin Sodium	IP	250	mg
		Eq. to Dicloxacillin			
	Excipients			q.s.	
	Approved Colour Used in empty capsules Shell				
505	Thiocolchicoside & Lornoxicam Tablet	Each Film Coated Tablet contains:			
		Thiocolchicoside	IP	4	mg
		Lornoxicam		8	mg
		Excipients			q.s.
		Colour: Approved colour used			
506	Terbutaline Sulphate, Ambroxol Hydrochloride & Guaiphenesin Tablet	Each Uncoated Tablet Contains:			
		Terbutaline Sulphate	IP		mg
		Eq. to Terbutaline		2.5	
		Ambroxol Hydrochloride	IP	30	mg
		Guaiphenesin	IP	100	mg
		Excipients			q.s.
	Colour: Approved colour Used				
507	Piracetam & Citicoline Sodium Tablet	Each Film Coated Tablet contains:			
		Piracetam	IP	800	mg
		Citicoline Sodium	IP	500	mg
		Eq. to Citicoline			
		Excipients			q.s.
	Colour: Approved colour used				
508	Piracetam & Citicoline Sodium Tablet	Each Film Coated Tablet contains:			
		Piracetam	IP	1200	mg
		Citicoline Sodium	IP	500	mg
		Eq. to Citicoline			

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Excipients		q.s.	
		Colour:Approved colour used			

509	CefpodoximeProxetil & Ofloxacin Tablet	Each Filmcoated Tablet contains:			
		CefpodoximeProxetil	IP	100	mg
		Eq. to Cefpodoxime			
		Ofloxacin	IP	100	mg
		Excipients		q.s.	
		Colour:Approved colour used			

510	CefpodoximeProxetil & Ofloxacin Tablet	Each Filmcoated Tablet contains:			
		CefpodoximeProxetil	IP		mg
		Eq. to Cefpodoxime		200	
		Ofloxacin	IP	200	mg
		Excipients		q.s.	
		Colour:Approved colour used			

511	CefiximeTrihydrate & Ofloxacin Tablet	Each Uncoated Tablet contains:			
		CefiximeTrihydrate	IP	50	mg
		Eq. to (Anhydrous)Cefixime			
		Ofloxacin	IP	50	mg
		Excipients		q.s.	
		Colour:Approved colour used			

512	Doxycycline Hydrochloride & Lactic Acid Bacillus Capsules	Each Hard Gelatin Capsule contains:			
		Doxycycline Hydrochloride	IP	100	mg
		Eq. to Doxycycline			
		Lactic Acid Bacillus		5	Billion spores
		Excipients		q.s.	
		Approved colour used in empty hard gelatin Capsules Shell			

513	Albendazole Bolus IP  VETERINARY USE NOT FOR HUMAN USE	Each Uncoated Bolus contains:			
		Albendazole	IP	600	mg
		Excipients		q.s.	
		Colour:Approved colour used			

514	Albendazole Bolus IP  VETERINARY USE NOT FOR HUMAN USE	Each Uncoated Bolus contains:			
		Albendazole	IP	1500	mg
		Excipients		q.s.	
		Colour:Approved colour used			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
515	Fenbendazole Bolus (For animal use only) (Not for human use)	Each Uncoated Bolus contains:-			
		Fenbendazole	IP(Vet)	1500	mg
		Excipients		q.s	gm
		Approved colour used in Bolus			

516	Ivermectin Tablets IP  VETERINARY USE NOT FOR HUMAN USE	Each Uncoated Tablet contains:			
		Ivermectin	IP	80	mg
		Excipients		q.s.	
		Colour:Approved colour used			

517	Ivermectin & Praziquantel Tablets  VETERINARY USE NOT FOR HUMAN USE	Each Uncoated Tablet contains:			
		Ivermectin	IP	2	mg
		Praziquantel	IP	50	mg
		Excipients		q.s.	
		Colour:Approved colour used			

518	Meloxicam , Paracetamol & Serratiopeptidase Bolus  VETERINARY USE NOT FOR HUMAN USE	Each Uncoated Bolus contains:			
		Meloxicam	IP	100	mg
		Paracetamol	IP	2000	mg
		Serratiopeptidase	IP	75	mg
		(As Enteric coated granules)			
		Eq. to 150,000 Enzymatic Units			
		Excipients		q.s.	
		Colour:Approved colour used			

519	Metronidazole, Furazolidone & Loperamide Bolus  VETERINARY USE NOT FOR HUMAN USE	Each Uncoated Bolus contains:			
		Metronidazole	IP	1000	mg
		Furazolidone	IP	500	mg
		Loperamide HCl	IP	7.5	mg
		Excipients		q.s.	
Colour:Approved colour used					

520	Oxytetracycline Hydrochloride Bolus  VETERINARY USE NOT FOR HUMAN USE	Each Uncoated Bolus contains:			
		Oxytetracycline Hydrochloride	IP	500	mg
		Excipients		q.s.	
		Colour:Approved colour used			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
521	Sucralfate&Oxetacaine Oral suspension	Each 10ml Contains:			
		Sucralfate	IP	1000	mg
		Oxetacaine	BP	10	mg
		In a flavoured syrup base		q.s.	
		Colour: Approved Colour		q.s.	
522	Terbutaline Sulphate, Bromhexine Hydrochloride, Guaiphenesin& Menthol Syrup	Each 5 ml contains			
		Terbutaline Sulphate	IP	1.25	mg
		Bromhexine Hydrochloride	IP	4	mg
		Guaiphenesin	IP	50	mg
		Menthol	IP	1	mg
		In a Flavoured Syrupy Base		q.s.	
		Colour:Approved colour used			
523	Terbutaline Sulphate, Bromhexine Hydrochloride, Guaiphenesin& Menthol Syrup	Each 5 ml contains			
		Terbutaline Sulphate	IP	1.25	mg
		Bromhexine Hydrochloride	IP	2	mg
		Guaiphenesin	IP	50	mg
		Menthol	IP	0.5	mg
		In a Flavoured Syrupy Base		q.s.	
		Colour:Approved colour used			
524	Roxithromycin Oral Suspension IP	Each 5ml contains:			
		Roxithromycin	IP	50	mg
		In a Flavoured Syrupy Base		q.s.	
		Colour:Approved colour used			
525	Salbutamol Sulphate ,Guaiphenesin & Ambroxol Hydrochloride Syrup	Each ml contains			
		Salbutamol Sulphate Eq. to Salbutamol	IP	0.5	mg
		Guaiphenesin	IP	12.5	mg
		Ambroxol Hydrochloride	IP	7.5	mg
		In a Flavoured Syrupy Base		q.s.	
		Colour:Approved colour used			
526	Paracetamol,	Each 5ml contains:			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	Phenylephrine HCl & Cetirizine Dihydrochloride suspension	Paracetamol	IP	250	mg
		Phenylephrine HCl	IP	5	mg
		Cetirizine Dihydrochloride	IP	2	mg
		Flavoured syrupy base		q.s.	
		Colour: Approved colour used			
527	Ondansetron Hydrochloride Oral Solution IP	Each 5ml contains: Ondansetron Hydrochloride Eq. to Ondansetron In a Flavoured Syrupy Base Colour: Approved colour used	IP	2	mg
528	Paracetamol Paediatric Oral Suspension IP	Each ml contains: Paracetamol In a Flavoured Syrupy Base Colour: Approved colour used	IP	100	mg
529	Mefenamic Acid & Paracetamol Suspension	Each 5ml contains Mefenamic Acid Paracetamol In a flavoured syrup base Colour: Approved Colour Used	IP IP	100 250	Mg Mg
530	Ofloxacin Oral Suspension IP	Each 5ml contains: Ofloxacin In a Flavoured Syrupy Base Colour: Approved colour used	IP	50	mg
531	Levosambutamol Sulphate , Ambroxol Hydrochloride & Guaiphenesin Syrup	Each 5 ml contains Levosambutamol Sulphate Eq. to Levosambutamol Ambroxol Hydrochloride Guaiphenesin In a Flavoured Syrupy Base Colour: Approved colour used	IP IP IP	1 30 50	Mg Mg Mg
532	Aceclofenac & Paracetamol Suspension	Each 5ml contains Aceclofenac Paracetamol In a flavoured syrupy base	IP IP	50 125	mg mg

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH  
List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Colour: Approved Colour Used		q.s.	
533	Calcium Carbonate & Vitamin D3 Suspension	Each 5ml contains			
		Calcium Carbonate IP 625mg	IP	250	mg
		Eq. to Elemental Calcium			
		Vitamin D3	IP	125	IU
		In a flavoured syrupy base			
		Colour: Approved Colour Used			
For Therapeutic use					
534	Cetirizine Hydrochloride, Phenylephrine Hydrochloride & Dextromethorphan Hydrobromide Syrup	Each 5 ml contains:			
		Cetirizine Hydrochloride	IP	2.5	mg
		Phenylephrine Hydrochloride	IP	5	mg
		Dextromethorphan Hydrobromide	IP	10	mg
		In a Flavoured Syrup Base			
		Colour: Approved Colour			
535	Clobetasol Propionate, Gentamicin Sulphate, Miconazole Nitrate & Clotrimazole Cream	Composition:			
		Clobetasol Propionate	IP	0.05%	w/w
		Gentamicin Sulphate IP	IP	0.10%	w/w
		Eq. to Gentamicin			
		Clotrimazole	IP	1%	w/w
		Miconazole Nitrate	IP	2%	w/w
Cream Base					
536	Chlorpheniramine Maleate & Dextromethorphan Hydrobromide Syrup	Each 5ml contains			
		Chlorpheniramine Maleate	IP	4	mg
		Dextromethorphan Hydrobromide	IP	10	mg
		In a flavoured syrupy base			
		Colour: Approved Colour Used			
537	Chlorpheniramine Maleate, Phenylephrine Hydrochloride & Paracetamol Suspension	Each 5 ml contains:			
		Chlorpheniramine Maleate	IP	1	mg
		Phenylephrine Hydrochloride	IP	2.5	mg
		Paracetamol	IP	125	mg
		In a Flavoured Syrup Base			
Colour: Approved Colour					
538	Chlorpheniramine Maleate, Phenylephrine Hydrochloride & Paracetamol	Each 5 ml contains:			
		Chlorpheniramine Maleate	IP	2	mg
		Phenylephrine Hydrochloride	IP	5	mg
		Paracetamol	IP	250	mg

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	Suspension	In a Flavoured Syrup Base		q.s	
		Colour: Approved Colour			
539	Dextromethorphan Hydrobromide, Phenylephrine Hydrochloride & Chlorpheniramine Maleate Syrup	Each 5ml Contains:			
		Dextromethorphan Hydrobromide	IP	5	mg
		Phenylephrine Hydrochloride	IP	5	mg
		Chlorpheniramine Maleate	IP	2	mg
		In a flavoured Syrupy base		q.s.	
		Colour: Approved colour Used			
540	Dicyclomine Hydrochloride & Activated Dimethicone Suspension	Each ml contains:			
		Dicyclomine Hydrochloride	IP	10	mg
		Activated Dimethicone	IP	40	mg
		In a Flavoured Syrupy Base		q.s.	
		Colour: Approved colour used			
541	Diphenhydramine HCl, Terpin Hydrate, Ammonium Chloride & Sodium Citrate Syrup	Each 5ml contains:			
		Diphenhydramine HCl	IP	12.5	mg
		Terpin Hydrate	USP	7.5	mg
		Ammonium Chloride	IP	125	mg
		Sodium Citrate	IP	55	mg
		Flavoured Mentholated syrupy base		q.s.	
		Colour: Approved colour used			
542	Disodium Hydrogen Citrate Syrup	Each 5ml contains:			
		Disodium Hydrogen Citrate	BP	1.25	gm
		In a flavoured syrup base		q.s.	
		Colour: Approved Colour Used			
543	Disodium Hydrogen Citrate Syrup	Each 5ml contains:			
		Disodium Hydrogen Citrate	BP	1.41	gm
		In a flavoured syrup base		q.s.	
		Colour: Approved Colour Used			
544	Domperidone Oral Suspension IP	Each ml contains:			
		Domperidone	IP	1	mg
		In a Flavoured Syrupy Base		q.s.	
		Colour: Approved colour used			
545	Dried Aluminium Hydroxide Gel, Magnesium Hydroxide & Simethicone	Each 10ml contains:			
		Dried Aluminium Hydroxide Gel	IP	250	mg
		Magnesium Hydroxide	IP	200	mg
		Simethicone	IP	50	mg

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	Suspension IP	Sorbitol Solution (Non Crystallizing)	IP	q.s	
		In a flavoured syrup base		q.s.	
		Colour: Approved Colour Used			

546	Ferric Ammonium Citrate, Foilc Acid & Cyanocobalamin Syrup	Each 10ml contains			
		Ferric Ammonium Citrate	IP	160	mg
		Foilc Acid	IP	1.5	mg
		Cyanocobalamin (Vitamin B12)	IP	15	mcg
		In a flavoured syrupy base		q.s.	
		Colour: Approved Colour Used			
		For Therapeutic use			

547	Ketoconazole, Iodochlorhydroxy-quinoline, Clobetasol Propionate, Gentamicin Sulphate & Chlorocresol Cream.	Composition:			
		Ketoconazole	IP	2.00%	w/w
		Iodochlorhydroxyquinoline	IP	1.00%	w/w
		Clobetasol Propionate	IP	0.05%	w/w
		Gentamicin Sulphate	IP	0.10%	w/w
		Chlorocresol	IP	0.10%	w/w
		In a cream base		q.s.	

548	Sertaconazole Nitrate Cream	Composition:			
		Sertaconazole Nitrate	BP	2%	w/w
		Preservative : Benzyl Alcohol	IP	1%	w/w
		In a Cream Base		q.s	

549	Thiocolchicoside, DiclofenacDiethylamine, Linseed Oil, Methyl Salicylate & Menthol Gel	Composition:			
		Thiocolchicoside	IP	0.125%	w/w
		DiclofenacDiethylamine (Eq to Diclofenac Sodium 1.0% w/w)	IP	1.16%	w/w
		Linseed Oil	BP	3%	w/w
		Methyl Salicylate	IP	10%	w/w
		Menthol	IP	5%	w/w
		Gel Base		q.s.	

550	Telmisartan , Chlorthalidone & Amlodipine Tablets	Each Uncoated Tablet contains:-			
		Telmisartan	IP	40	mg
		Chlorthalidone	IP	12.5	mg
		Amlodipine Besilate	IP		
		eq. to Amlodipine		5	mg

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Excipients		q.s	
		Approved colour used in Tablets.			
551	Telmisartan & Chlorthalidone Tablets	Each Uncoated Tablet contains:-			
		Telmisartan	IP	40	mg
		Chlorthalidone	IP	12.5	mg
		Excipients		q.s	
		Approved colour used in Tablets.			
552	Ranitidine HCl Tablets IP	Each Filmcoated Tablet contains:			
		Ranitidine HCl	IP		
		eq. to Ranitidine		150	mg
		Excipients		q.s.	
		Colour:Approved colour used			
553	Ranitidine HCl Tablets IP	Each Filmcoated Tablet contains:			
		Ranitidine HCl	IP		
		eq. to Ranitidine		300	mg
		Excipients		q.s.	
		Colour:Approved colour used			
554	Prednisolone Tablets IP	Each Filmcoated Tablet contains:			
		Prednisolone	IP	5	mg
		Excipients		q.s.	
		Colour:Approved colour used			
555	Prednisolone Tablets IP	Each Filmcoated Tablet contains:			
		Prednisolone	IP	10	mg
		Excipients		q.s.	
		Colour:Approved colour used			
556	Ivermectin Tablets IP	Each Uncoated Tablet contains:			
		Ivermectin	IP	3	mg
		Excipients		q.s.	
		Colour:Approved colour used			
557	Hydroxyzine HCl Tablets IP	Each Filmcoated Tablet contains:			
		Hydroxyzine HCl	IP	10	mg
		Excipients		q.s.	
		Colour:Approved colour used			
558	Paracetamol Chlorpheniramine Maleate & Phenylephrine HCl	Each Uncoated tablet contains:			
		Paracetamol	IP	325	mg
		Chlorpheniramine Maleate	IP	2	mg

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	Tablets	Phenylephrine HCl	IP	5	mg
		Excipients		q.s.	
		Colour:Approved colour used			

559	Paracetamol & Ibuprofen Tablets IP	Each Uncoated tablet contains:			
		Paracetamol	IP	325	mg
		Ibuprofen	IP	400	mg
		Excipients		q.s.	
		Colour:Approved colour used			

560	MetronidazoleTablets IP	Each Filmcoated Tablet contains:			
		Metronidazole Benzoate	IP		
		eq. to Metronidazole		200	mg
		Excipients		q.s.	
		Colour:Approved colour used			

561	MetronidazoleTablets IP	Each Filmcoated Tablet contains:			
		Metronidazole Benzoate	IP		
		eq. to Metronidazole		400	mg
		Excipients		q.s.	
		Colour:Approved colour used			

562	Diclofenac Potassium, Paracetamol , Cetirizine HCl & Magnesium Trisilicate Tablets	Each Uncoated tablet contains:			
		Diclofenac Potassium	BP	50	mg
		Paracetamol	IP	325	mg
		Cetirizine HCl	IP	5	mg
		Magnesium Trisilicate	IP	100	mg
		Excipients		q.s.	
	Colour:Approved colour used				

563	Diacerein, Methyl Sulfonyl Methane & Glucosamine Tablets	Each Uncoated tablet contains:			
		Diacerein	IP	50	mg
		Methyl Sulfonyl Methane		250	mg
		Glucosamine Sulphate			
		Sodium Chloride	IP	750	mg
		Excipients		q.s.	
	Colour:Approved colour used				

564	<b>Combikit of Azithromycin, Fluconazole &amp; Secnidazole Tablets</b>				
	<b>A. Azithromycin Tablets IP 1000mg</b>	Each Filmcoated tablet contains:			
		Azithromycin Dihydrate	IP		

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	<b>B. Fluconazole Tablets IP 150 mg</b>  <b>C. 2 Secnidazole Tablets IP</b>	Eq. to Anhydrous Azithromycin		1000	mg
		Excipients		qs.	
		Colour: Approved colour used			
		Each uncoated tablet contains:			
		Fluconazole	IP	150	mg
		Excipients		qs.	
		Colour: Approved colour used			
		Each Filmcoated tablet contains:			
		Secnidazole	IP	1000	mg
		Excipients		qs.	
		Colour: Approved colour used			

565	Norfloxacin Tinidazole & Lactic Acid Bacillus Bolus  (For animal use only) (Not for human use)	Each Uncoated Bolus contains:-			
		Norfloxacin	IP	1200	mg
		Tinidazole	IP	1800	mg
		Lactic Acid Bacillus		100	million spores
		Excipients		q.s	
		Approved colour used in Bolus			

566	Ranitidine HCl Oral Solution IP	Each 5ml contains:			
		Ranitidine HCl	IP		
		eq. to Ranitidine		75	mg
		Excipients		q.s.	
		Colour: Approved colour used			

567	Ofloxacin & Metronidazole Suspension	Each 5 ml contains:			
		Ofloxacin	IP	50	mg
		Metronidazole Benzoate	IP		
		eq. to Metronidazole		100	mg
		In a flavoured syrup base		q.s.	
Colour: Approved colour used					

568	Magaldrate & Activated Dimethicone Suspension USP	Each 10 ml contains:			
		Magaldrate (Anhydrous)	IP	480	mg
		Activated Dimethicone	IP	20	mg
		In a flavoured syrup base		q.s.	
		Colour: Approved colour used			

569	Dried Aluminium Hydroxide Gel Magnesium Hydroxide Simethicone	Each 10 ml contains:			
		Magnesium Hydroxide	IP	185	mg
		Sodium Carboxymethylcellulose	IP	100	mg

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	&Sodium Carboxymethylcellulose Suspension	Simethicone	IP	50	mg
		Dried Aluminium Hydroxide Gel	IP	830	mg
		In a flavoured syrup base		q.s.	
		Colour:Approved colour used			

570	Disodium Hydrogen Citrate & Dipotassium Hydrogen Citrate Syrup	Each 5 ml contains:			
		Disodium Hydrogen Citrate	BP	625	mg
		Dipotassium Hydrogen Citrate	BP	625	mg
		In a flavoured syrup base		q.s.	
		Colour:Approved colour used			

571	Chlorhexidine Gluconate Solution & cetrimide Antiseptic Liquid	Chlorhexidine Gluconate Solution	IP	1.5%	v/v
		Cetrimide Solution	BP		
		eq. to Cetrimide		3%	v/v
		purified water	IP	qs	
		Approved Colour used			

572	Luliconazole Lotion	Composition:-			
		Luliconazole		1%	w/v
		Lotion Base		q. s.	

573	Povidone Iodine Solution IP	Povidone Iodine	IP	5%	w/v
		eq. to Available Iodine (0.5% w/w)			
		purified water	IP	qs	
		Colour:Approved colour used			

574	Povidone Iodine Solution IP	Povidone Iodine	IP	7.5%	w/v
		eq. to Available Iodine (0.75% w/w)			
		purified water	IP	qs	
		Colour:Approved colour used			

575	Povidone Iodine Solution IP	Povidone Iodine	IP	10%	w/v
		eq. to Available Iodine (1.0% w/w)			
		purified water	IP	qs	
		Colour:Approved colour used			

576	Povidone Iodine &	Povidone Iodine	IP	5%	w/w
-----	-------------------	-----------------	----	----	-----

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	Ornidazole Ointment	eq. to Available Iodine (0.5% w/w)			
		Ornidazole	IP	1%	w/w
		Water Soluble Ointment Base			

577	Amoxicillin Tryhydrate, Cloxacillin Sodium & Lactic Acid bacillus Capsules	Each hard geletin capsule contains:-			
		Amoxicillin Tryhydrate	IP		
		Eq.to Amoxicillin		250	mg
		Cloxacillin Sodium	IP		
		Eq.to Cloxacillin		250	mg
		Lactic Acid Bacillus		2	Billion spores
		Excipients		qs	
		Approved colour used in empty capsule shell			

578	Amoxicillin Tryhydrate, Lactic Acid bacillus Capsules	Each hard geletin capsule contains:-			
		Amoxicillin Tryhydrate	IP		
		Eq.to Amoxicillin		125	mg
		Lactic Acid Bacillus		1.66	Billion spores
		Excipients		qs	
				Approved colour used in empty capsule shell	

579	Amoxicillin Tryhydrate, Lactic Acid bacillus Capsules	Each hard geletin capsule contains:-			
		Amoxicillin Tryhydrate	IP		
		Eq.to Amoxicillin		250	mg
		Lactic Acid Bacillus		1.66	Billion spores
		Excipients		qs	
				Approved colour used in empty capsule shell	

580	Amoxicillin Tryhydrate, Lactic Acid bacillus Capsules	Each hard geletin capsule contains:-			
		Amoxicillin Tryhydrate	IP		
		Eq.to Amoxicillin		500	mg
		Lactic Acid Bacillus		1.66	Billion spores
		Excipients		qs	
				Approved colour used in empty capsule shell	

581	Doxycycline & Ambroxol HCl Capsule	Each Hard Gelatin Capsule contains:			
		Doxycycline Hydrochloride	IP		
		Eq. to Doxycycline		100	mg

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH  
List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Ambroxol HCl	IP	7.5	mg
		Excipients		q.s.	
		Colour:Approved colour used Empty Capsule Shell			

582	Trypsin - Chymotrypsin with Paracetamol and Aceclofenac Tablets	Each Film Coated Tablet Contains			
		50,000 Armour units enzymatic activity (supplied by a purified concentrate which has specific Trypsin & Chymotrypsin activity in a ratio of approximately six to one )			
		(As enteric coated granules)			
		Aceclofenac	IP	100	mg
		Paracetamol	IP	325	mg
		Excipients		q.s.	
		Colour:Approved colour used			

583	Trypsin , Bromelain and Rutoside Trihydrate Tablets	Each Enteric Coated Tablet Contains			
		Trypsin	BP	96	mg
		Bromelain		180	mg
		Rutoside Trihydrate	BP	200	mg
		Excipients		q.s.	
Colour:Approved colour used					

584	Trypsin , Bromelain , Rutoside Trihydrate and Diclofenac Sodium Tablets	Each Enteric Coated Tablet Contains			
		Trypsin	BP	48	mg
		Bromelain		90	mg
		Rutoside Trihydrate	BP	100	mg
		Diclofenac Sodium	IP	50	mg
		Excipients		q.s.	
Colour:Approved colour used					

585	Thiocolchicoside , Aceclofenac and Paracetamol Tablets	Each Film Coated Tablet Contains			
		Thiocolchicoside	IP	4	mg
		Aceclofenac	IP	100	mg
		Paracetamol	IP	325	mg
		Excipients		q.s.	
Colour:Approved colour used					

586	Rifaximin Tablets 550mg	Each film coated tablet contains			
		Rifaximin Ph. Eur.	IP	550	mg

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Excipients		q.s.	
		Colour:Approved colour used			

587	Paracetamol, Phenylephrine Hydrochloride, Caffeine and Chlorpheniramine Maleate Tablets	Each uncoated tablet contains			
		Paracetamol	IP	500	mg
		Phenylephrine Hydrochloride	IP	12.5	mg
		Caffeine (Anhydrous)	IP	30	mg
		Chlorpheniramine Maleate	IP	2	mg
		Excipients		q.s.	
		Colour:Approved colour used			

588	Ranitidine HCl & Domperidone Tablets	Each Filmcoated Tablet contains:			
		Ranitidine HCl	IP		
		eq. to Ranitidine		150	mg
		Domperidone	IP	10	mg
		Excipients		q.s.	
		Colour:Approved colour used			

589	Rifaximin Tablets 200mg	Each film coated tablet contains			
		Rifaximin Ph. Eur.	IP	200	mg
		Excipients		q.s.	
		Colour:Approved colour used			

590	Levocetirizine, Montelukast and Ambroxol HCl (SR) Tablets	Each UnCoated bilayered Tablet Contains			
		Levocetirizine Dihydrochloride	IP	5	mg
		Montelukast Sodium	IP		
		eq. to Anhydrous Montelukast		10	mg
		Ambroxol Hydrochloride (as sustained release)	IP	75	mg
		Excipients		q.s.	
		Colour:Approved colour used			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
--------	--------------------------------------	-------------	---------------	----------	------

591	Glucosamine, Methyl Sulfonyl Methane & Diacerein Tablets	Each film coated tablet contains:			
		Glucosamine Sulphate Potassium Chloride	USP	750	mg
		Equivalent to Glucosamine		446	mg
		Methylsulfonylmethane	USP	250	mg
		Diacerein	IP	50	mg
		Excipients		q.s.	
		Colour:Approved colour used			

592	Gabapentin and Nortriptyline Tablets	Each Film Coated Tablet Contains			
		Gabapentin	IP	400	mg
		Nortriptyline Hydrochloride	IP		
		equivalent to Nortriptyline		10	mg
		Excipients		q.s.	
Colour:Approved colour used					

593	Ferrous Ascorbate, Folic Acid and Zinc Tablets	Each Film Coated Tablet Contains			
		Ferrous Ascorbate			
		equivalent to elemental iron		100	mg
		Folic Acid	IP	1.5	mg
		Zinc Sulphate monohydrate	IP		
		equivalent to elemental zinc		22.5	mg
		Excipients		q.s.	
Colour:Approved colour used					

594	Doxofylline Tablets IP 400mg	Each uncoated tablet contains			
		Doxofylline	IP	400	mg
		Excipients		q.s.	
		Colour:Approved colour used			

595	Ferrous Ascorbate, Folic Acid Zinc and Adenosylcobalamin Tablets	Each Film Coated Tablet Contains			
		Ferrous Ascorbate			
		equivalent to elemental iron		100	mg
		Folic Acid	IP	1.5	mg
		Zinc Sulphate monohydrate	IP		
		equivalent to elemental zinc		5	mg
		Adenosylcobalamin		500	mcg

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Excipients		q.s	
		Colour:Approved colour used			
596	Dried Aluminium Hydroxide, Magnesium Aluminium Silicate Hydrate, Magnesium Hydroxide and Simethicone Chewable Tablets	Each UnCoated Chewable Tablet Contains Dried Aluminium Hydroxide Magnesium Aluminium Silicate Hydrate Magnesium Hydroxide Simethicone Excipients Colour:Approved colour used	IP	300	mg
				50	mg
			IP	25	mg
			IP	25	mg
				q.s.	
597	Disulfiram tablets IP	Each uncoated tablet contains Disulfiram Excipients Colour:Approved colour used	IP	500	mg
				q.s.	
598	Cinnarizine Tablets IP	Each uncoated tablet contains Cinnarizine Excipients Colour:Approved colour used	IP	10	mg
				q.s.	
599	Cefpodoxime Proxetil and Potassium Clavulanate Tablets	Each film coated tablet contains Cefpodoxime Proxetil equivalent to Cefpodoxime Potassium Clavulanate Diluted equivalent to Clavulanic Acid Excipients Colour:Approved colour used	IP	200	mg
			IP	125	mg
				q.s.	
600	Cefixime and Potassium Clavulanate Tablets	Each film coated tablet contains Cefixime Trihydrate Eq. to Anhydrous Cefixime Potassium Clavulanate Diluted equivalent to Clavulanic Acid Excipients Colour:Approved colour used	IP	200	mg
			IP	125	mg
				q.s.	
601	Pre & Pro Biotic Capsules	Each hard gelatin capsule contains: Streptococcus faecalis Clostridium butyricum		30	million
				2	million

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Bacillus mesentericus		1	million
		Lactic acid bacillus (lactobacillus sporogenes)		50	million
		Excipients		q.s.	
		Approved colours used in empty hard gelatin capsule shells			

602	Biotin and Folic Acid Tablets	Each Film Coated Tablet Contains			
		Biotin	USP	5	mg
		Folic Acid	IP	5	mg
		Excipients		q.s.	
		Colour:Approved colour used			

603	Pregabalin, Mecobalamin, Alpha Lipoic Acid , Folic Acid and Pyridoxine Hydrochloride Capsules	Each hard gelatin capsule contains			
		Pregabalin	IP	75	mg
		Mecobalamin	IP	750	mcg
		Alpha Lipoic Acid	USP	100	mg
		Folic Acid	IP	1.5	mg
		Pyridoxine Hydrochloride	IP	3	mg
		Excipients		q.s.	
		Colour:Approved colour used			

604	Racecadotril Capsules IP	Each hard gelatin capsule contains			
		Racecadotril	IP	100	mg
		Excipients		q.s.	
		Colour:Approved colour used			

605	Cefixime and Ofloxacin for Oral Suspension	Each 5ml of the Reconstituted suspension Contains			
		Cefixime Trihydrate	IP		
		eq. to Anhydrous Cefixime		50	mg
		Ofloxacin	IP	50	mg
		Excipients		q.s.	
		Colour:Approved colour used			

606	Ambroxol Hydrochloride, Guaiphenesin and Terbutaline Sulphate Syrup	Each 5ml Contains			
		Ambroxol Hydrochloride	IP	15	mg
		Guaiphenesin	IP	50	mg
		Terbutaline Sulphate	IP	1.5	mg
		Mentholated syrupy base		q.s.	
		Colour:Approved colour used			

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
607	Fexofenadine HCl suspension	Each 5 ml contains:			
		Fexofenadine HCl	IP	30	mg
		In a flavoured syrup base		q.s.	
		Colour:Approved colour used			
608	Chlorhexidine Gluconate, Sodium Fluoride & Zinc Chloride Solution Mouthwash	Composition :-			
		Chlorhexidine Gluconate Solution	IP		
		Eq. to Chlorhexidine Gluconate		0.20%	w/v
		Sodium Fluoride	IP	0.05%	w/v
		Zinc Chloride	IP	0.09%	w/v
		In a pleasantly flavoured aqueous base		q.s.	
Colour:Approved colour used					
609	Paracetamol & Caffeine Tablets IP	Each Un Coated tablet contains:			
		Paracetamol	IP	500	mg
		Caffeine (Anhydrous)	IP	50	mg
		Excipients		q.s.	
Colour:Approved colour used					
610	N-Acetylcysteine, Vitamins and Minerals Tablets	Each film coated tablet contains			
		Biotin	USP	10	mg
		N-Acetylcysteine	USP	50	mg
		Calcium Pantothenate	IP	100	mg
		Sodium Selenite			
		Eq. to Elemental Selenium		65	mcg
		Cupric Oxide			
		Eq. to Elemental Copper		3	mg
		Zinc Oxide	IP		
		Equivalent to Elemental Zinc		22.5	mg
		Excipients		q.s.	
Colour:Approved colour used					
611	Sertaconazole Nitrate & Beclomethasone Dipropionate Cream IP	Composition:-			
		Sertaconazole Nitrate	BP	2%	w/w
		Beclomethasone Dipropionate	IP	0.025%	w/w
In a Cream Base		q. s.			
612	Vitamin A (as Acetate)	Each film Coated Tablet Contains:			

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	Vitamin D3, Vitamin B1 , Vitamin B2 , Vitamin B6 , Calcium Pantotheanate, Niacinamide , Vitamin C and Folic Acid Tablets	Vitamin A (as Acetate)	IP	2500	IU
		Vitamin D3	IP	200	IU
		Vitamin B1	IP	2	mg
		Vitamin B2	IP	2	mg
		Vitamin B6	IP	0.5	mg
		Calcium Pantotheanate	IP	1	mg
		Niacinamide	IP	25	mg
		Vitamin C	IP	50	mg
		Folic Acid	IP	0.2	mg
		Excipients		q.s.	
		Colour:Approved colour used			

613	Sodium Feredetate, Folic Acid and Cyanocobalamin Tablets	Each Film Coated Tablet Contains :			
		Sodium Feredetate	BP	231	mg
		eq. to Elemental Iron		33	mg
		Folic Acid	IP	1.5	mg
		Cyanocobalamin	IP	15	mcg
		Excipients		q.s.	
	Colour:Approved colour used				

614	Sodium Feredetate, Folic Acid and Cyanocobalamin Tablets	Each Film Coated Tablet Contains :			
		Sodium Feredetate	BP	231	mg
		eq. to Elemental Iron		33	mg
		Folic Acid	IP	1.5	mg
		Cyanocobalamin	IP	5	mcg
		Excipients		q.s.	
	Colour:Approved colour used				

615	Ranitidine HCl, Magaldrate and Simethicone Tablets	Each Film Coated Tablet Contains :			
		Ranitidine HCl	IP		
		eq. to Ranitidine		150	mg
		Magaldrate (as Anhydrous)	IP	200	mg
		Simethicone	IP	20	mg
		Excipients		q.s.	
	Colour:Approved colour used				

616	Paracetamol & Caffeine Tablets IP	Each Un Coated tablet contains:			
		Paracetamol	IP	250	mg
		Caffeine (Anhydrous)	IP	25	mg
		Excipients		q.s.	

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Colour:Approved colour used			
617	Paracetamol & Caffeine Tablets IP	Each Un Coated tablet contains:			
		Paracetamol	IP	650	mg
		Caffeine (Anhydrous)	IP	50	mg
		Excipients		q.s.	
		Colour:Approved colour used			
618	Paracetamol Tablets IP	Each Un Coated tablet contains:			
		Paracetamol	IP	250	mg
		Excipients		qs	
		Colour:Approved colour used			
619	Paracetamol Tablets IP	Each Un Coated tablet contains:			
		Paracetamol	IP	1000	mg
		Excipients		qs	
		Colour:Approved colour used			
620	Norfloxacin & Tinidazole Tablets	Each Film Coated Tablet contains:-			
		Norfloxacin	IP	400	mg
		Tinidazole	IP	600	mg
		(with Betacyclodextrin)			
		Excipients		q.s	
		Approved colour used		q.s	
621	Metronidazole, Furazolidone & Dicyclomine Tablets	Each Uncoated Tablets contains:			
		Metronidazole	IP	200	mg
		Furazolidone	IP	50	mg
		Dicyclomine HCl	IP	10	mg
		Excipients		q.s.	
		Colour:Approved colour used			
622	Loperamide HCl and Lactic Acid Bacillus Tablet	Each UnCoated Tablet Contains :			
		Loperamide HCl		2	mg
		Lactic Acid Bacillus		100	Million spores
		Excipients		q.s.	
		Colour:Approved colour used			
623	Levocarnitine,	Each Film Coated Tablet Contains :			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH  
List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	Methylcobalamin and Folic Acid Tablets	Levocarnitine	USP	250	mg
		Methylcobalamin	IP	1500	mcg
		Folic Acid	IP	1.5	mg
		Excipients		q.s.	
		Colour:Approved colour used			

624	Biotin Tablets	Each Film Coated Tablet Contains			
		Biotin	USP	10	mg
		Excipients		q.s.	
		Colour:Approved colour used			

625	L-Carnitine L-Tartrate and Folic acid Tablets	Each Film Coated Tablet Contains :			
		L-Carnitine L-Tartrate			
		eq. to L-Carnitine		500	mg
		Folic Acid	IP	1.5	mg
		Excipients		q.s.	
	Colour:Approved colour used				

626	Ibuprofen, Paracetamol & Chlorpheniramine Maleate Tablets	Each Un Coated Tablet Contains :			
		Ibuprofen	IP	400	mg
		Paracetamol	IP	325	mg
		Chlorpheniramine Maleate	IP	2	mg
		Excipients		q.s.	
	Colour:Approved colour used				

627	Dicyclomine Hydrochloride, Oxetacaine and Magaldrate Tablets	Each UnCoated Dispersible Tablet Contains :			
		Dicyclomine Hydrochloride	IP	10	mg
		Oxetacaine	BP	5	mg
		Magaldrate (as Anhydrous)	IP	400	mg
		Excipients		q.s.	
	Colour:Approved colour used				

628	Dicyclomine Hydrochloride, Oxetacaine and Magaldrate Tablets	Each UnCoated Dispersible Tablet Contains :			
		Dicyclomine Hydrochloride	IP	10	mg
		Oxetacaine	BP	5	mg
		Magaldrate (as Anhydrous)	IP	540	mg
		Excipients		q.s.	
	Colour:Approved colour used				

629	Dicyclomine Hydrochloride, Oxetacaine, Magaldrate and Simethicone Tablet	Each Film Coated Tablet Contains :			
		Dicyclomine Hydrochloride	IP	10	mg
		Oxetacaine	BP	10	mg

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH  
List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Magaldrate (as Anhydrous)	IP	400	mg
		Simethicone	IP	25	mg
		Excipients		q.s.	
		Colour:Approved colour used			

630	Cetirizine Hydrochloride & Ambroxol Hydrochloride Tablets	Each Film Coated tablet contains:			
		Cetirizine Hydrochloride	IP	5	mg
		Ambroxol Hydrochloride	IP	60	mg
		Excipients		q.s.	
		Colour:Approved colour used			

631	Ambroxol Hydrochloride, Guaiphenesin and Salbutamol Sulphate Tablets	Each Un Coated Tablet Contains :			
		Ambroxol Hydrochloride	IP	15	mg
		Guaiphenesin	IP	100	mg
		Salbutamol Sulphate	IP	2	mg
		Excipients		q.s.	
		Colour:Approved colour used			

632	L- Carnitine, Coenzyme Q10, Vitamin K2 -7, Astaxanthin , Magnesium Sulphate and Zinc Sulphate Monohydrate Capsules	Each Hard Gelatin Capsule Contains:			
		L-Carnitine	USP	500	mg
		Coenzyme Q 10	USP	100	mg
		Vitamin K2 -7		50	mcg
		Astaxanthin	USP	8	mg
		Magnesium Sulphate	IP	50	mg
		Zinc Sulphate Monohydrate	IP		
		eq. to elemental zinc		7.5	mg
		Excipients		q.s.	
		Colour:Approved colour used			

633	Amoxicillin Trihydrate and Potassium Clavulanate Suspension	Each 5ml of Constituted Suspension Contains :			
		Amoxicillin Trihydrate	IP		
		eq. to Amoxicillin		200	mg
		Potassium Clavulanate	IP		
		eq. to Clavulanic acid		28.5	mg
		Excipients		q.s.	
		Colour:Approved colour used			

634	Amoxicillin Trihydrate and Potassium Clavulanate Suspension	Each 5ml of Constituted Suspension Contains :			
		Amoxicillin Trihydrate	IP		
		eq. to Amoxicillin		400	mg
		Potassium Clavulanate	IP		
		eq. to Clavulanic acid		57	mg
		Excipients		q.s.	
		Colour:Approved colour used			

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
635	Dextromethorphan Hydrobromide, Phenylephrine Hydrochloride & Chlorpheniramine Maleate Syrup	Each 5ml Contains:			
		Dextromethorphan Hydrobromide	IP	10	mg
		Phenylephrine Hydrochloride	IP	5	mg
		Chlorpheniramine Maleate	IP	2	mg
		In a flavoured Syrupy base		q.s.	
		Colour: Approved colour Used			
636	Cyproheptadine HCl & Tricholine Citrate Drops	Each ml Contains :			
		Cyproheptadine Hydrochloride	IP	1.5	mg
		Tricholine Citrate	IP	55	mg
		In A Flavoured Sarbitol Base		q.s.	
		Colour: Approved colour used			
637	Ambroxol Hydrochloride, Guaiphenesin and Levosalbutamol Sulphate Syrup	Each 5ml Contains			
		Ambroxol Hydrochloride	IP	15	mg
		Guaiphenesin	IP	50	mg
		Levosalbutamol Sulphate Eq. to Levosalbutamol	IP	0.5	mg
		Mentholated syrupy base		q.s.	
		Colour: Approved colour used			
638	Nimesulide, Methyl Salicylate , Menthol and Capsaicin Gel	Each Gram Contains :-			
		Nimesulide	BP	10	mg
		Methyl Salicylate	IP	100	mg
		Menthol	IP	50	mg
		Capsaicin	USP	0.25	mg
		In a gel base		q.s.	
		Colour: Approved colour used			
639	Ferric Ammonium Citrate, Folic Acid , L- Lysine Monohydrochloride , Vitamin B12 , Niacinamide , and Zinc Sulphate oral liquid	Each 5ml oral liquid contains:			
		Ferric Ammonium Citrate	IP	160	mg
		Folic Acid	IP	1	mg
		L-Lysine Monohydrochloride	USP	12	mg
		Vitamin B12	IP	7.5	mcg
		Niacinamide	IP	15	mg
		Zinc Sulphate	IP	10	mg
		In a flavoured syrurpy base		q.s.	
		Colour: Approved colour used			
640	Diclofenac Diethylamine, Mephenesin, Capsaicin, Menthol and	Each 1 ml of Liniment Contains :			
		Diclofenac Diethylamine	BP	17.4	mg
		eq. to Diclofenac Sodium		15	mg

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	Camphor Liniment	Mephesisin	IP	50	mg
		Capsaicin Powder 95%	USP	0.02	mg
		Menthol	IP	70	mg
		Camphor	USP	10	mg
		In a liniment liquid base		q.s.	
		Colour:Approved colour used			

641	Diclofenac Diethylamine, Methyl Salicylate, Menthol and Camphor Liniment	Each 1 ml of Liniment Contains :			
		Diclofenac Diethylamine	BP	17.4	mg
		eq. to Diclofenac Sodium		15	mg
		Methyl Salicylate	IP	100	mg
		Menthol	IP	70	mg
		Camphor	USP	10	mg
		In a liniment liquid base		q.s.	
Colour:Approved colour used					

642	Diclofenac Diethylamine, Methyl Salicylate, Mephesisin, Linseed Oil, Menthol and Chlorocresol gel	Composition			
		Diclofenac Diethylamine	BP	1.16%	w/w
		eq. to Diclofenac Sodium		1.00%	w/w
		Methyl Salicylate	IP	5.00%	w/w
		Mephesisin	IP	10.00%	w/w
		Linseed Oil	BP	3.00%	w/w
		Menthol	IP	5.00%	w/w
		Capsaicin	USP	0.025%	w/w
		Chlorocresol (as preservative)	IP	0.10%	w/w
		In a gel base		q.s.	
Colour:Approved colour used					

643	Thymol, Ichthammol, Menthol & Lignocaine Hydrochloride Ointment	Thymol	IP	0.50%	w/w
		Ichthammol	BP	0.20%	w/w
		Menthol	IP	1.00%	w/w
		Lignocaine Hydrochloride	IP	1.00%	w/w
		In a Ointment Base		qs	

644	Ubidecarenone and Betacarotene gel	Composition :			
		Ubidecarenone	BP	0.10%	w/w
		Betacarotene 30% despersion		0.10%	w/w
In a gel base		q.s.			

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Colour:Approved colour used			

645	Troloxerutin, Calcium Dobesilate Monohydrate, Lignocaine Hcl, Hydrocortisone Acetate, Zinc Oxide & Phenylephrine HCl Cream	Troloxerutin	BP	2%	w/w
		Calcium Dobesilate Monohydrate	IP		
		Eq. to Anhydrous Calcium Dobesilate		0.25%	w/w
		Lignocaine Hydrochloride	IP	3%	w/w
		Hydrocortisone Acetate	IP	0.25%	w/w
		Zinc Oxide	IP	5%	w/w
		Phenylephrine Hydrochloride	IP	0.10%	W/w
		In a cream base		q.s.	
		Colour:Approved colour used			

646	Vildagliptin & Metformin HCl Tablets IP	Each film coated tablets contains:			
		Vildagliptin	IP	50	mg
		Metformin HCl	IP	500	mg
		Excipients		q. s.	
		Colour :- Approved colour used			

647	Vildagliptin & Metformin HCl IP Tablets	Each film coated tablets contains:			
		Vildagliptin		50	mg
		Metformin HCl	IP	850	mg
		Excipients		q. s.	
		Colour :- Approved colour used			

648	Vildagliptin & Metformin HCl Tablets IP	Each film coated tablets contains:			
		Vildagliptin		50	mg
		Metformin HCl	IP	1000	mg
		Excipients		q. s.	
		Colour :- Approved colour used			

649	Vitamin D3 (Cholecalciferol) & Vitamin K2-7 Tablets	Each Uncoated Tablet Contains:			
		Vitamin D3 (Cholecalciferol)	IP	2000	IU

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Vitamin K2-7	IP	50	mcg
		Excipients		q.s	
		Colour :- Approved colour used			

650	Vitamin B1 mononitrate Vitamin B2, Vitamin B6 Vitamin B12, Niacinamide , Folic Acid, Calcium D-Panththenate , Vitamin C , Glutamic Acid and Zinc Oxide Tablets	Each Film Coated Tablet Contains:			
		Vitamin B1 mononitrate	IP	5	mg
		Vitamin B2	IP	5	mg
		Vitamin B6	IP	3	mg
		Vitamin B12	IP	15	mcg
		Niacinamide	IP	50	mcg
		Folic Acid	IP	1	mg
		Calcium D-Panththenate	IP	10	mg
		Vitamin C	IP	75	mg
		Glutamic Acid		50	mg
		Zinc Oxide	IP	20	mg
		Excipients		q.s.	
Colour:Approved colour used					

651	Trypsin & Chymotrypsin Tablets	Each gastro-resistant Tablet Contains			
		1,00,000 Armour units of enzymatic			
		Excipients		q.s.	
		Colour:Approved colour used			

652	Trypsin , Bromelain and Rutoside Trihydrate Tablets	Each Enteric Coated Tablet Contains			
		Trypsin	BP	48	mg
		Bromelain		90	mg
		Rutoside Trihydrate	BP	100	mg
		Excipients		q.s.	
Colour:Approved colour used					

653	Terbinafine HCL Tablets IP	Each Film Coated tablets contains:			
		Terbinafine HCL eq.to Terbinafine	IP	500	mg
		Excipients		q. s.	
		Colour :- Approved colour used			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
--------	--------------------------------------	-------------	---------------	----------	------

654	Telmisartan & Chlorthalidone Tablets	Each Film Coated tablet contains:			
		Telmisartan	IP	80	mg
		Chlorthalidone	IP	12.5	mg
		Excipients		q. s.	
		Colour :- Approved colour used			

655	Salbutamol Tablets IP	Each Uncoated Tablet Contains:			
		Salbutamol Sulphate	IP		
		eq. to Salbutamol		2	mg
		Excipients		q.s.	
		Colour: Approved colour Used			

656	Salbutamol Tablets IP	Each Uncoated Tablet Contains:			
		Salbutamol Sulphate	IP		
		eq. to Salbutamol		4	mg
		Excipients		q.s.	
		Colour: Approved colour Used			

657	Roxithromycin Tablets IP	Each uncoated tablet contains:			
		Roxithromycin	IP	300	mg
		Excipients			q.s.

658	Rosuvastatin & Telmisartan Tablets	Each Film Coated tablets contains:			
		Rosuvastatin calcium eq to Rosuvastatin	IP	10	mg
		Telmisartan	IP	40	mg
		Excipients		q. s.	
		Colour :- Approved colour used			

659	Rosuvastatin & Aspirin Tablets	Each Uncoated tablets contains:			
		Rosuvastatin calcium eq to Rosuvastatin	IP	10	mg
		Aspirin	IP	150	mg
		Excipients		q. s.	
		Colour :- Approved colour used			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
660	Rosuvastatin & Aspirin Tablets	Each Uncoated tablets contains:			
		Rosuvastatin calcium eq to Rosuvastatin	IP	5	mg
		Aspirin	IP	75	mg
		Excipients		q. s.	
		Colour :- Approved colour used			
661	Rosuvastatin & Aspirin Tablets	Each Uncoated tablets contains:			
		Rosuvastatin calcium eq to Rosuvastatin	IP	10	mg
		Aspirin	IP	75	mg
		Excipients		q. s.	
		Colour :- Approved colour used			
662	Paracetamol & Ibuprofen Tablets	Each Uncoated Dispersible tablets contains:			
		Ibuprofen	IP	100	mg
		Paracetamol	IP	125	mg
		Excipients		q. s.	
		Colour :- Approved colour used			
663	Paracetamol & Mefenamic Acid Tablets	Each Uncoated Tablet Contains			
		Mefenamic Acid	IP	500	mg
		Paracetamol	IP	325	Mg
		Excipients		q.s.	
		Colour: Approved Colour used			
664	Paracetamol & Dicyclomine HCl Tablets	Each Uncoated tablets contains:			
		Paracetamol	IP	500	mg
		Dicyclomine HCl	IP	20	mg
		Excipients		q. s.	
		Colour :- Approved colour used			
665	Ondansetron orally Disintegrating Tablets IP	Each un coated orally Disintegrating tablet contains:			
		Ondansetron Hydrochloride	IP		
		Eq. to Ondansetron		8	mg.
		Excipients			q.s.
		Colour: Approved colour used			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH  
List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
666	Nebivolol Hcl & Telmisartan Tablets	Each Uncoated tablets contains:			
		Nebivolol Hcl	IP	5	mg
		Telmisartan	IP	40	mg
		Excipients		q. s.	
Colour :- Approved colour used					
667	Nortriptyline HCl Tablets IP	Each Filmcoated tablet contains:-			
		Nortriptyline HCl eq. to Nortriptyline	IP	25	mg
		Excipients		q.s	
		Approved colour used in Tablets			
668	Magaldrate, Dicyclomine Hydrochloride, Dimethicone Tablets	Each film coated tablets contains:			
		Magaldrate	IP	540	mg
		Dicyclomine Hydrochloride	IP	20	mg
		Dimethicone	IP	20	mg
		Excipients		q. s.	
Colour :- Approved colour used					
669	Loperamide HCl and Simethicone Tablets	Each Uncoated Tablet Contains:			
		Loperamide HCl	IP	2	mg
		Simethicone	IP	125	mg
		Excipients		q.s.	
Colour:Approved colour used					
670	Levofloxacin Tablets IP	Each Film Coated tablet Contains:-			
		Levofloxacin Hemihydrate eq. to Levofloxacin	IP	750	mg
		Excipients		q.s	
		Approved colour used in Coating			
671	Ibuprofen Tablets IP	Each Uncoated Tablet Contains:			
		Ibuprofen	IP	200	mg
		Excipients		q.s.	
		Colour: Approved colour Used			
672	Ibuprofen Tablets IP	Each Uncoated Tablet Contains:			
		Ibuprofen	IP	400	mg
		Excipients		q.s.	
		Colour: Approved colour Used			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
673	Griseofulvin Tablets IP	Each Uncoated Tablet Contains:			
		Griseofulvin	IP	125	mg
		Excipients		q.s.	
		Colour: Approved colour Used		q.s.	
674	Griseofulvin Tablets IP	Each Uncoated Tablet Contains:			
		Griseofulvin	IP	250	mg
		Excipients		q.s.	
		Colour: Approved colour Used		q.s.	
675	Griseofulvin Tablets IP	Each Uncoated Tablet Contains:			
		Griseofulvin	IP	500	mg
		Excipients		q.s.	
		Colour: Approved colour Used		q.s.	
676	Glimepiride & Metformin Hydrochloride Tablets	Each Uncoated tablets contains:			
		Glimepiride	IP	2	mg
		Metformin Hydrochloride	IP	850	mg
		Excipients		q. s.	
		Colour :- Approved colour used			
677	Glibenclamide Tablets IP	Each Uncoated Tablet Contains:			
		Glibenclamide	IP	5	mg
		Excipients		q.s.	
		Colour: Approved colour Used			
678	Gliclazide Tablets & Metformin Hydrochloride	Each Uncoated tablets contains:			
		Metformin Hydrochloride	IP	500	mg
		Gliclazide	IP	40	mg
		Excipients		q. s.	
Colour :- Approved colour used					
679	Gabapentin , Methylcobalamin & Alpha Lipoic Acid Tablets	Each Film Coated tablets contains:			
		Gabapentin	USP	300	mg
		Methylcobalamin	IP	500	mcg
		Alpha Lipoic Acid	USP	100	mg
		Excipients		q. s.	
Colour :- Approved colour used					
680	Folic Acid & Riboflavin , Niacinamide Tablets	Each Uncoated tablets contains:			
		Folic Acid	IP	1.5	mg
		Riboflavin	IP	10	mg
		Niacinamide	IP	50	mg

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Excipients		q. s.	
		Colour :- Approved colour used			
681	Etodolac & Thiocolchicoside Tablets	Each Film Coated tablet contains:			
		Etodolac	IP	300	mg
		Thiocolchicoside	IP	8	mg
		Excipients		q. s.	
		Colour :- Approved colour used			
682	Etodolac & Thiocolchicoside Tablets	Each Film Coated tablet contains:			
		Etodolac	IP	200	mg
		Thiocolchicoside	IP	4	mg
		Excipients		q. s.	
		Colour :- Approved colour used			
683	Esomeprazole Magnesium & Domperidone Tablets	Each Enteric coated tablets contains:			
		Esomeprazole Magnesium eq. To Esomeprazole	IP	20	mg
		Domperidone	IP	15	mg
		Excipients		q. s.	
		Colour :- Approved colour used			
684	Epalrestat & Methylcobalamin Tablets	Each Film Coated Sustained Release tablet contains:			
		Epalrestat		150	mg
		Methylcobalamin	IP	1500	mcg
		Excipients		q. s.	
		Colour :- Approved colour used			
685	Doxycycline Hydrochloride and Ambroxol HCl Tablets	Each Film Coated Tablet Contains			
		Doxycycline Hydrochloride equivalent to Doxycycline	IP	100	mg
		Ambroxol Hydrochloride	IP	7.5	mg
		Excipients		q.s.	
		Colour:Approved colour used			
686	Doxylamine Succinate & Pyridoxine HCl Tablets	Each Enteric Coated tablets contains:			
		Doxylamine Succinate	USP	10	mg
		Pyridoxine HCl	IP	10	mg
		Excipients		q. s.	
		Colour :- Approved colour used			

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
687	Diclofenac Sodium Tablets IP (Not for Veterinary Use)	Each Uncoated Prolong Release Tablet contains:-			
		Diclofenac Sodium	IP	100	mg
		Excipients		q.s	
		Approved colour used in Coating			
688	Diclofenac Potassium & Drotaverine Hcl Tablets	Each film coated Tablet Contains:			
		Diclofenac Potassium	BP	50	mg
		Drotaverine HCl		80	mg
		Excipients		q.s	
		Colour :- Approved colour used			
689	Cvproheptadine Hydrochloride Tablets IP 4mg	Each uncoated tablet contains			
		Cyproheptadine Hydrochloride	IP	4	mg
		Excipients		q.s.	
		Colour:Approved colour used			
690	Clarithromycin Tablets IP	Each film coated tablet contains			
		Clarithromycin	IP	250	mg
		Excipients		q.s.	
		Colour:Approved colour used			
691	Chlorpheniramine maleate and Phenylephrine Hydrochloride Tablets	Each Uncoated Tablet Contains			
		Chlorpheniramine Maleate	IP	4	mg
		Phenylephrine Hydrochloride	IP	2.5	mg
		Excipients		q.s.	
		Colour:Approved colour used			
692	Cetirizine HCL Tablets IP	Each Uncoated tablets contains:			
		Cetirizine HCL	IP	5	mg
		Excipients		q. s.	
		Colour :- Approved colour used			
693	Cefixime and Lactic Acid Bacillus Dispersible Tablets	Each Uncoated Dispersible Tablet Contains:			
		Cefixime Trihydrate	IP		
		eq. to Anhydrous Cefixime		200	mg
		Lactic Acid Bacillus		60	Million spores
		Excipients		q.s.	
Colour:Approved colour used					
694	Cefixime Tablets IP	Each Uncoated Tablets Contains:-			
		Cefixime Trihydrate	IP		

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Eq. to Anhydrous Cefixime		400	mg
		Excipients		q.s	
		Approved colour used in Tablets			

695	Cefadroxil Tablets IP	Each Uncoated tablet contains:-			
		Cefadroxil Monohydrate	IP		
		eq. to Anhydrous Cefadroxil		500	mg
		Excipients		q.s	
		Approved colour used in Tablets			

696	Cefadroxil Tablets IP	Each Uncoated tablet contains:-			
		Cefadroxil Monohydrate	IP		
		eq. to Anhydrous Cefadroxil		125	mg
		Excipients		q.s	
		Approved colour used in Tablets			

697	Cefadroxil Tablets IP	Each Uncoated tablet contains:-			
		Cefadroxil Monohydrate	IP		
		eq. to Anhydrous Cefadroxil		250	mg
		Excipients		q.s	
		Approved colour used in Tablets			

698	Baclofen Tablets IP	Each uncoated tablet contains			
		Baclofen	IP	5	mg
		Excipients		q.s.	
		Colour:Approved colour used			

699	Baclofen Tablets IP	Each uncoated tablet contains			
		Baclofen	IP	10	mg
		Excipients		q.s.	
		Colour:Approved colour used			

700	Baclofen Tablets IP	Each uncoated tablet contains			
		Baclofen	IP	20	mg
		Excipients		q.s.	
		Colour:Approved colour used			

701	Atenolol & Chlorthalidone	Each Uncoated tablet contains:			
-----	---------------------------	--------------------------------	--	--	--

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	Tablets IP	Atenolol	IP	50	mg
		Chlorthalidone	IP	12.5	mg
		Excipients		q. s.	
		Colour :- Approved colour used			

702	Amoxicillin Trihydrate, Potassium Clavulanate Diluted and Lactic Acid Bacillus Tablets	Each Film Coated Tablet Contains:			
		Amoxicillin Trihydrate	IP		
		eq. to Amoxicillin		500	mg
		Potassium Clavulanate Diluted	IP		
		eq. to Clavulanic Acid		125	mg
		Lactic Acid Bacillus		60	Million spores
		Excipients		q.s.	
Colour: Approved colour used					

703	Atenolol & Chlorthalidone Tablets IP	Each Uncoated tablet contains:			
		Atenolol	IP	25	mg
		Chlorthalidone	IP	12.5	mg
		Excipients		q. s.	
		Colour :- Approved colour used			

704	Aspirin & Prasugrel HCL Tablets	Each Enteric coated tablets contains:			
		Aspirin	IP	75	mg
		Prasugrel HCL		10	mg
		Excipients		q. s.	
Colour :- Approved colour used					

705	Tetracycline HCl Capsule IP	Each hard geletin capsule contains:-			
		Tetracycline HCl	IP	500	mg
		Excipients		qs	
		Approved colour used in empty capsule shell			

706	Tetracycline HCl Capsule IP	Each hard geletin capsule contains:-			
		Tetracycline HCl	IP	250	mg
		Excipients		qs	
		Approved colour used in empty capsule shell			

707	Ferrous Fumarate, Folic Acid and Vitamin B12 Capsules	Each Hard Gelatin Capsule Contains			
		Ferrous Fumarate	IP	300	mg

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Folic Acid	IP	1.5	mg
		Vitamin B12	IP	15	mcg
		Excipients		q.s.	
		Colour: Approved colour used in empty capsule shell			

708	Lansoprazole Capsule IP	Each hard geletin capsule contains:-			
		Lansoprazole	IP	15	mg
		As enteric coated pellets			
		Excipients		qs	
		Approved colour used in empty capsule shell			

709	Lansoprazole Capsule IP	Each hard geletin capsule contains:-			
		Lansoprazole	IP	30	mg
		As enteric coated pellets			
		Excipients		qs	
		Approved colour used in empty capsule shell			

710	Phenylephrine (Sustained Release) & Chlorpheniramine Maleate (Sustained Release) Capsules	Each Hard Gelatin Capsule Contains:				
		Phenylephrine Hydrochloride (as sustained release pelletes)	IP	20	mg	
		Chlorpheniramine Maleate (as sustained release pelletes)	IP	8	mg	
		Excipients		q.s.		
		Colour: Approved colour used				

711	Phenylephrine (Sustained Release) & Chlorpheniramine Maleate (Sustained Release) Capsules	Each Hard Gelatin Capsule Contains:				
		Phenylephrine Hydrochloride (as sustained release pelletes)	IP	10	mg	
		Chlorpheniramine Maleate (as sustained release pelletes)	IP	4	mg	
		Excipients		q.s.		
		Colour: Approved colour used				

712	Amlodipine & Atenolol Tablets	Each Uncoated tablets contains:			
		Amlodipine	IP	5	mg
		Atenolol	IP	250	mg
		Excipients		q. s.	
		Colour :- Approved colour used			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
--------	--------------------------------------	-------------	---------------	----------	------

713	Indomethacin (EC) and Paracetamol Capsules	Each Hard Geletin Capsule Contains:-			
		Indomethacin	IP	25	mg
		As Enteric Coated Granules			
		Paracetamol	IP	325	mg
		Excipients		q.s.	
		Colour:Approved colour used in empty capsule shell			

714	Cephalexin Monohydrate and Bromhexine HCl Capsules	Each Hard Gelatin Capsule Contains:			
		Cephalexin Monohydrate	IP		
		eq. to Cephalexin		250	mg
		Bromhexine HCl	IP	4	mg
		Excipients		q.s.	
		Colour:Approved colour used in empty capsule shell			

715	Cephalexin Monohydrate and Bromhexine HCl Capsules	Each Hard Gelatin Capsule Contains:			
		Cephalexin Monohydrate	IP		
		eq. to Cephalexin		500	mg
		Bromhexine HCl	IP	8	mg
		Excipients		q.s.	
		Colour:Approved colour used			

716	Chloramphenicol Capsule IP	Each hard geletin capsule contains:-			
		Chloramphenicol	IP	250	mg
		Excipients		qs	
				Approved colour used in empty capsule shell	

717	Chloramphenicol Capsule IP	Each hard geletin capsule contains:-			
		Chloramphenicol	IP	500	mg
		Excipients		qs	
				Approved colour used in empty capsule shell	

718	Amoxicillin Tryhydrate, Cloxacillin Sodium & Lactic Acid bacillus Capsules	Each hard geletin capsule contains:-			
		Amoxicillin Tryhydrate	IP		
		Eq.to Amoxicillin		250	mg
		Cloxacillin Sodium	IP		

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Eq.to Cloxacillin		250	mg
		Lactic Acid Bacillus		90	Million spores
		Excipients		qs	
		Approved colour used in empty capsule shell			

719	Albendazole and Ivermectin Oral Suspension  (For Animal Use Only) (Not For Human Use)	Each 30ml Contains			
		Albendazole	IP	750	mg
		Ivermectin (Vet.)	IP	25	mg
		In a flavoured syrupy base		q.s.	
		Colour:Approved colour used			

720	Ivermectin Bolus  (For Animal Use Only) (Not For Human Use)	Each Uncoated Bolus Contains:			
		Ivermectin (Vet.)	IP	100	mg
		Excipients		q.s.	
		Colour:Approved colour used			

721	Meloxicam <i>Bolus BP</i>  (For Animal Use Only) (Not For Human Use)	Each Uncoated Bolus Contains:			
		Meloxicam	BP	100	mg
		Excipients		q.s.	
		Colour:Approved colour used			

722	Nimesulide , Paracetamol and Serratiopeptidase Bolus  (For Animal Use Only) (Not For Human Use)	Each Uncoated Bolus Contains:			
		Nimesulide	BP	400	mg
		Paracetamol	IP	1500	mg
		Serratiopeptidase (as enteric coated granules)	IP	60	mg
		Excipients		q.s.	
		Colour:Approved colour used			

723	Trimethoprim and Sulphadiazine Bolus IP  (For Animal Use Only) (Not For Human Use)	Each Uncoated Bolus Contains:			
		Trimethoprim	IP	400	mg
		Sulphadiazine	IP	2000	mg
		Excipients		q.s.	
		Colour:Approved colour used			

724	Vitamin B1, Vitamin B2 , Vitamin B6, Vitamin B12, Folic Acid and Niacinamide Capsules	Each Hard Geletin Capsule Contains:-			
		Vitamin B1	IP	1	mg
		Vitamin B2	IP	1	mg
		Vitamin B6	IP	0.5	mg
		Vitamin B12	IP	5	mcg
		Folic Acid	IP	100	mcg
		Niacinamide	IP	15	mg

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Excipients		q.s.	
		Colour:Approved colour used in empty capsule shell			

725	Vitamin B1 ,Vitamin B2, Vitamin B6, Vitamin B12 , Folic Acid, Niacinamide , Lactic Acid Bacillus and Diabasic Calcium Phosphate Capsules	Each Hard Gelatin Capsule Contains:			
		Vitamin B1	IP	2	mg
		Vitamin B2	IP	1	mg
		Vitamin B6	IP	1.5	mg
		Vitamin B12	IP	1	mcg
		Folic Acid	IP	400	mcg
		Niacinamide	IP	15	mg
		Lactic Acid Bacillus		100	Million Spores
		Diabasic Calcium Phosphate	IP	100	mg
		Excipients		q.s.	
		Colour:Approved colour used in empty capsule shell			

726	Cephalexin Monohydrate and Bromhexine HCl Suspension	Each 5ml reconstituted Suspension Contains:			
		Cephalexin monohydrate	IP		
		eq. to Cephalexin		125	mg
		Bromhexine HCl	IP		
		eq. to Bromhexine		2	mg
		In a Flavoured Syrupy Base		q.s.	
		Colour:Approved colour used			

727	Cephalexin Monohydrate and Bromhexine HCl Suspension	Each 5ml reconstituted Suspension Contains:			
		Cephalexin monohydrate	IP		
		eq. to Cephalexin		250	mg
		Bromhexine HCl	IP		
		eq. to Bromhexine		4	mg
		In a Flavoured Syrupy Base		q.s.	
		Colour:Approved colour used			

728	Zinc Sulphate Monohydrate, Vitamin B12, Calcium Pantothenate , Nicotinamide and Vitamin C Capsules	Each Hard Geletin Capsules Contains:			
		Zinc Sulphate Monohydrate	IP	41.17	mg
		eq. to elemental Zinc		15	mg
		Vitamin B12	IP	15	mcg
		Calcium Pantothenate	IP	25	mg
		Nicotinamide	IP	50	mg
		Vitamin C	IP	150	mg
		Excipients		q.s.	
		Colour:Approved colour used in empty capsule shell			

729	Vitamin B1,	Each 5ml Contains:-			
-----	-------------	---------------------	--	--	--

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	Riboflavin sodium Phosphate , Vitamin B6 , Vitamin B12, Niacinamide , D-Panthenol and L-lysine HCl Syrup	Vitamin B1	IP	0.5	mg
		Riboflavin sodium Phosphate	IP	0.5	mg
		Vitamin B6	IP	0.25	mg
		Vitamin B12	IP	0.25	mcg
		Niacinamide	IP	7.5	mg
		D-Panthenol	USP	0.5	mg
		L-lysine HCl	BP	30	mg
		In a flavoured syrupy base			q.s.
		Colour:Approved colour used			

730	Protein Hydrolysate, Vitamin B1, Vitamin B2, Vitamin B6, Cyanocobalamin, D-Panthenol, Iron choline Citrate, L-lysine Monohydrate, Zinc Sulphate and Niacinamide Oral Liquid	Each 15ml Oral Liquid Contains:			
		Protein Hydrolysate		1	gm
		Vitamin B1	IP	2.5	mg
		Vitamin B2	IP	2.5	mg
		Vitamin B6	IP	0.75	mg
		Cyanocobalamin	IP	5	mcg
		D-Panthenol	USP	5	mg
		Iron Choline Citrate		100	mg
		L-lysine Monohydrate	BP	40	mg
		Zinc Sulphate	IP	8	mg
		Niacinamide	IP	25	mg
		In a flavoured syrupy base			q.s.
		Colour:Approved colour used			

731	Ofloxacin , Metronidazole & Simethicone Suspension	Each 5 ml contains:			
		Ofloxacin	IP	50	mg
		Metronidazole Benzoate	IP		
		eq. to Metronidazole		120	mg
		Simethicone	IP	10	mg
		In a flavoured syrup base			q.s.
		Colour:Approved colour used			

732	Liquid Paraffin , Milk of Magnesia and Sodium Picosulphate Suspension	Each 5ml Suspension Contains:			
		Liquid Paraffin	IP	1.25	ml
		Milk of Magnesia	IP	3.75	ml
		Sodium Picosulphate	BP	3.33	mg
		In a Flavoured Syrupy Base			q.s.
		Colour:Approved colour used			

733	Fexofenadine HCl & Montelukast Sodium suspension	Each 5 ml contains:			
		Fexofenadine HCl	IP	60	mg
		Montelukast Sodium	IP		

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		eq. to Montelukast		4	mg
		In a flavoured syrup base		q.s.	
		Colour:Approved colour used			
734	Calcium Gluconate, Calcium Lactate, Cyanocobalamin ,Vitamin D3 and Niacinamide Syrup	Each 5ml Contains:			
		Calcium Gluconate	IP	20	mg
		Calcium Lactate	IP	40	mg
		Cyanocobalamin	IP	2.5	mcg
		Vitamin D3	IP	200	IU
		Niacinamide	IP	22.5	mg
		In a flavoured syrurpy base		q.s.	
		Colour:Approved colour used			
735	Calcium Gluconate, Cholecalciferol, Vitamin B12 and Ferric Ammonium Citrate Oral Liquid	Each 5ml oral liquid contains:			
		Calcium Gluconate	IP	200	mg
		Cholecalciferol	IP	400	IU
		Vitamin B12	IP	3.5	mcg
		Ferric Ammonium Citrate	IP	45	mg
		In a flavoured syrurpy base		q.s.	
		Colour:Approved colour used			
736	Calamine, Zinc Oxide, Cetrimide & Dimethicone ointment	Calamine	IP	1.5%	w/w
		Zinc Oxide	IP	7.5%	w/w
		Cetrimide	IP	1.125%	w/w
		Dimethicone	IP	20.0%	w/w
		In a Ointment Base		q.s	
		Colour:Approved colour used			
737	Calamine, Phenylephirine HCl & Lignocaine HCl Cream	Calamine	IP	5.0%	w/w
		Phenylephirine HCl	IP	0.1%	w/w
		Lignocaine HCl	IP	3.0%	w/w
		Chlorocresol	IP	0.1%	w/w
		As a Preservatives			
		In a Cream Base		q.s	
		Colour:Approved colour used			
738	Calamine, Aloe Vera Gel & Light Liquid Paraffin Lotion	Calamine	IP	8.0%	w/v
		Light Liquid Paraffin	IP	10.0%	w/v
		Aloe Vera Gel	IP	10.0%	w/v
		In a Lotion Base		q.s	

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH  
List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Colour:Approved colour used			
739	Chlorhexidine Mouthwash IP	Chlorhexidine Gluconate Solution	IP		
		Eq. to Chlorhexidine Gluconate		0.20%	w/v
		In a pleasantly flavoured aqueous base		q.s.	
		Colour:Approved colour used			
740	Vitamin - E Cream  With Aloe Vera	Composition:			
		Vitamin E Acetate	IP	0.50%	w/w
		Moisturizing Cream Base with Aloe Vera		q.s.	
		Colour:Approved colour used			
741	Povidone - Iodine Gargle	Composition:			
		Povidone-iodine	IP	2.00%	w/v
		(Available Iodine 0.2% w/v)			
		Absolute Alcohol Content		8.38%	v/v
		In a mint flavour aqueous base			
Colour:Approved colour used					
742	Atorvastatin , Fenofibrate & Ezetimibe Tablets	Each film coated tablet contains :-			
		Atorvastatin Calcium	IP		
		Eq. to Atorvastatin		10	mg
		Fenofibrate	BP	160	mg
		Ezetimibe		10	mg
		Excipients		qs	
		Approved colour used in coating			
743	Betahistine Hydrochloride Tablets IP	Each Uncoated Tablets Contains:-			
		Betahistine Hydrochloride	IP	24	mg
		Excipients		qs	
		Approved colour used in Tablets			
744	Betahistine Hydrochloride Tablets IP	Each Uncoated Tablets Contains:-			
		Betahistine Hydrochloride	IP	48	mg
		Excipients		qs	
		Approved colour used in Tablets			
745	Cefaclor Tablets IP	Each Film Coated Tablet Contains:-			
		Cefaclor Monohydrate	IP		
		Eq. to Cefaclor		125	mg
		Excipients		q.s	

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Approved colour used in Coating			

746	Cefaclor Tablets IP	Each Film Coated Tablet Contains:-			
		Cefaclor Monohydrate	IP		
		Eq. to Cefaclor		250	mg
		Excipients		q.s	
		Approved colour used in Coating			

747	Cefadroxil & Lactic Acid Bacillus Tablets	Each Filmcoated tablet Contains:-			
		Cefadroxil Monohydrate	IP		
		eq. to Anhydrous Cefadroxil		250	mg
		Lactic Acid Bacillus		60	Million Spores
		Excipients		q.s	
Approved colour used in Coating					

748	Clarithromycin Tablets IP	Each Film Coated Tablet Contains:-			
		Clarithromycin	IP	500	mg
		Excipients		q.s	
		Approved colour used in Coating			

749	Betacarotene, Vitamin B1, Vitamin B2, Vitamin B6, Vitamin C, Mecobalamin, Folic Acid, Lycopene, Inositol, DL-Methionine, Calcium Pantothenate, Nicotinamide, Vitamin E, Copper, Zinc, Potassium & Manganese Tablets	Each Film coated Tablet Contains:-			
		Betacarotene 30% dispersion		10	mg
		Vitamin B1	IP	10	mg
		Vitamin B2	IP	10	mg
		Vitamin B6	IP	3	mg
		Vitamin C	IP	75	mg
		Mecobalamin	IP	500	mcg
		Folic Acid	IP	1	mg
		Lycopene 6 %		2000	mcg
		Inositol	USP	25	mg
		DL-Methionine	USP	25	mg
		Calcium Pantothenate	IP	12.5	mg
		Nicotinamide	IP	50	mg
		Vitamin E Acetate	IP	25	mg
		Copper Sulphate Anhydrous	BP		
		eq. to Elemental Copper		40	mcg
		Zinc Sulphate Monohydrate	IP		
		eq. to Elemental Zinc		22.5	mg
		Manganese Sulphate	USP		
		eq. to Elemental Manganese		2	mg
Potassium Sulphate	USP				
eq. to Elemental Potassium		1	mg		
Excipients		qs			
Approved colour used in Coating					

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
--------	--------------------------------------	-------------	---------------	----------	------

750	<b>Combikit of 2 Clarithromycin Tablets IP 500 mg , 2 Pantoprazole Tablets IP 40 mg &amp; 2</b>				
	<b>A. 2 Clarithromycin Tablets IP 500 mg</b>	Each Filmcoated tablet contains:			
		Clarithromycin	IP	500	mg
		Excipients		qs.	
		Colour: Approved colour used in coating			
	<b>B. 2 Pantoprazole Tablets IP 40 mg</b>	Each Enteric coated tablet contains:			
		Pantoprazole Sodium	IP		
		Pantoprazole		40	mg
		Excipients		qs.	
	<b>C. 2 Amoxicillin Tablets IP 750 mg</b>	Each Filmcoated tablet contains:			
		Amoxicillin Trihydrate	IP		
		Eq. to Amoxicillin		750	mg
		Excipients		qs.	
		Colour: Approved colour used in coating			

751	<b>Combikit of 3 Artesunate Tablets IP &amp; 6 Mefloquine HCl Tablets</b>				
	<b>A. 3 Artesunate Tablets IP</b>	Each uncoated tablet contains:			
		Artesunate	IP	200	mg
		Excipients		qs.	
		Colour: Approved colour used			
	<b>B. 6 Mefloquine HCl Tablets</b>	Each uncoated tablet contains:			
		Mefloquine HCl	IP		
		Eq. to Mefloquine		250	mg
		Excipients		qs.	
		Colour: Approved colour used			

752	<b>Combikit of 1 Biotin Tablets &amp; 1 Finasteride Tablets</b>				
	<b>A. 1 Biotin Tablets</b>	Each Filmcoated tablet contains:			
		Biotin	BP	5	mg
		Excipients		qs.	
		Colour: Approved colour used in coating			
	<b>B. 1 Finasteride Tablets</b>	Each Filmcoated tablet contains:			
		Finasteride	IP	1	mg
		Excipients		qs.	
Colour: Approved colour used in coating					

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
753	<b>Combikit of 30 Calcium , Vitamin-D3 &amp; Zinc Tablets &amp; 1 Ibandronic Acid Tablets</b>	<b>A. 30 Calcium , Vitamin-D3 &amp; Zinc Tablets</b>			
		Each Filmcoated tablet contains:			
		Calcium Carbonate	IP	1250	mg
		Eq. to Elemental Calcium		500	mg
		Vitamin-D3 (As Stabilised)	IP	500	IU
		Zinc sulphate Monohydrate	IP		
		Eq. to Elemental Zinc		7.5	mg
				<b>qs.</b>	
		Excipients			
		Colour:Approved colour used in Coating			
		<b>B 1 Ibandronic Acid Tablets</b>			
		Each Filmcoated tablet contains:			
		Ibandronate Sodium Monohydrate	IP		
		Eq. to Ibandronic Acid		150	mg
Excipients		<b>qs.</b>			
Colour:Approved colour used in Coating					

754	Deflazacort Tablets	Each Uncoated tablet contains:-			
		Deflazacort		1	mg
		Excipients		q.s	
		Approved colour used in Tablets			

755	Deflazacort Tablets	Each Uncoated tablet contains:-			
		Deflazacort		12	mg
		Excipients		q.s	
		Approved colour used in Tablets			

756	Deflazacort Tablets	Each Uncoated tablet contains:-			
		Deflazacort		18	mg
		Excipients		q.s	
		Approved colour used in Tablets			

757	Deflazacort Tablets	Each Uncoated tablet contains:-			
		Deflazacort		30	mg
		Excipients		q.s	
		Approved colour used in Tablets			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
758	Dosulepin Tablets IP	Each Filmcoated tablet contains:-			
		Dosulepin Hydrochloride	IP	25	mg
		Excipients		q.s	
		Approved colour used in Coating			
759	Dosulepin Tablets IP	Each Filmcoated tablet contains:-			
		Dosulepin Hydrochloride	IP	50	mg
		Excipients		q.s	
		Approved colour used in Coating			
760	Erythromycin stearate & Lactic Acid Bacillus Tablets	Each Film Coated Tablet Contains:-			
		Erythromycin stearate	IP		
		eq to Erythromycin		500	mg
		Lactic Acid Bacillus		60	Million spores
		Excipients		q.s	
Approved colour used in Coating					
761	Erythromycin stearate & Lactic Acid Bacillus Tablets	Each Film Coated Tablet Contains:-			
		Erythromycin stearate	IP		
		eq to Erythromycin		250	mg
		Lactic Acid Bacillus		60	Million spores
		Excipients		q.s	
Approved colour used in Coating					
762	Fungal Diastase (1 : 800), Papain & Activated Charcoal Tablets	Each Uncoated tablets contains:			
		Fungal Diastase (1 : 800)	IP	100	mg
		Papain	IP	60	mg
		Activated Charcoal	IP	75	mg
		Excipients		q. s.	
Colour :- Approved colour used					
763	Glimepiride Tablet IP	Each Uncoated Tablets Contains:-			
		Glimepiride	IP	3	mg
		Excipients		q.s	
		Approved colour used in Tablet			
764	Glimepiride Tablet IP	Each Uncoated Tablets Contains:-			
		Glimepiride	IP	4	mg
		Excipients		q.s	
		Approved colour used in Tablet			

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
--------	--------------------------------------	-------------	---------------	----------	------

765	Glimepiride and Metformin Hydrochloride (Prolonged Release) Tablets IP	Each uncoated Bilayered tablet contains:			
		Glimepiride	IP	4	mg
		Metformin Hydrochloride (As Prolonged Release form)	IP	500	mg
		Excipients			q.s.

766	Glimepiride & Metformin Hydrochloride Tablets	Each Uncoated tablets contains:			
		Glimepiride	IP	1	mg
		Metformin Hydrochloride (in sustained release form)	IP	850	mg
		Excipients		q. s.	
		Colour :- Approved colour used			

767	Glimepiride & Metformin Hydrochloride Tablets	Each Uncoated tablets contains:			
		Glimepiride	IP	2	mg
		Metformin Hydrochloride (in sustained release form)	IP	850	mg
		Excipients		q. s.	
		Colour :- Approved colour used			

768	Glimepiride & Metformin Hydrochloride Tablets	Each Uncoated tablets contains:			
		Glimepiride	IP	3	mg
		Metformin Hydrochloride (in sustained release form)	IP	850	mg
		Excipients		q. s.	
		Colour :- Approved colour used			

769	Glimepiride & Metformin Hydrochloride Tablets	Each Uncoated tablets contains:			
		Glimepiride	IP	1	mg
		Metformin Hydrochloride (in sustained release form)	IP	1000	mg
		Excipients		q. s.	
		Colour :- Approved colour used			

770	Glimepiride & Metformin Hydrochloride Tablets	Each Uncoated tablets contains:			
		Glimepiride	IP	2	mg
		Metformin Hydrochloride (in sustained release form)	IP	1000	mg

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Excipients		q. s.	
		Colour :- Approved colour used			

771	Glimepiride & Metformin Hydrochloride Tablets	Each film coated tablets contains:			
		Glimepiride	IP	3	mg
		Metformin Hydrochloride (in sustained release form)	IP	1000	mg
		Excipients		q. s.	
		Colour :- Approved colour used in coating			

772	Glimepiride & Metformin Hydrochloride Tablets	Each film coated tablets contains:			
		Glimepiride	IP	4	mg
		Metformin Hydrochloride (in sustained release form)	IP	1000	mg
		Excipients		q. s.	
		Colour :- Approved colour used in coating			

773	Itraconazole & Terbinafine Tablets	Each Filmcoated tablet contains:-			
		Itraconazole	BP	200	mg
		Terbinafine HCl	IP		
		Eq. to Terbinafine		250	mg
		Excipients		q.s	
Approved colour used in Coating					

774	Itraconazole & Terbinafine Tablets	Each Filmcoated tablet contains:-			
		Itraconazole	BP	100	mg
		Terbinafine HCl	IP		
		Eq. to Terbinafine		250	mg
		Excipients		q.s	
Approved colour used in Coating					

775	Ketorolac Tromethamine Tablets IP	Each Uncoated Tablet Contains:			
		Ketorolac Tromethamine	IP	10	mg
		Excipients		q.s.	
		Colour:Approved colour used			

776	Meberevine HCl & Chlordiazepoxide Tablets	Each Filmcoated tablet contains:-			
		Meberevine HCl	IP	135	mg
		Chlordiazepoxide	IP	5	mg
		Excipients		q.s	
		Approved colour used in Coating			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
--------	--------------------------------------	-------------	---------------	----------	------

777	Methylcobalamin and Gabapentin Tablets	Each film coated tablet contains:			
		Methylcobalamin	IP	500	mcg
		Gabapentin	IP	100	mg
		Excipients			qs
		Colour: Approved colour used			

778	Metronidazole, Furazolidone & Dicyclomine HCl Tablet	Each Un Coated Tablet Contains :			
		Metronidazole	IP	200	mg
		Furazolidone	IP	50	mg
		Dicyclomine Hcl	IP	10	mg
		Excipients		q.s	
		Colour: Approved colour used			

779	Ofloxacin Tablets IP	Each Film Coated Tablet Contains:-			
		Ofloxacin	IP	100	mg
		Excipients		q.s	
		Approved colour used in Coating			

780	Pirfenidone Tablets IP	Each Film Coated Tablet Contains:-			
		Pirfenidone	IP	200	mg
		Excipients		q.s	
		Approved colour used in Coating			

781	Ofloxacin & Cefixime Tablets	Each Filmcoated tablet Contains:-			
		Ofloxacin	IP	400	mg
		Cefixime Trihydrate	IP		
		eq. to anhydrous Cefixime		400	mg
		Excipients		q.s	
		Approved colour used in Coating			

782	Paracetamol & Chlorpheniramine Maleate Tablets	Each Uncoated tablets contains:			
		Paracetamol	IP	325	mg
		Chlorpheniramine Maleate	IP	2	mg
		Excipients		q. s.	
		Colour :- Approved colour used			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS &amp; COSMETIC ACT 1945

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
783	Rabeprazole Sodium Tablets IP	Each Enteric Coated tablet Contains:-			
		Rabeprazole Sodium	IP	10	mg
		Excipients		q.s	
		Approved colour used in Coating			
784	Rabeprazole Sodium Tablets IP	Each Enteric Coated tablet Contains:-			
		Rabeprazole Sodium	IP	40	mg
		Excipients		q.s	
		Approved colour used in Coating			
785	Rabeprazole Sodium & Domperidone Tablets	Each Enteric Coated tablets contains:			
		Rabeprazole Sodium	IP	20	mg
		Domperidone	IP	30	mg
		Excipients		q. s.	
Colour :- Approved colour used					
786	Rabeprazole Sodium & Ondansetron Tablets	Each Enteric Coated tablet Contains:-			
		Rabeprazole Sodium	IP	20	mg
		Ondansetron HCl	IP		
		eq. to Ondansetron		4	mg
		Excipients		q.s	
Approved colour used in Coating					
787	Telmisartan, Amlodipine Besylate & Chlorthalidone Tablets	Each Film Coated tablet contains:			
		Telmisartan	IP	40	mg
		Amlodipine Besylate	IP		
		eq. to Amlodipine		5	mg
		Chlorthalidone	IP	6.25	mg
		Excipients		q. s.	
Colour: Approved colour used in coating					
788	Telmisartan, Amlodipine Besylate & Chlorthalidone Tablets	Each Film Coated tablet contains:			
		Telmisartan	IP	80	mg
		Amlodipine Besylate	IP		
		eq. to Amlodipine		5	mg
		Chlorthalidone	IP	6.25	mg
		Excipients		q. s.	
Colour :- Approved colour used					

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
789	Telmisartan , Chlorthalidone & Amlodipine Tablets	Each Film coated Tablet contains:-			
		Telmisartan	IP	80	mg
		Chlorthalidone	IP	12.5	mg
		Amlodipine Besilate	IP		
		eq. to Amlodipine		5	mg
		Excipients		q.s	
		Approved colour used in Coating			
790	Teneligliptin & Metformin HCl Tablets	Each Uncoated Bilayered tablet contains:-			
		Teneligliptin hydrobromide hydrate			
		eq. to Teneligliptin		20	mg
		Metformin HCl	IP	500	mg
		(As Extended Release)			
		Excipients		q.s	
		Approved colour used in Tablets			
791	Teneligliptin Tablets	Each Filmcoated tablet contains:-			
		Teneligliptin hydrobromide hydrate			
		eq. to Teneligliptin		20	mg
		Excipients		q.s	
		Approved colour used in Coating			
792	Teneligliptin & Metformin HCl Tablets	Each Uncoated Bilayered tablet contains:-			
		Teneligliptin hydrobromide hydrate			
		eq. to Teneligliptin		20	mg
		Metformin HCl	IP	1000	mg
		(As Extended Release)			
		Excipients		q.s	
		Approved colour used in Tablets			
793	Sparfloxacin Tablets	Each Filmcoated tablet contains:-			
		Sparfloxacin		200	mg
		Excipients		q.s	
		Approved colour used in Tablets			
794	Terbutaline Sulphate , Bromhexine HCL & Guaiphenesin Tablets	Each Uncoated tablet contains:			
		Terbutaline Sulphate	IP	1.25	mg
		Bromhexine HCL	IP	8	mg
		Guaiphenesin	IP	100	mg
		Excipients		q. s.	
		Colour :- Approved colour used			

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
795	Terbutaline Sulphate , Bromhexine HCL & Guaiphenesin Tablets	Each Uncoated tablet contains:			
		Terbutaline Sulphate	IP	2.5	mg
		Bromhexine HCL	IP	8	mg
		Guaiphenesin	IP	100	mg
		Excipients		q. s.	
Colour :- Approved colour used					

796	Tranexamic Acid & Etamsylate  Tablets	Each Film Coated tablets contains:			
		Tranexamic Acid	IP	250	mg
		Etamsylate	BP	250	mg
		Excipients		q. s.	
		Colour: Approved colour used in coating			

797	Thiamine mononitrate, Riboflavin ,Pyridoxine HCl, Cyanocobalamin,Niacinamide, Calcium Pantothenate, Tablets	Each Film coated Tablet Contains:-			
		Thiamine mononitrate	IP	10	mg
		Riboflavin	IP	10	mg
		Pyridoxine HCl	IP	3	mg
		Cyanocobalamin Triturate in Geletin			
		eq. to Cyanocobalamin	IP	15	mcg
		Niacinamide	IP	45	mg
		Calcium Pantothenate	IP	50	mg
		Excipients		q.s	
Approved colour used in Coating					

798	Tranexamic Acid and Etamsylate Tablets	Each film coated tablet contains:			
		Tranexamic Acid	IP	500	mg
		Etamsylate	IP	250	
		Excipients			q.s.
		Colour: Approved colour used in Coating			

799	Ascorbic Acid , Sodium Ascorbic & Zinc Citrate Chewable Tablets	Each Uncoated Chewable Tablets contains:			
		Ascorbic Acid	IP	100	mg
		Sodium Ascorbic	IP	450	mg
		Eq. to Ascorbic Acid		400	mg
		Zinc Citrate	IP		
		Eq. to Elemental Zinc		5	mg
		Excipients		q.s.	
Colour: Approved colour used					

800	Rabeprazole Sodium	Each hard geletin capsule contains:-			
-----	--------------------	--------------------------------------	--	--	--

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	& Domperidone Capsule	Rabeprazole Sodium	IP	20	mg
		(As enteric coated pellets)			
		Domperidone	IP	10	mg
		(As pellets)			
		Excipients		qs	
		Approved colour used in empty capsule shell			

801	Rabeprazole Sodium & Domperidone Capsule	Each hard geletin capsule contains:-			
		Rabeprazole Sodium	IP	40	mg
		(As enteric coated pellets)			
		Domperidone	IP	30	mg
		(As Sustained release pellets)			
		Excipients		qs	
		Approved colour used in empty capsule shell			

802	Oxytetracycline Hydrochloride Bolus VETERINARY USE NOT FOR HUMAN USE	Each Uncoated Bolus contains:			
		Oxytetracycline Hydrochloride	IP	300	mg
		Excipients		q.s.	
		Colour: Approved colour used			

803	Cefaclor Oral Suspension IP	Each 5ml of reconstituted suspension contains:			
		Cefaclor Monohydrate	IP		
		Eq. to Cefaclor		125	mg
		In a flavoured suspension base		q.s.	
		Approved colour used			

804	Cefaclor Oral Suspension IP	Each 5ml of reconstituted suspension contains:			
		Cefaclor Monohydrate	IP		
		Eq. to Cefaclor		250	mg
		In a flavoured suspension base		q.s.	
		Approved colour used			

805	Cefixime Oral Suspension IP	Each ml of reconstituted suspension contains:			
		Cefixime Trihydrate	IP		
		Eq. to Anhydrous Cefixime		25	mg
		In a flavoured suspension base		q.s.	
		Approved colour used			

806	Cefixime & Lactic Acid Bacillus Oral Suspension	Each 5ml of reconstituted suspension contains:			
		Cefixime Trihydrate	IP		
		Eq. to Anhydrous Cefixime		50	mg
		Lactic Acid Bacillus		20	Million Spores
		In a flavoured suspension base		q.s.	
		Colour: Approved colour used			

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
807	Cefixime & Lactic Acid Bacillus Oral Suspension	Each 5ml of reconstituted suspension contains:			
		Cefixime Trihydrate	IP		
		Eq. to Anhydrous Cefixime		100	mg
		Lactic Acid Bacillus		20	Million Spores
		In a flavoured suspension base		q.s	
		Colour:Approved colour used			
808	Prednisolone Oral Liquid USP	Each 5ml contains:			
		Prednisolone Sodium Phosphate	IP		
		eq. to Prednisolone		5	mg
		Flavoured syrupy Base		q.s	
		Approved colour used			
809	Prednisolone Oral Liquid USP	Each 5ml contains:			
		Prednisolone Sodium Phosphate	IP		
		eq. to Prednisolone		15	mg
		Flavoured syrupy Base		q.s	
		Approved colour used			
810	Paracetamol Oral Suspension IP	Each 5ml contains:			
		Paracetamol	IP	500	mg
		Flavoured syrupy Base		q.s	
		Approved colour used			
811	Clotrimazole, Menthol, Boric Acid, Ichthammol & zinc Oxide Cream	Clotrimazole	IP	0.5%	w/w
		Menthol	IP	1.0%	w/w
		Boric Acid	IP	1.0%	w/w
		Ichthammol	USP	0.2%	w/w
		zinc oxide	IP	5%	w/w
		As Preservative:-			
		Phenoxyethanol	IP	0.2%	w/w
		Benzyl Alcohol	IP	1.0%	w/w
		In cream Base		q.s	
812	Diltiazem Gel 2 % W/W	Diltiazem HCl	IP	2.00%	w/w
		In Gel Base		q.s	
813	Glycerin & Olive Oil Lotion	Glycerine	IP	15.00%	w/v
		Olive Oil	BP	0.50%	w/v
		Lotion Base		q.s	

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
814	Glycerin , Methyl Paraben & Propyl Paraben Gel	Glycerine	IP	11.25%	w/w
		Preservative:			
		Methyl Paraben	IP	0.10%	w/w
		Propyl Paraben	IP	0.04%	w/w
		Gel Base		q.s	
815	ISOPROPYL ALCOHOL 70%HAND SANITIZER	Composition:			
		Isopropyl Alcohol	IP	70%	v/v
		Excipients		q.s.	
		Perfumed Solution Base		q.s.	
816	ISOPROPYL ALCOHOL 70%HAND SANITIZER	Composition:			
		Isopropyl Alcohol	IP	70%	v/v
		Excipients		q.s.	
		Perfumed Gel Base		q.s.	
817	Itraconazole & Terbinafine  Cream	Composition :-			
		Itraconazole	BP	1%	W/W
		Terbinafine HCl	IP		
		Eq. to Terbinafine		1%	W/W
		Cream Base		q.s	
818	Amoxicillin Tryhydrate & Lactic Acid bacillus Capsules	Each hard geletin capsule contains:-			
		Amoxicillin Tryhydrate	IP		
		Eq.to Amoxicillin		250	mg
		Lactic Acid Bacillus		60	Million Spores
		Excipients		qs	
		Approved colour used in empty capsule shell			
819	Amoxicillin Tryhydrate & Lactic Acid bacillus Capsules	Each hard geletin capsule contains:-			
		Amoxicillin Tryhydrate	IP		
		Eq.to Amoxicillin		500	mg
		Lactic Acid Bacillus		60	Million Spores
		Excipients		qs	
		Approved colour used in empty capsule shell			

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH  
List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
820	Loratadine 5mg & Ambroxol 60 mg Tablets	Each Film Coated Tablets contains:-			
		Loratadine	USP	5	mg
		Ambroxol HCl	IP	60	mg
		Excipients		q.s	
		Approved Colours Used Coating			
821	Cholecalciferol Chewable tablets 60000 IU	Each Uncoated Chewable Tablets contains:-			
		Cholecalciferol	IP	60,000	IU
		Excipients		q.s	
		Approved Colours Used			
822	L-Methylfolate Calcium 5.6mg, Mecobalamin 2mg, Acetylcysteine 600mg tablets	Each Film Coated Tablets contains:-			
		L-Methylfolate Calcium		5.6	mg
		Mecobalamin	IP	2	mg
		Acetylcysteine	BP	600	mg
		Excipients		q.s.	
Approved Colours Used in coting					
823	Diclofenac 50 mg & Thiocolchicoside 4 mg Capsules	Each hard gelatin capsule Contains:-			
		Diclofenac Sodium	IP	50	mg
		Thiocolchicoside	IP	4	mg
		Excipients		q.s	
		Approved colour used in Empty casules shell			
824	Diclofenac 50 mg (E.C.)& Thiocolchicoside 8 mg Capsules	Each hard gelatin capsule Contains:-			
		Diclofenac Sodium	IP	50	mg
		(As Enteric Coated )			
		Thiocolchicoside	IP	8	mg
		Excipients		q.s	
Approved colour used in Empty casules shell					
825	Diclofenac 100 mg (SR) & Thiocolchicoside 16 mg (SR) Capsules	Each hard gelatin capsule Contains:-			
		Diclofenac Sodium	IP	100	mg
		(as sustained Release)			
		Thiocolchicoside	IP	16	mg
		(as sustained Release)			
Excipients		q.s			
Approved colour used in Empty casules shell					

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
826	Diclofenac Diethylamine, Peppermint oil, Eucalyptus Oil, Methyl salicylate & Turpentine Oil OIL	Composition			
		Diclofenac Diethylamine	IP	2.00%	w/w
		Methyl salicylate	IP	10%	w/w
		Peppermint oil	IP	10%	w/w
		Turpentine Oil	BP	10%	w/w
		Eucalyptus Oil	IP	5%	w/w
		Benzyl alcohol	IP	1%	w/w
		(As a Preservative)			
In Oil base			q.s		
827	Calcium Citrate 1000mg, vitamin D3 200mcg, Methylcobalamin 500mcg, pyridoxine HCl 10mg, folic acid 5mg tablets	Each Film Coated Tablets contains:-			
		Calcium Citrate	USP	1000	mg
		Vitamin D3	IP	200	mcg
		Methylcobalamin	IP	500	mcg
		Pyridoxine HCl	IP	10	mg
		Folic Acid	IP	5	mg
		Excipients		q.s.	
		Approved Colours Used in coting			
828	Calcium Citrate 1000 mg, Vitamin D3 200 IU, Methylcobalamin 500 mcg, Pyridoxine HCl 10 mg, Folic Acid 5mg tablets	Each Film Coated Tablets contains:-			
		Calcium Citrate	USP	1000	mg
		Vitamin D3	IP	200	IU
		Methylcobalamin	IP	500	mcg
		Pyridoxine HCl	IP	10	mg
		Folic Acid	IP	5	mg
		Excipients		q.s.	
		Approved Colours Used in coting			
829	Calcium Citrate 1000 mg, Calcitriol 0.25 mcg, Folic Acid 1.5 mg, Zinc 7.5 mg, Methylcobalamin 1500 mcg Vitamin K 27.50 mcg tablets Vitamin K 27.50 mcg tablets	Each Film Coated Tablets contains:-			
		Calcium Citrate	USP	1000	mg
		Calcitriol	BP	0.25	mcg
		Folic Acid	IP	1.5	mg
		Zinc Sulphate monohydrate	IP		
		eq. to elemental Zinc		7.5	mg
		eq. to elemental Zinc		7.5	mg
		Methylcobalamin	IP	1500	mcg
		Phytonadione(Vitamin K)	BP	27.5	mcg
		Excipients		q.s.	
		Approved Colours Used in coting			
830	Diclofenac Diethylamine, Menthol, Eucalyptus Oil,	Composition			
		Diclofenac Diethylamine	IP	1.16%	W/W

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	Methyl salicylate, Camphor & Capsicum Ointment	Eq. to Diclofenac Sodium		1.00%	w/w
		Methyl salicylate	IP	20%	w/w
		Menthol	IP	10%	w/w
		Camphor	USP	5%	w/w
		Eucalyptus Oil	IP	5%	w/w
		Oleoresin Capsicum			
		Eq. to Capsicum	USP	0.075%	w/w
		Benzyl alcohol	IP	1%	w/w
		(As a Preservative)			
		In Ointment base			q.s
831	Sucralfate 0.07gm, Metronidazole 0.01gm, Lignocaine 0.04gm Cream	Each Gram contains:-			
		Sucralfate	USP	0.07	gm
		Metronidazole	IP	0.01	gm
		Lignocaine	IP	0.04	gm
		Cream Base		q.s.	
832	Pirfenidone Tablets IP 400mg	Each Film Coated Tablet Contains:-			
		Pirfenidone	IP	400	mg
		Excipients		q.s	
		Approved colour used in Coating			
833	Olmesartan Medoxomil and Hydrochlorothiazide Tablets IP	Each film coated tablet contains:			
		Olmesartan Medoxomil	IP	20	mg
		Hydrochlorothiazide	IP	12.5	mg
		Excipients			qs
		Colour: Approved colour used			
834	Mefenamic acid and Dicyclomine Hydrochloride Tablets IP	Each uncoated tablet contains:			
		Mefenamic acid	IP	500	mg
		Dicyclomine Hydrochloride	IP	20	mg
		Excipients			q.s.
		Approved Colour Used in Tablets			
835	Lornoxicam & Paracetamol Tablets	Each Film Coated Tablet Contains:-			
		Lornoxicam		4	mg
		Paracetamol	IP	325	mg
		Excipients		q.s	
		Approved colour used in Coating			
836	Calcium Pantothenate Tablets IP	Each film coated tablet contains:			
		Calcium Pantothenate	IP	200	mg

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Colour: Approved colour used			
837	Pregabalin Capsules 75mg IP	Each hard gelatin capsule contains:			
		Pregabalin	IP	75	mg
		Excipients		qs	
		Approved colour used in empty capsule shells			
838	Pregabalin Capsules 150mg IP	Each hard gelatin capsule contains:			
		Pregabalin	IP	150	mg
		Excipients		qs	
		Approved colour used in empty capsule shells			
839	Pregabalin and Natriptyline HCL Tablets	Each Film Coated Tablet contains:			
		Pregabalin	IP	75	mg
		Natriptyline HCL	IP		
		Eq. to Natriptyline		10	mg
		Excipients		q.s.	
Colour: Approved colour used in Coating					
840	Clarithromycin Oral Suspension USP	Each 5ml of constituted suspension contains:			
		Clarithromycin	IP	125	mg
		Excipients		q.s.	
		In a flavoured suspension base			
Approved colour used					
841	Nebivolol Hydrochloride Tablets IP 5mg	Each Uncoated tablets contains:			
		Nebivolol Hydrochloride	IP		
		eq. to Nebivolol		5	mg
		Excipients		q. s.	
Colour :- Approved colour used					
842	Nebivolol Hydrochloride Tablets IP 2.5mg	Each Uncoated tablets contains:			
		Nebivolol Hydrochloride	IP		
		eq. to Nebivolol		2.5	mg
		Excipients		q. s.	
Colour :- Approved colour used					
843	Vildagliptin Tablets IP 50 mg	Each Uncoated tablets contains:			
		Vildagliptin		50	mg
		Excipients		q. s.	
Colour :- Approved colour used					

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
844	Rosuvastatin & Fenofibrate Tablets IP	Each Film coated tablet contains:-		IP	
		Rosuvastatin Calcium	IP		
		Rosuvastatin		10	mg
		Fenofibrate	IP	160	mg
		Excipients		q.s	
		Approved colour used in Coating			
845	Promethazine Theoclate Tablets IP 25mg	Each Uncoated Tablet contains:			
		Promethazine Theoclate	IP	25	mg
		Excipients		q.s.	
		Colour:Approved colour used			
846	Methylergometrine Maleate Tablets IP	Each Film Coated Tablets Contains:-			
		Methylergometrine Maleate	IP	0.125	mg
		Excipients		q.s	
		Approved colour used in Coating			
847	Methylergometrine Maleate Tablets IP	Each Film Coated Tablets Contains:-			
		Methylergometrine Maleate	IP	0.2	mg
		Excipients		q.s	
		Approved colour used in Coating			
848	Tacrolimus Capsules IP 1 mg	Each hard geletin capsule contains:-			
		Tacrolimus	IP	1	mg
		Excipients		qs	
		Approved colour used in empty capsule shell			
849	Diclofenac Sodium, Paracetamol & Chlorzoxazone Tablets (Not for Veterinary Use)	Each Filmcoated Tablet contains:-			
		Diclofenac Sodium	IP	50	mg
		paracetamol	IP	325	mg
		Chlorzoxazone	USP	250	mg
		Excipients		q.s	
		Approved colour used in Tablets.			
850	Atorvastatin & Fenofibrate Tablets IP	Each film coated tablet contains :-			
		Atorvastatin Calcium	IP		
		Eq. to Atorvastatin		10	mg
		Fenofibrate	IP	160	mg
		Excipients		qs	
		Approved colour used in coating			

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
851	Calcium with & Vitamin D3 Tablets IP	Each Uncoated Tablet Contains:-			
		Calcium Carbonate	IP		
		(Derived From Coral Grains)			
		eq. to Calcium		500	mg
		Vitamin D3	IP	500	IU
		Excipients		q.s	
Approved colour used in Tablets					
852	Cefuroxime Axetil Oral Suspension USP	Each 5ml of reconstituted suspension contains:			
		Cefuroxime axetil	IP		
		Eq. to Cefuroxime		125	mg
		In a flavoured suspension base			
		Excipients		q.s	
Approved colour used					
853	Loperamide Hydrochloride Solution USP	Each 5ml contains:			
		Loperamide Hydrochloride	IP	1	mg
		Excipients		q.s.	
		In aqueous Non Syrupy Base			
Colour: Approved colour used					
854	Etodolac Tablets IP 600mg	Each uncoated Extended Release tablet contains:			
		Etodolac	IP	600	mg
		Excipients		qs	
Colour: Approved colour used in Tablets					
855	Prochlorperazine maleate and Paracetamol Tablets	Each uncoated tablet contains:-			
		Prochlorperazine Maleate	IP	5	mg
		Paracetamol	IP	500	mg
		Excipients		q.s.	
Colour: Approved colour used					
856	Luliconazole and Clobetasol Propionate Cream	Composition:-			
		Luliconazole		1%	w/w
		Clobetasol Propionate	IP	0.05%	w/w
		Excipients		q.s.	
Cream Base					
857	Nimesulide, Paracetamol & Serratiopeptidase Tablets	Each Film Coated Tablet Contains:-			
		Nimesulide	BP	100	mg
		Paracetamol	IP	325	mg
		Serratiopeptidase (as enteric coated granules 20000 units of peptidase)	IP	10	mg
		Excipients		q.s	
		Approved colour used in Coating			

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
858	Azithromycin with Lactic acid Bacillus Tablets	Each Film Coated Tablet Contains:-			
		Azithromycin	IP		
		eq. to anhydrous Azithromycin		250	mg
		Lactic Acid Bacillus		60	Million Spores
		Excipients		q.s	
		Approved colour used in Coating			
859	Azithromycin with Lactic acid Bacillus Tablets	Each Film Coated Tablet Contains:-			
		Azithromycin	IP		
		eq. to anhydrous Azithromycin		500	mg
		Lactic Acid Bacillus		60	Million Spores
		Excipients		q.s	
		Approved colour used in Coating			
860	Amoxicillin Trihydrate with Sulbactam Bolus  (For animal use only) (Not for human use)	Each Uncoated Bolus contains:-			
		Amoxicillin Trihydrate	IP		
		eq. to Amoxicillin		1250	mg
		Sulbactam Sodium	USP		
		eq. to Sulbactam		250	mg
		Excipients		q.s	
861	Etodolac Extended - Release Tablets IP	Each Uncoated Extended-Release tablet contains:			
		Etodolac	IP	400	mg
		Excipients		qs	
		Colour: Approved colour used			
862	Pregabalin, Natriptyline HCL & Methylcobalamin Tablets	Each Film Coated Tablet contains:			
		Pregabalin	IP	75	mg
		Natriptyline HCL	IP		
		Eq. to Natriptyline		10	mg
		Methylcobalamin	IP	1500	mcg
		Excipients		q.s.	
863	Ambroxol Hcl, Guaiphenesin, Phenylephrine Hcl, Chlorpheniramine Maleate & Menthol Syrup	Each 5ml contains:			
		Ambroxol Hydrochloride	IP	15	mg
		Guaiphenesin	IP	50	mg
		Phenylephrine Hydrochloride	IP	5	mg
		Chlorpheniramine Maleate	IP	2	mg

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Menthol	IP	1	mg
		In flavoured Syrupy base		q.s.	
		Colour:Approved colour used .			
864	Cyproheptadine & Tricholine Citrate syrup	Each 10ml contains:			
		Cyproheptadine Hydrochloride (Anhydrous)	IP	2	mg
		Tricholine Citrate(65%)	IP	275	mg
		In flavoured Sorbitolbase		q.s.	
		Colour:Approved colour used .			
865	Loratadine Tablets IP 10mg	Each Uncoated tablet contains:			
		Loratadine	IP	10	mg
		Excipients		qs	
		Colour: Approved colour used			
866	Gabapentin Tablets IP 300mg	Each Film-coated tablet contains:			
		Gabapentin	IP	300	mg
		Excipients		qs	
		Colour: Approved colour used			
867	Ofloxacin & Metronidazole Benzoate Oral Suspension	Each 5ml contains:			
		Ofloxacin	IP	100	mg
		Metronidazole Benzoate	IP		
		Eq. to Metronidazole		200	mg
		In flavoured Syrupy base		q.s.	
		Colour:Approved colour used .			
868	Esomeprazole(EC) & Levosulpiride (SR) Capsule	Each Hard Gelatin capsule contains:-			
		Esomeprazole Magnesium Trihydrate	IP		
		eq. to Esomeprazole (As Enteric Coated Pellets)		40	mg
		Levosulpiride (As Sustained Release Pellets)		75	mg
		Excipients		qs	
		Approved Colour used in Capsule shell			
869	Esomeprazole(EC) & Domperidone (SR) Capsule	Each Hard Gelatin capsule contains:-			
		Esomeprazole Magnesium Trihydrate	IP		
		eq. to Esomeprazole (As Enteric Coated Pellets)		40	mg
		Domperidone (As Sustained Release Pellets)	IP	30	mg
		Excipients		qs	

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
		Colour: Approved Colour used in Empty hardgelatin Capsule shells & Pellets			
870	Rosuvastatin ,Aspirin & Clopidogrel Capsules	Each Hard Gelatin capsule contains:-			
		Rosuvastatin Calcium	IP		
		eq. to Rosuvastatin		20	mg
		(As Un- Coated Pellets)			
		Aspirin	IP	75	mg
		(As Enteric-coated Pellets)			
		Clopidogrel Bisulphate	IP		
		eq. to Clopidogrel		75	mg
		(As Un- Coated Pellets)			
		Excipients		qs	
Colour: Approved Colour used in Empty hardgelatin Capsule shells & Pellets					
871	Rosuvastatin ,Aspirin & Clopidogrel Capsules	Each Hard Gelatin capsule contains:-			
		Rosuvastatin Calcium	IP		
		eq. to Rosuvastatin		10	mg
		(As Un- Coated Pellets)			
		Aspirin	IP	75	mg
		(As Enteric-coated Pellets)			
		Clopidogrel Bisulphate	IP		
		eq. to Clopidogrel		75	mg
		(As Un- Coated Pellets)			
		Excipients		qs	
Colour: Approved Colour used in Empty hardgelatin Capsule shells & Pellets					
872	Prochlorperazine Maleate Mouth Dissolving Tablets 5mg	Each Uncoated Mouth Dissolving tablet contains:			
		Prochlorperazine Maleate	IP	5	mg
		Excipients		qs	
		Colour: Approved colour used			
873	Paracetamol, Phenylephrine Hydrochloride, Caffeine & Diphenhydramine Hydrochloride Tablets	Each Uncoated Tablets contains:			
		Paracetamol	IP	500	mg
		Phenylephrine Hydrochloride	IP	5	mg
		Caffeine (Anhydrous)	IP	30	mg
		Diphenhydramine Hydrochloride	IP	25	mg
		Excipients		q.s.	
Colour: Approved colour used					
874	Magaldrate, Simethicone & Oxetacaine Suspension	Each 5ml contains:			
		Magaldrate	IP		
		Eq. to Anhydrous Magaldrate		540	mg
		Simethicone	IP	50	mg
		Oxetacaine	BP	10	mg
		In flavoured Syrupy base		q.s.	mg
Colour: Approved colour used .					

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
875	Fluticasone Cream IP	Fluticasone Propionate	IP	0.05%	w/w
		In CreamBase		q.s	
876	Paracetamol, Phenylephrine Hydrochloride, Guaiphenesin, Cetirizine Hydrochloride & Ambroxol Hydrochloride Tablets	Each Uncoated Tablet contains:			
		Paracetamol	IP	325	mg
		Phenylephrine Hydrochloride	IP	5	mg
		Guaiphenesin	IP	50	mg
		Cetirizine Hydrochloride	IP	5	mg
		Ambroxol Hydrochloride	IP	15	mg
		Excipients		q.s.	
Colour: Approved colour used					
877	Methylcobalamin, Alpha Lipoic Acid, Pyridoxine Hydrochloride & Folic Acid Capsules	Each hard gelatin Capsule contains :			
		Methylcobalamin	IP	1500	mcg
		Alpha Lipoic Acid	USP	100	mg
		Pyridoxine Hydrochloride	IP	3	mg
		Folic Acid	IP	1.5	mg
		Excipients		q.s.	
Colour: Approved colour used in hard gelatin Capsule shell					
878	Pyridoxine Hydrochloride Tablets IP	Each Un-coated tablet contains:			
		Pyridoxine Hydrochloride	IP	40	mg
		Excipients		qs	
		Colour: Approved colour used			
879	Clobetasol Propionate & Salicylic Acid Ointment	Each Gram contains:-			
		Clobetasol Propionate	IP	0.05%	W/W
		Salicylic Acid	IP	6%	w/w
		In an Ointment base		q.s.	
880	Dextromethorphan HBr, Chlorpheniramine Maleate & Phenylephrine Hydrochloride Syrup	Each 5ml contains:			
		Dextromethorphan Hydrobromide	IP	15	mg
		Chlorpheniramine Maleate	IP	2	mg
		Phenylephrine Hydrochloride	IP	5	mg
		In flavoured Syrupy base		q.s.	
		Colour: Approved colour used .			
881	Ambroxol HCl, Levocetirizine HCl, Guaiphenesin & Menthol Syrup	Each 5ml contains:			
		Ambroxol Hydrochloride	IP	15	mg
		Levocetirizine Hydrochloride	IP	2.5	mg
		Guaiphenesin	IP	50	mg
		Menthol	IP	1	mg
		In flavoured Syrupy base		q.s.	
Colour: Approved colour used .					
882	Esomeprazole Gastro-resistant	Each Enteric-Coated tablet contains:			

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	Tablets IP	Esomeprazole Magnesium Trihydrate Equivalent to Esomeprazole	IP	20	mg
		Excipients		qs	
		Colour: Approved colour used			

883	Deflazacort Oral Suspension	Each 5ml contains:			
		Deflazacort		6	mg
		In flavoured suspension base		qs	
		Colour: Approved colour used			

884	Lycopene with Multivitamin & Multimineral Syrup	Each 10ml contains:			
		Lycopene 10%	USP	2000	mcg
		Niacinamide	IP	25	mg
		Pyridoxine Hydrochloride	IP	1.5	mg
		Cyanocobalamin	IP	1	mcg
		Folic Acid	IP	100	mcg
		Selenium(as Sodium Selenate)	USP	35	mcg
		Zinc (as Zinc Gluconate)	USP	3	mg
		Manganese (as Manganese Gluconate)	USP	2	mg
		Iodine (As Potassium Iodide)	IP	100	mcg
		Copper (As Cupric Sulphate )	USP	500	mcg
		In flavoured Syrupy base		q.s.	
	Colour: Approved colour used .				

885	Camylofin Dihydrochloride & Paracetamol Tablets	Each Film-coated Tablets contains:			
		Camylofin Dihydrochloride		25	mg
		Paracetamol	IP	300	mg
		Excipients		q.s.	
	Colour: Approved colour used				

886	L-Carnitine L-tartrate, Methylcobalamin & Folic Acid Tablets	Each Film Coated Tablet contains:			
		L-Carnitine L-tartrate Equivalent to L-Carnitine	IP	500	mg
		Methylcobalamin	IP	1500	mcg
		Folic Acid	IP	1.5	mg
		Excipients		q.s.	
	Colour: Approved colour used				

887	Aceclofenac & Thiocolchicoside Sustained Released Tablets	Each Uncoated bilayered Tablet Contains :			
		Aceclofenac (As sustained Released)	IP	200	mg
		Thiocolchicoside (As Sustained Released)	IP	8	mg
		Excipients		q.s.	
		Colour: Approved colour used			

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
888	Telmisartan & Cilnidipine Tablets	Each Film Coated Tablet contains:			
		Telmisartan	IP	40	mg
		Cilnidipine	IP	10	mg
		Excipients		q.s.	
		Colour: Approved colour used			
889	Povidone Iodine Ointment USP10%W/W	Povidone Iodine	IP	10%	w/w
		eq. to Available Iodine (1.0% w/w)			
		Water Soluble Ointment Base		q.s.	
890	Bilastine Tablets IP20mg	Each uncoated tablet contains:			
		Bilastine	IP	20	mg
		Excipients		qs	
		Colour: Approved colour used			
891	Hydroxyzine Hydrochloride Tablets IP	Each film-coated tablet contains:			
		Hydroxyzine Hydrochloride	IP	50	mg
		Excipients		qs	
		Colour: Approved colour used			
892	Levetiracetam Tablets IP	Each Un-coated tablet contains:			
		Levetiracetam	IP	750	mg
		Excipients		qs	
		Colour: Approved colour used			
893	Doxycycline & Lactic Acid Bacilli Tablets	Each Uncoated Tablets contains:			
		Doxycycline HCl	IP		
		Eq. to Doxycycline		100	mg
		Lactic Acid Bacillus		5	Billion Spores
		Excipients		qs	
		Colour: Approved colour used			
894	Bilastine & Montelukast Sodium Tablets	Each Film-Coated Tablets contains:			
		Bilastine	IP	20	mg
		Montelukast Sodium	IP		
		Eq. to Montelukast		10	mg
		Excipients		qs	
		Colour: Approved colour used			
895	Etoricoxib & Paracetamol Tablets	Each Film Coated Tablet contains:			
		Etoricoxib	IP	60	mg
		Paracetamol	IP	325	mg
		Excipients		q.s.	
		Colour: Approved colour used			
896	L-Carnitine L-Tartrate,	Each Film-Coated Tablets contains:			
		L-Carnitine L-Tartrate			

**NO.HFW-H(DRUGS)279/07**

**HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
 having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027

**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	Methylcobalamin & Folic Acid  Tablets	Eq. to L-Carnitine		500	mg
		Methylcobalamin	IP	1500	mcg
		Folic Acid	IP	1.5	mg
		Excipients		qs	
		Colour: Approved colour used			
897	Cephalexin Tablets IP 250mg	Each Un-coated tablet contains:			
		Cephalexin	IP		
		Equivalent to Anhydrous Cephalexin		250	mg
		Excipients		qs	
		Colour: Approved colour used			
898	Cephalexin Tablets IP 500mg	Each Un-coated tablet contains:			
		Cephalexin	IP		
		Equivalent to Anhydrous Cephalexin		500	mg
		Excipients		qs	
		Colour: Approved colour used			
899	Nefopam Hydrochloride Tablets 30mg	Each Film-coated tablet contains:			
		Nefopam Hydrochloride		30	mg
		Excipients		qs	
		Colour: Approved colour used			
900	Acebrophylline SR Tablets 200 mg	Each Un-coated Sustained Release tablet contains:			
		Acebrophylline		200	mg
		Excipients		qs	
		Colour: Approved colour used			
901	Zinc Acetate Oral Solution USP	Each 5ml contains:			
		Zinc Acetate (As Dihydrate)	USP		
		Equivalent to Elemental Zinc		20	mg
		In a Palatable Syrup base		qs	
		Colour: Approved colour used			
902	Zinc Gluconate Oral solution	Each 5ml contains:			
		Zinc Gluconate	USP		
		Equivalent to Elemental Zinc		20	mg
		In a flavoured Syrupy base		qs	
		Colour: Approved colour used			
903	Dapagliflozin Tablets 10mg	Each Film-coated tablet contains:			
		Dapagliflozin			
		Propanediol Monohydrate	USP		
		Equivalent to Dapagliflozin		10	mg
		Excipients		qs	
Colour: Approved colour used					

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
904	Tranexamic Acid Tablets IP 500mg	Each Film-coated tablet contains:			
		Tranexamic Acid	IP	500	mg
		Excipients		qs	
		Colour: Approved colour used			
905	Sodium Picosulphate, Milk of Magnesia and Liquid Parafin Suspension	Each 5ml contains:			
		Sodium Picosulphate	BP	3.33	mg
		Milk of Magnesia	IP	3.75	ml
		Liquid Parafin	IP	1.25	ml
		In flavoured Syrupy base		q.s.	
Colour: Approved colour used .					
906	Ebastine Tablets IP 20mg	Each Film-coated tablet contains:			
		Ebastine	IP	20	mg
		Excipients		qs	
		Colour: Approved colour used			
907	Flunarizine Dihydrochloride Tablets IP 10mg	Each Un-coated tablet contains:			
		Flunarizine Dihydrochloride	IP		
		Equivalent to Flunarizine		10	mg
		Excipients		qs	
		Colour: Approved colour used			
908	Ebastine Tablets IP 10mg	Each Film-coated tablet contains:			
		Ebastine	IP	10	mg
		Excipients		qs	
		Colour: Approved colour used			
909	Phenylephrine Hydrochloride and Chlorpheniramine maleate Drops IP	Each ml contains:			
		Phenylephrine Hydrochloride	IP	5	mg
		Chlorpheniramine maleate	IP	2	mg
		In a flavoured Syrupy base		qs	
		Colour: Approved colour used			
910	Etamsylate Tablets 250mg	Each Film-coated tablet contains:			
		Etamsylate	BP	250	mg
		Excipients		qs	
		Colour: Approved colour used			
911	Etamsylate Tablets 500mg	Each Film-coated tablet contains:			
		Etamsylate	BP	500	mg
		Excipients		qs	
		Colour: Approved colour used			
912	Ofloxacin, Tinidazole,	Ofloxacin	IP	0.75%	w/w
		Tinidazole	IP	2.0%	w/w

**NO.HFW-H(DRUGS)279/07****HEALTH AND FAMILY WELFARE DEPARTMENT, HIMACHAL PRADESH**  
**List of Retention Products Approved to be Manufactured by : Boffin Biotech Pvt. L**  
having license No. FORM25:MNB/07/642 AND MB/07/643 28:S-MB/07/643 For the period from 01.12.2022 to 30.11.2027**PACK SIZE AS PER SCHEDULE-P-1 OF DRUGS & COSMETIC ACT 1945**

S. No.	DOSAGE FORM, GENERIC NAME/BRAND NAME	COMPOSITION	SPECIFICATION	QUANTITY	UNIT
	Terbinafine Hydrochloride, Dexpanthenol & Clobetasole Propionate Cream	Terbinafine Hydrochloride	IP	1.0%	w/w
		Clobetasole Propionate	IP	0.05%	w/w
		Dexpanthenol	USP	0.05%	w/w
		Methylparaben (As Preservative )	IP	0.20%	w/w
		Propyl Paraben (As preservative)	IP	0.02%	w/w
		In cream Base			q.s
913	Ferrous Ascorbate, Folic Acid, Cyanocobalamin and Zinc Sulphate Tablets	Each Film-Coated Tablets contains:			
		Ferrous Ascorbate	IP		
		Equivalent to Elemental Iron		100	mg
		Folic Acid	IP	1.5	mg
		Cyanocobalamin	IP	15	mcg
		Zinc Sulphate monohydrate	IP		
		Equivalent to Elemental Zinc		22.5	mg
		Excipients		qs	
	Colour: Approved colour used				
914	Ferrous Ascorbate & Folic Acid Suspension IP	Each 5ml contains:			
		Ferrous Ascorbate	IP		
		Equivalent to Elemental Iron		30	mg
		Folic Acid	IP	550	mcg
		In flavoured Syrupy base		q.s.	
	Colour: Approved colour used .				
915	Naproxen Sodium And Domperidone Tablets	Each Film Coated Tablet contains:			
		Naproxen Sodium	USP	500	mg
		Domperidone Maleate	IP		
		Equivalent to Domperidone		10	mg
		Excipients		q.s.	
	Colour: Approved colour used				
916	Etodolac Extended Release Tablets IP	Each Film-coated Extended Release tablet contains:			
		Etodolac	IP	300	mg
		Excipients		qs	
	Colour: Approved colour used				

TILL DATE 08.08.2025

td.

APPROVED  
ON DATED

9/21/2015

9/21/2015

9/21/2015

9/21/2015

td.

APPROVED  
ON DATED

9/21/2015

9/21/2015

9/21/2015

9/21/2015

9/21/2015

9/21/2015

9/21/2015

9/21/2015

td.

APPROVED  
ON DATED  
9/21/2015

9/21/2015

9/21/2015

9/21/2015

9/21/2015

9/21/2015

9/21/2015

td.

APPROVED  
ON DATED

9/21/2015

9/21/2015

9/21/2015

9/21/2015

9/21/2015

td.

APPROVED  
ON DATED

9/21/2015

9/21/2015

9/21/2015

9/21/2015

9/21/2015

9/21/2015

td.

APPROVED  
ON DATED

9/21/2015

9/21/2015

9/21/2015

9/21/2015

9/21/2015

9/21/2015

td.

APPROVED  
ON DATED

9/21/2015

9/21/2015

9/21/2015

12/1/2017

12/1/2017

td.

APPROVED  
ON DATED

12/1/2017

12/1/2017

12/1/2017

12/1/2017

12/1/2017

12/1/2017

td.

APPROVED  
ON DATED

12/1/2017

12/1/2017

12/1/2017

12/1/2017

12/1/2017

12/1/2017

td.

APPROVED  
ON DATED

12/1/2017

12/1/2017

12/1/2017

12/1/2017

12/1/2017

12/1/2017

td.

APPROVED  
ON DATED

12/1/2017

12/1/2017

12/1/2017

12/1/2017

12/1/2017

12/1/2017

12/1/2017

td.

APPROVED  
ON DATED  
12/1/2017

12/1/2017

12/1/2017

12/1/2017

td.

APPROVED  
ON DATED

12/1/2017

12/1/2017

12/1/2017

12/1/2017

12/1/2017

td.

APPROVED  
ON DATED

12/1/2017

12/1/2017

4/12/2021

12/1/2017

td.

APPROVED  
ON DATED

12/1/2017

12/1/2017

12/1/2017

12/1/2017

12/1/2017

td.

APPROVED  
ON DATED

12/1/2017

12/1/2017

12/1/2017

12/1/2017

12/1/2017

12/1/2017

12/1/2017

td.

APPROVED  
ON DATED

12/1/2017

12/1/2017

11/30/2012

11/30/2012

11/30/2012

11/30/2012

td.

APPROVED  
ON DATED

11/30/2012

11/30/2012

11/30/2012

11/30/2012

td.

APPROVED  
ON DATED

11/30/2012

1/31/2013

1/31/2013

1/31/2013

1/31/2013

1/31/2013

td.

APPROVED  
ON DATED

1/31/2013

3/26/2013

3/26/2013

3/26/2013

6/25/2013

8/14/2013

8/14/2013

8/14/2013

td.

APPROVED  
ON DATED

8/14/2013

9/3/2013

10/21/2013

10/21/2013

10/21/2013

10/21/2013

10/21/2013

10/21/2013

td.

APPROVED  
ON DATED

10/21/2013

12/26/2013

4/9/2014

4/9/2014

4/9/2014

4/9/2014

5/27/2014

td.

APPROVED  
ON DATED

5/27/2014

5/27/2014

5/27/2014

5/27/2014

5/27/2014

5/27/2014

td.

APPROVED  
ON DATED

5/27/2014

5/27/2014

5/27/2014

5/27/2014

7/14/2014

7/14/2014

7/14/2014

td.

APPROVED  
ON DATED

7/14/2014

7/14/2014

7/14/2014

7/14/2014

7/14/2014

7/14/2014

td.

APPROVED  
ON DATED

7/14/2014

7/14/2014

7/14/2014

7/14/2014

7/14/2014

7/14/2014

td.

APPROVED  
ON DATED

7/14/2014

7/14/2014

7/14/2014

7/14/2014

7/14/2014

7/14/2014

7/14/2014

td.

APPROVED  
ON DATED

7/14/2014

7/14/2014

9/1/2014

9/1/2014

9/1/2014

9/1/2014

9/1/2014

9/1/2014

td.

APPROVED  
ON DATED

9/1/2014

9/1/2014

9/1/2014

9/1/2014

9/1/2014

9/1/2014

td.

APPROVED  
ON DATED

9/1/2014

9/1/2014

9/1/2014

9/1/2014

9/1/2014

9/1/2014

9/1/2014

td.

APPROVED  
ON DATED

9/1/2014

9/1/2014

9/1/2014

9/1/2014

10/1/2014

10/1/2014

10/1/2014

10/1/2014

10/1/2014

td.

APPROVED  
ON DATED

10/1/2014

10/1/2014

10/1/2014

10/1/2014

10/1/2014

10/1/2014

10/1/2014

10/29/2014

10/29/2014

td.

APPROVED  
ON DATED

10/29/2014

10/29/2014

10/29/2014

10/29/2014

10/29/2014

10/29/2014

10/29/2014

10/29/2014

td.

APPROVED  
ON DATED

10/29/2014

11/13/2014

11/13/2014

11/13/2014

td.

APPROVED  
ON DATED

11/13/2014

11/13/2014

11/13/2014

11/13/2014

11/13/2014

td.

APPROVED  
ON DATED

11/13/2014

11/13/2014

12/15/2014

12/15/2014

12/15/2014

12/15/2014

12/15/2014

12/15/2014

td.

APPROVED  
ON DATED

1/8/2015

1/8/2015

1/8/2015

1/8/2015

1/8/2015

1/8/2015

1/8/2015

1/8/2015

td.

APPROVED  
ON DATED

1/8/2015

1/8/2015

1/8/2015

2/24/2015

2/24/2015

2/24/2015

2/24/2015

td.

APPROVED  
ON DATED

2/24/2015

2/24/2015

2/24/2015

2/24/2015

2/24/2015

2/24/2015

2/24/2015

td.

APPROVED  
ON DATED

2/24/2015

2/24/2015

2/24/2015

2/24/2015

2/24/2015

2/24/2015

2/24/2015

2/24/2015

td.

APPROVED  
ON DATED

3/10/2015

3/10/2015

3/10/2015

3/10/2015

3/10/2015

3/10/2015

3/10/2015

td.

APPROVED  
ON DATED

4/8/2015

4/8/2015

4/8/2015

4/8/2015

4/8/2015

4/8/2015

4/8/2015

td.

APPROVED  
ON DATED

4/8/2015

4/8/2015

4/8/2015

4/8/2015

4/8/2015

4/8/2015

td.

APPROVED  
ON DATED

4/8/2015

4/8/2015

4/8/2015

4/8/2015

5/15/2015

5/15/2015

5/15/2015

5/15/2015

td.

APPROVED  
ON DATED

5/15/2015

5/15/2015

5/15/2015

5/15/2015

5/15/2015

5/15/2015

5/15/2015

td.

APPROVED  
ON DATED

5/15/2015

5/15/2015

5/15/2015

5/15/2015

6/18/2015

6/18/2015

6/18/2015

6/18/2015

td.

APPROVED  
ON DATED

6/18/2015

5/8/2015

5/8/2015

5/8/2015

5/8/2015

td.

APPROVED  
ON DATED

8/20/2015

8/20/2015

9/22/2015

9/22/2015

11/27/2015

11/27/2015

11/27/2015

td.

APPROVED  
ON DATED

11/27/2015

11/27/2015

11/27/2015

11/27/2015

11/27/2015

11/27/2015

11/27/2015

td.

APPROVED  
ON DATED

11/27/2015

11/27/2015

11/27/2015

11/27/2015

11/27/2015

11/27/2015

11/27/2015

td.

APPROVED  
ON DATED

11/27/2015

11/27/2015

11/27/2015

12/5/2015

12/5/2015

12/5/2015

td.

APPROVED  
ON DATED

12/5/2015

12/5/2015

12/5/2015

1/23/2016

1/23/2016

1/23/2016

1/23/2016

td.

APPROVED  
ON DATED

1/23/2016

1/23/2016

1/23/2016

1/23/2016

1/23/2016

1/23/2016

1/23/2016

1/23/2016

td.

APPROVED  
ON DATED

1/23/2016

1/23/2016

1/23/2016

1/23/2016

1/23/2016

td.

APPROVED  
ON DATED

1/23/2016

1/23/2016

1/23/2016

2/17/2016

2/17/2016

2/17/2016

td.

APPROVED  
ON DATED

2/17/2016

2/17/2016

2/17/2016

2/17/2016

2/17/2016

2/17/2016

2/17/2016

2/17/2016

td.

APPROVED  
ON DATED

2/26/2016

2/26/2016

2/26/2016

2/26/2016

2/26/2016

2/26/2016

2/26/2016

2/26/2016

td.

APPROVED  
ON DATED  
2/26/2016

2/26/2016

3/16/2016

3/16/2016

3/16/2016

3/16/2016

3/16/2016

td.

APPROVED  
ON DATED

3/16/2016

3/18/2016

3/18/2016

3/18/2016

3/18/2016

td.

APPROVED  
ON DATED

4/6/2016

4/6/2016

4/6/2016

4/6/2016

5/24/2016

5/24/2016

5/24/2016

5/24/2016

td.

APPROVED  
ON DATED  
5/24/2016

5/24/2016

5/24/2016

5/24/2016

5/24/2016

5/24/2016

td.

APPROVED  
ON DATED

6/15/2016

6/15/2016

6/15/2016

6/15/2016

6/15/2016

7/27/2016

td.

APPROVED  
ON DATED

7/27/2016

7/27/2016

7/27/2016

7/27/2016

7/27/2016

7/27/2016

8/31/2016

td.

APPROVED  
ON DATED

8/31/2016

8/31/2016

8/31/2016

8/31/2016

8/31/2016

8/31/2016

8/31/2016

td.

APPROVED  
ON DATED

8/31/2016

2/21/2017

2/21/2017

2/21/2017

2/21/2017

2/23/2017

2/23/2017

td.

APPROVED  
ON DATED

2/23/2017

2/23/2017

2/23/2017

2/23/2017

2/23/2017

4/26/2017

4/26/2017

td.

APPROVED  
ON DATED

4/26/2017

5/25/2017

5/25/2017

5/25/2017

5/25/2017

5/25/2017

td.

APPROVED  
ON DATED

5/25/2017

1/24/2018

1/24/2018

1/24/2018

1/24/2018

1/24/2018

td.

APPROVED  
ON DATED

1/24/2018

1/24/2018

1/24/2018

1/24/2018

1/24/2018

1/24/2018

1/24/2018

1/24/2018

td.

APPROVED  
ON DATED

1/24/2018

1/24/2018

1/24/2018

1/24/2018

1/24/2018

6/4/2018

6/4/2018

6/4/2018

td.

APPROVED  
ON DATED

7/23/2018

7/23/2018

7/23/2018

7/23/2018

7/23/2018

7/23/2018

td.

APPROVED  
ON DATED

7/23/2018

7/23/2018

10/1/2018

10/1/2018

10/1/2018

10/1/2018

10/1/2018

10/1/2018

td.
APPROVED ON DATED
10/1/2018

10/1/2018

10/1/2018

10/1/2018

10/1/2018

10/1/2018

3/5/2021

3/5/2021

3/5/2021

td.

APPROVED  
ON DATED

3/5/2021

3/5/2021

3/5/2021

3/5/2021

3/5/2021

3/5/2021

3/5/2021

td.

APPROVED  
ON DATED

3/5/2021

3/5/2021

3/5/2021

3/5/2021

3/5/2021

3/5/2021

td.

APPROVED  
ON DATED

3/5/2021

3/5/2021

3/5/2021

3/5/2021

3/5/2021

3/5/2021

td.

APPROVED  
ON DATED

3/5/2021

3/5/2021

3/5/2021

3/5/2021

3/5/2021

3/5/2021

3/5/2021

td.

APPROVED  
ON DATED

3/5/2021

3/5/2021

3/15/2021

3/15/2021

3/15/2021

3/15/2021

td.

APPROVED  
ON DATED

3/15/2021

3/15/2021

3/15/2021

3/15/2021

3/15/2021

3/15/2021

td.

APPROVED  
ON DATED

3/15/2021

3/15/2021

3/15/2021

3/15/2021

3/15/2021

3/15/2021

td.

APPROVED  
ON DATED

3/15/2021

3/15/2021

3/15/2021

3/15/2021

3/15/2021

td.

APPROVED  
ON DATED

3/15/2021

3/15/2021

3/15/2021

3/15/2021

3/15/2021

3/15/2021

3/15/2021

td.

APPROVED  
ON DATED

3/15/2021

3/15/2021

3/15/2021

3/15/2021

3/15/2021

3/15/2021

td.

APPROVED  
ON DATED

3/15/2021

3/15/2021

3/15/2021

3/15/2021

3/15/2021

3/15/2021

3/15/2021

td.

APPROVED  
ON DATED  
3/15/2021

3/15/2021

3/15/2021

3/15/2021

3/15/2021

3/23/2021

td.

APPROVED  
ON DATED

3/23/2021

3/23/2021

3/23/2021

3/23/2021

3/23/2021

3/23/2021

3/23/2021

3/23/2021

td.

APPROVED  
ON DATED  
3/23/2021

3/23/2021

3/23/2021

3/23/2021

3/23/2021

3/23/2021

td.

APPROVED  
ON DATED

3/23/2021

3/23/2021

3/23/2021

3/23/2021

3/23/2021

td.

APPROVED  
ON DATED

3/23/2021

3/23/2021

3/23/2021

3/23/2021

3/23/2021

3/23/2021

3/23/2021

td.

APPROVED  
ON DATED

3/23/2021

3/23/2021

3/23/2021

3/23/2021

3/23/2021

3/23/2021

td.

APPROVED  
ON DATED

3/26/2021

3/26/2021

3/26/2021

3/26/2021

3/26/2021

td.

APPROVED  
ON DATED  
3/26/2021

3/26/2021

3/26/2021

3/26/2021

3/26/2021

td.

APPROVED  
ON DATED

3/26/2021

3/26/2021

3/26/2021

3/26/2021

3/26/2021

td.

APPROVED  
ON DATED

3/26/2021

3/26/2021

3/26/2021

3/26/2021

3/26/2021

td.

APPROVED  
ON DATED

3/26/2021

3/26/2021

3/26/2021

3/26/2021

3/26/2021

3/26/2021

td.

APPROVED  
ON DATED

3/26/2021

3/26/2021

3/30/2021

3/26/2021

3/26/2021

td.

APPROVED  
ON DATED

3/30/2021

3/30/2021

3/30/2021

3/30/2021

3/30/2021

td.

APPROVED  
ON DATED

3/30/2021

3/30/2021

3/30/2021

3/30/2021

3/30/2021

3/30/2021

td.

APPROVED  
ON DATED

3/30/2021

3/30/2021

3/30/2021

3/30/2021

3/30/2021

3/30/2021

3/30/2021

td.

APPROVED  
ON DATED  
3/30/2021

3/30/2021

3/30/2021

3/30/2021

3/30/2021

3/30/2021

td.

APPROVED  
ON DATED

3/30/2021

3/30/2021

3/30/2021

3/30/2021

3/30/2021

td.

APPROVED  
ON DATED

3/30/2021

3/30/2021

3/30/2021

3/30/2021

3/30/2021

td.

APPROVED  
ON DATED

3/30/2021

4/12/2021

4/12/2021

4/12/2021

td.

APPROVED  
ON DATED

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

td.

APPROVED  
ON DATED

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

td.

APPROVED  
ON DATED

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

td.

APPROVED  
ON DATED

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

td.

APPROVED  
ON DATED

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

td.

APPROVED  
ON DATED

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

td.

APPROVED  
ON DATED

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

td.

APPROVED  
ON DATED

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

td.

APPROVED  
ON DATED

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

td.

APPROVED  
ON DATED

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

td.

APPROVED  
ON DATED

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

td.

APPROVED  
ON DATED  
4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

td.

APPROVED  
ON DATED

4/12/2021

4/12/2021

4/12/2021

4/12/2021

td.

APPROVED  
ON DATED

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

td.

APPROVED  
ON DATED  
4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

4/12/2021

td.

APPROVED  
ON DATED

4/12/2021

4/12/2021

4/12/2021

4/22/2021

4/22/2021

4/22/2021

4/22/2021

td.

APPROVED  
ON DATED

4/22/2021

4/22/2021

4/22/2021

4/22/2021

td.

APPROVED  
ON DATED

4/22/2021

4/22/2021

4/22/2021

td.

APPROVED  
ON DATED

4/22/2021

4/22/2021

4/22/2021

4/22/2021

4/22/2021

td.

APPROVED  
ON DATED

4/22/2021

4/22/2021

4/22/2021

4/22/2021

4/22/2021

4/22/2021

4/22/2021

td.

APPROVED  
ON DATED

4/22/2021

4/22/2021

4/22/2021

4/22/2021

4/22/2021

4/22/2021

td.

APPROVED  
ON DATED

4/22/2021

4/22/2021

4/22/2021

4/22/2021

4/22/2021

4/22/2021

td.

APPROVED  
ON DATED

4/22/2021

4/22/2021

4/22/2021

4/22/2021

4/22/2021

4/22/2021

td.

APPROVED  
ON DATED

4/22/2021

4/22/2021

4/22/2021

4/22/2021

4/22/2021

4/22/2021

td.

APPROVED  
ON DATED

4/22/2021

4/22/2021

4/22/2021

4/22/2021

4/22/2021

4/22/2021

td.

APPROVED  
ON DATED

4/22/2021

4/22/2021

4/22/2021

4/22/2021

4/22/2021

td.

APPROVED  
ON DATED

4/22/2021

4/22/2021

4/22/2021

4/22/2021

4/22/2021

4/22/2021

4/22/2021

td.

APPROVED  
ON DATED

4/22/2021

4/22/2021

4/22/2021

4/22/2021

4/22/2021

4/22/2021

4/22/2021

td.

APPROVED  
ON DATED

4/22/2021

4/22/2021

4/22/2021

4/22/2021

4/22/2021

4/22/2021

td.

APPROVED  
ON DATED

9/22/2021

9/22/2021

9/22/2021

9/22/2021

9/22/2021

9/22/2021

td.

APPROVED  
ON DATED

9/22/2021

9/22/2021

9/22/2021

9/22/2021

td.

APPROVED  
ON DATED

9/22/2021

9/22/2021

10/25/2021

10/25/2021

10/25/2021

10/25/2021

10/25/2021

td.

APPROVED  
ON DATED

10/25/2021

10/25/2021

11/9/2021

11/9/2021

1/10/2022

1/10/2022

1/10/2022

td.

APPROVED  
ON DATED

1/10/2022

1/10/2022

1/10/2022

1/10/2022

1/10/2022

2/17/2022

2/17/2022

td.

APPROVED  
ON DATED

4/22/2022

4/22/2022

4/22/2022

4/22/2022

4/22/2022

4/22/2022

5/20/2022

td.

APPROVED  
ON DATED

5/20/2022

5/20/2022

5/20/2022

9/29/2022

9/29/2022

12/24/2022

td.

APPROVED  
ON DATED

12/24/2022

12/24/2022

27-02-2023

4/25/2023

4/25/2023

5/29/2023

td.

APPROVED  
ON DATED

5/29/2023

5/29/2023

12/1/2023

12/1/2023

12/1/2023

td.

APPROVED  
ON DATED

12/1/2023

12/1/2023

12/1/2023

12/13/2023

12/13/2023

12/13/2023

12/13/2023

td.

APPROVED  
ON DATED

12/13/2023

12/13/2023

12/13/2023

1/11/2024

1/11/2024

6/20/2024

td.

APPROVED  
ON DATED

6/20/2024

6/20/2024

8/9/2024

10/18/2024

10/18/2024

11/3/2025

11/3/2025

11/3/2025

td.

APPROVED  
ON DATED

11/3/2025

4/17/2025

4/17/2025

4/17/2025

4/17/2025

5/14/2025

5/14/2025

22.05.2025

td.

APPROVED  
ON DATED

6/3/2025

6/3/2025

06-06-2025

6/6/2025

12-06-2025

6/12/2025

15-07-2025

15-07-2025

td.

APPROVED  
ON DATED

7/15/2025

7/15/2025

8/8/2025

8/8/2025

8/8/2025

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

|

—

—

|

|

—

—

|

|

|

|

|

|

|

|

|

|

|

T

|

|

|

|